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SUMMARY 
 
Macrophages are a heterogeneous population of the innate immune system operating  at the 
boundary between health and disease. They represent the most plastic elements of the hematopoietic 
system, they are found in all tissues, and their main sake is the response to pathogens by processing 
and presenting the antigens to the adaptive immune mediators. Among their functions macrophages 
mediate generation and resolution of inflammation, tissue repair and homeostasis maintenance [1]. 
These cells undergo specific differentiation based on the local microenvironment [2] and the 
presence of cytokines [3]. In accordance with the Th1/Th2 polarization, two extreme states of 
macrophages polarization can be defined: the classically activated, pro-inflammatory M1 
macrophage phenotype induced by IFNγ and  LPS and the alternatively activated anti-inflammatory 
M2 macrophage phenotype [4, 5]. Among all the intermediate subpopulations of activating and 
suppressive macrophages [6], tumor associated macrophages (TAM) embody a peculiar M2-like 
subset favoring tumor progression and survival, angiogenesis and  metastatization, making of these 
cells a negative prognostic index in many malignances. 
 Membrane spanning 4-domains subfamily A (MS4A) is a newly described tetraspanin-like protein 
family, including 26 proteins in human and  mice, whose members have been poorly characterized, 
with few exceptions [7, 8]. Most of them have been demonstrated playing a role in the immune 
system, either functioning as adaptor molecules for pivotal receptors (e.g. CD20/MS4A1-BCR; 
MS4A4B -TCR), or clustering complexes on the plasma membrane, or regulating the cell cycle. 
In the present study we identified and characterized a novel MS4A protein associated with 
alternative macrophage polarization, in two different contexts: TAMs association and fungal 
infections. 
MS4A4A is indeed a transmembrane molecule expressed by a special subset of M2 macrophages 
induced by glucocorticoids.  
The topology of the protein resembles the one of the other MS4A members, since it is re-localizes 
within lipid raft microdomains only upon macrophage activation and its surface expression is 
abolished upon cholesterol depletion. Also the murine homologue we identified as Ms4a4a shares 
the same features of the human one. 
The target has been found in human samples of Hodgkin’s lymphoma (HL) with a characteristic 
distribution, and its abundance varies among different types of HL. However, no or very faint 
5 
 
staining resulted from healthy tissues, such as  lymph nodes and spleen, suggesting the molecule 
might be implicated in both tumorgenesis and fibrosis.  
Evidences of MS4A4A association with TAM also derive from the murine models in vivo. 
Its distribution and topology makes MS4A4A an ideal target for antibody, potentially with a 
therapeutic significance.  
In the attempt of generating a human anti-human antibody directed against MS4A4A, we identified 
a clone able to recognize the human and cross-reacting with the murine protein, mediating 
cytotoxicity of the target bearing cells. Unfortunately, the tool turned out not being able to 
recognize the native protein in primary cells, given that the screening was originally performed 
against transfectants expressing the recombinant MS4A4A. 
Trying to uncover potential partners for the molecule, split-ubiquitin genetic screening was 
performed using MS4A4A as bait on a GC treated macrophages library. 
The screening showed interactions between MS4A4A and other two MS4A members, MS4A6A, 
MS4A7, and two tetraspanins, CD63 and CD9, suggesting the existence of platforms resembling 
the tetraspanin enriched microdomains, where these proteins might gather to facilitate the formation 
of signaling complexes. Furthermore, the molecule turned out interacting with the b-glucan receptor 
Dectin1, indicating a possible role in orchestrating the responses to fungal and yeast infections [9].   
The relationship with Dectin1 was assessed making use of the Dectin1 ligand Zymosan, and 
revealed an inverse correlation between the two molecules. An increase in MS4A4A at the surface 
of the Zymosan treated macrophages corresponds in fact to an internalization of the b-glucan 
receptor, and occur only in the presence of the particulate polymer, not the soluble one, underlying 
the specificity of the interaction. The evidence that in resting conditions neither MS4A4A nor 
Dectin1 are localized within lipid raft, MS4A4A becomes co-localized upon GC, opposite to 
Dectin1, which instead becomes upon Zymosan engagement when the gathering of a receptor 
complex is required, suggest a modulatory role for the tetraspanin. 
This putative role became even more solid in vivo, where the response to the β-glucan in the KO 
macrophages was severely impaired both in terms of cytokines production and induction of the 
respiratory burst, and was observed along with a reduced internalization of Dectin1 upon 
stimulation. 
Although further investigations need to be done, our results strongly suggest MS4A4A may act as a 
regulatory adaptor for Dectin1 during the recognition of pathogens. 
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1. INTRODUCTION 
 
1.1. The mononuclear phagocyte system  
 
Since first described by Elie Metchnikoff in the 19th century, it was widely accepted the monocyte-
macrophage system originates from the bone marrow’s hematopoietic stem cells that once 
committed, enter the circulation as monocytes and spread throughout the body to eventually 
differentiate into dendritic cells (DCs) or macrophages by entering the endothelium [10]. These 
bone marrow derived cells are considered mainly as professional phagocytic cells responsible for 
antigen presentation and cytokines production [11] and express a great number of receptors on their 
surface, particularly scavenger receptors and pattern recognition receptors (PRRs) (such as toll like 
receptors (TLRs) and C-type lectin receptors) [12]. Recently, some evidences diverted from the 
effective macrophages affiliation with the van Furth ‘s “mononuclear phagocyte system”, showing 
how actually those cells already exist within the yolk sac much before the appearance of definitive 
hematopoietic stem cells and the evidences that monocytopenic mice do not present impairment in 
the tissue-resident macrophages content contributes corroborating this hypothesis [13] [14]. Indeed, 
fate mapping studies acknowledged that microglia may derive from the yolk sac, while Langerhans 
cells originate from the fetal liver [15-17], although both can develop also from blood monocytes, 
under specific conditions [18-21]. Also alveolar, F4/80
hi
 peritoneal and splenic macrophages from 
the red pulp were shown having a prenatal origin [17]. 
Hence, resident macrophages can arise from both circulating adult monocytes and embryonic–
derived macrophages [22]. 
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Fig.1. The Mononuclear Phagocyte System:  Haematopoietic stem cells (HSC) in the bone 
marrow (BM) generate common myeloid  progenitors (CMP), which in turn originate the 
macrophage and dendritic cell precursor (MDP). This latter  gives rise to the monocytic and 
dendritic subsets. The MDP originates monocytes, which comprise at least two acknowledged 
subsets: Ly6ChighCX3CR1intCCR2+, or 'inflammatory' monocytes, producing high amounts of 
TNFα and iNOS; and Ly6ClowCX3CR1+CCR2- monocytes,  or 'resident', which are involved in 
the homeostasis maintainance. MDP also originates all DC subsets. Classical DC are from DC-
committed precursors (pre-cDC), following the MDP. Plasmacytoid DC (pDC) are from the 
MDP/CDP.  
 
1.1.1. Monocytes development and functions 
 
Monocytes are a heterogeneous population of nucleated cells (4% and 10% in mice and humans, 
respectively) that can be subdivided in more than a few functional subsets on the basis of their 
surface markers pattern and emerged as a dynamic and plastic system able to replenish the tissue 
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resident phagocytic compartment when required. They can even exert several cell specific activities 
as effector cells, including supporting arteriogenesis and angiogenesis [23].   
These cells arise from myeloid precursor cells (MPC) in BM and fetal liver during hematopoiesis 
and their development totally depends on colony stimulating factor 1 (M-CSF) [24-26]. 
Fogg  identified a clonotypic precursor , the macrophage/DC precursor (MDP) within the murine 
BM expressing a characteristic signature: LIN-/KIT+/CD135+/CSF1R+ able to give rise to both 
monocytes and DCs, while more recently another precursor in the BM was acknowledged that does 
not express FLT3 (the common monocyte progenitor, cMoP) which is not able to generate DCs 
[27]. 
Currently, two main human Mo subpopulations have been distinguished: CD14+ (which includes 
CD14+CD16+ and CD14+CD16-) and CD14lowCD16+ [28] 
The classical monocytes represent 80-90% of the whole circulating ones and express high levels of 
CCR2 and release IL-10 upon LPS [29, 30]. On the other hand, non-classical and intermediate Mo  
exhibit a CX3CR1hiCCR2lo phenotype [31, 32].  
In mice, the main subsets, both deriving from MDP and cMoPs, are 
Ly6C
hi
CX3CR1
mid
CCR2
+
CD62L
+
CD43
lo
 and LY6C
lo
CX3CR1
hi
CCR2
-
CD62L-CD43
hi
 [33-36]. 
Both human CD14
+
 and murine LY6C
hi
 resemble the “classical monocytes” that once recruited 
upon inflammation, are rapidly trans located from the BM to the injured site (through a process 
highly dependent on the chemokine CCR2) [37, 38],where they can differentiate into human 
CD14
lo
CD16
+
 or murine LY6C
lo
 phagocytes respectively, which are instead likely to represent the 
future blood-derived resident macrophages [38]. Development of these mature monocytes requires a 
step of differentiation into monoblasts and pro-monocytes, which occurs constitutively within the 
BM [13]. Opposite to their pro-monocytic precursors, these newly differentiated monocytes exit cell 
cycle and therefore lose their proliferative potential [34]. 
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Fig.2. The murine monocyte compartment.  Monocytes arose  from  hematopoietic stem cells 
(HSCs) in the bone marrow through  macrophage and dendritic cell precursor (MDP) and common 
monocyte progenitor (cMoP)  intermediates. Once entered the blood,  LY6C
low
 cells patrol the 
endothelial surface while LY6C
hi
 cells migrate to sites of inflammation or remodeling, where they 
can differentiate in  DCs and macrophages. Taken from Ghinoux, Nat. Rev. 2014. 
 
 
The constitutive affluence of LY6C
hi
 monocytes derived macrophages seems somehow to be 
restricted to areas permanently exposed to a low-grade state of chronic inflammation such as gut, 
skin and spleen marginal zone, where these cells acquire a robust anti-inflammatory phenotype, 
most likely consistent with their role in maintaining the homeostasis of tissues rich in commensal 
microorganisms [39].   
Recent intravital microscopy experiments have demonstrated how both CD14
lo
CD16
+
 and LY6C
lo
 
can move within the intraluminal endothelium orchestrating the stress responses [40, 41]. 
Even though commonly associated with macrophages development, monocytes can also give rise to 
classical dendritic cells. This differentiation is thought to take place following trans endothelial 
migration, while monocytes stack in the sub endothelial matrix differentiate into macrophages [42]. 
What is known by far is that there are some monocytes-independent DC-committed precursors. The 
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MDP can originate plasmacytoid DC (pDC) directly, and pre-cDC, that can differentiate into cDC, 
but neither pDC nor macrophages [27]. The existence of a common DCs precursor (CDP) 
intermediate has been proposed [43, 44], although it seems that the MDP and the CDP are 
phenotypically and developmentally linked [45].  
 
1.1.2. Macrophages development  
 
Based on their phenotype and anatomical localization, macrophages can be divided into numerous 
subpopulations (e.g. alveolar macrophages, Kupffer cells, osteoclasts, spleen marginal zone 
macrophages, sub capsular sinus macrophages.) [5].  The functions they may cover ranges from 
remodeling and homeostasis maintenance to scavenging activities, antigen presentation,  immune 
response triggering. 
As already mentioned, most adult tissue macrophages are not of monocytic origin but arise from 
embryonic progenitors and can be maintained through in situ self-renewal. 
The so termed primitive hematopoiesis constitutes the first step that takes place in the yolk sac and 
involves only myeloid-erythroid cells, while the definitive hematopoiesis occurs in the aorta-
gonads-mesonephros and originates the hematopoietic stem cells (HSCs) [46, 47] 
In the middle of the embryonic life, both these progenitors move first to the fetal liver, where all the 
subsequent hematopoietic lineages will arise from, then to the other hematopoietic organs through 
the circulation and here they will differentiate [48]. 
The yolk sac fetal macrophages origin independently from the MYB transcription factor, but 
dependently from PU.1 and seem to skip the monocytic intermediate stage, typical of BMDMs. 
These cells will eventually specifically give rise to some of the skin, kidneys, spleen, brain, 
pancreas and lung tissue macrophages [17]. After the onset of yolk derived macrophages, 
monocytic precursors in the liver start differentiating into adult CD11b, F4/80, CSFR1 and LY6C 
expressing Mo through a MYB dependent process, and are then released and migrate to the fetal 
tissues, proliferate, and differentiate in tissue macrophages [16, 22, 49].  
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Fig. 3. Embryonic macrophage development. From embryonic day 8.5–9.0 (E8.5–E9.0) the 
primitive  macrophages arise from  hematopoietic progenitors within the yolk sac, colonizing the 
embryo as soon as a circulatory system is established, around E9.0–E10.0, originating the fetal 
primitive macrophages. Simultaneously, from E10.5 definitive hematopoiesis takes place in the 
aorta–gonads– mesonephros (AGM) generating hematopoietic stem cells (HSCs) with multi-lineage 
potential. Monocytes begin to develop in the fetal liver around E11.5–E12.5 and subsequently  
(E12.5–E13.5) transfer into the blood. invading embryonic tissues about  E13.5–E14.5, following  
yolk sac macrophage colonization. It is still not clear to which extent yolk sac progenitors 
contribute to the development of fetal liver hematopoiesis, but that seems to occur around E8.5 
(dashed arrow). The origin of resting macrophages can substantially differ among tissues. Taken 
from Ghinoux. Nat. Rev. 2014. 
 
Up to date, it is still not clear which is the actual percentage of tissue macrophages derives from the 
embryonic hematopoiesis or is replenished from the bone marrow derived monocytes. 
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1.1.3. Macrophages polarization and function 
 
Macrophages are extraordinarily plastic cells capable to adapt to several microenvironments 
assuming a range of different phenotypes, getting activated upon disruption of tissue homeostasis 
by infection, inflammation or trauma. As components of the immune system, macrophages patrol 
all tissues, in areas close to epithelial surfaces. Through a bunch of pattern recognition receptors 
(PRR) expressed on their surface, are able to recognize conserved motifs (PAMP) on the 
microorganism membrane, engulfing them within the phagosomal compartment and subsequently 
getting rid of them through lysosomal degradation [5, 10]. Recognition of the antigen leads to the 
secretion of cytokines, capable of recruiting mediators of the adaptive immunity, mainly neutrophils 
and T leukocytes, contrasting the infection [50-52]. 
During the recovery from derived inflammation, the tissue resident macrophages initiate a 
resolution phase,  throughout which  debris and apoptotic cells are cleared and homeostasis restored 
[53, 54]. 
However, anomalous macrophage activation can result in chronic inflammatory conditions, 
including atherosclerosis and rheumatoid arthritis, as well as malignant disease [55-57].  
Indeed, depending on the cues they are exposed to, macrophages can polarize towards two main 
phenotypes: “classically activated” M1 and “alternatively activated” M2 macrophages.  
M1 macrophages originates following in vitro stimulation with NK, interferon gamma (IFN-γ) 
alone or combined with TLR ligands (LPS) (M1a), and PAMPs (M1b) [58] via STAT1 and IRF5 
transcription factors activity [59, 60]. The main feature of this group of macrophages is the 
production of pro-inflammatory cytokines and the improved  ability in bacteria, protozoa and 
viruses killing and mediation of anti-tumor immunity [61]. They mainly secrete reactive oxygen and 
nitrogen intermediates via the inducible nitric oxide synthase (iNOS), involved in microbicide 
process [61], together with pro-inflammatory cytokines and chemokines, like TNFα, IL-6, IL-1β 
and IL-12, CCL2, CCL5 and CXCL8, [62, 63] and express genes for co-stimulatory molecules like 
CD80 and CD86 required for antigen presentation Two families of GTPases dominate the complex 
cellular response [64]. They are usually active in early phases of damage, when can promote cell 
cycle arrest and apoptosis of the surrounding cells, destroying intracellular microorganisms and 
acting as antigen presenting cells boosting the innate immune response [65]. The fate of these pro-
inflammatory populations following resolution is still not clear, although it has been suggested their 
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exit through lymphatic [66-68] as well as their Fas-mediated cell death [69]. Also the hypothesis of 
an in situ conversion in tissue-resident is not to be excluded [70]. 
 
Opposite to M1, alternatively activated M2 macrophages show anti-inflammatory phenotype and 
are found in parasitic infection, allergy, tissue remodeling and waste elimination processes 
following the acute phase inflammation, and respond to exposure to IL-4 and IL-13 via IRF4, 
STAT6 and PPARɣ transcription factors [71, 72]. M2 macrophages display up regulation 
of  arginase 1 (Arg1), blocking iNOS activity and therefore inhibiting NO production, secrete anti-
inflammatory cytokines like  IL-10, TGF-β, IL-4, IL-19, VDGF, PDGF and IL-20 crucial for 
inflammation resolution and are characterized by the overexpression of Yim1/2 and CD206 whereas 
inflammatory cytokines are down-regulated [73]. Macrophages stimulated with IL-4 and IL-13 are 
referred as M2a, those responding to LPS and immune complexes as M2b and those stimulated with 
IL-10, TGF-β or glucocorticoids as M2c [74]   
In line with their involvement with TH2-mediated immune responses, M2 can also produce CCR3 
and CCR4 ligands CCL22, CCL17, and CCL24 [75-77]. Based on the pivotal role they cover in 
homeostasis maintenance and their IL4 dependent ability of self-renewal, tissue resident 
macrophages are generally considered M2-like macrophages [74, 78].  
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Fig.4. Regulation of inflammation and wound healing by different MQ phenotypes: Once 
damage occurs, the pro-inflammatory mediators which are released recruit leukocyte within the site 
of injury. Herein, the monocyte into M1 due to the IFNɣ produced by NK, neutrophils ecc. The 
main role of these M1 macrophages is the production of ROS, NO, TNFa as well as 
metalloproteinases to degrade the extracellular matrix, supporting the further recruitment of 
leukocytes and mediators of inflammation. The tissue damage that results from this activation leads 
to the production of IL33 and IL25 from the epithelial cells, which promotes M2 accumulation, 
supporting fibrosis initiation and wound healing through the secretion of growth factors and anti-
inflammatory cytokines. Taken from Murray, Nat.Rev. 2011. 
 
 
The preservation of this delicate M1/M2  balance seems to involve distinct mechanisms. Indeed is 
thought M1 are originate from circulating blood monocytes, whereas M2 macrophages are more 
likely being  maintained by self-renewal, a process mainly dependent on IL4 [79]. 
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1.1.4. Regulatory macrophages 
 
The idea of a strict functional classification of macrophage phenotype is more likely representing a 
simplified version of a more complex scenario, which covers a much wider spectrum of different 
polarization stages [1]. 
A perfectly matching example of this variety is given by regulatory macrophages, which share 
common features with both pro and anti-inflammatory subsets. Indeed, this type of cells display 
high expression of CD206 and CD163 markers and secrete abundant IL10 and no IL12 or TNF. 
However, they show high phagocytic activity and up-regulate MHC-II and others co-stimulatory 
molecules which may support interaction with lymphocytes [6]. Although the specific milieu 
required for the development of these cells has not been determined yet, it has been demonstrated 
that it depends at least in part on IL10, GC and TGFβ [80, 81] and, interestingly, immune 
complexes via FcR mediated signaling induced by TLR ligands [82]. This type of macrophages are 
constitutively found in uterus and placenta and represent the main  subtype in tumors [83, 84]. 
 
 
 
Figure. 5. Regulatory macrophages. Typical features of M2-like regulatory MQ. 
 
1.1.5. Tumor associated macrophages 
 
Macrophages infiltrating solid cancers can constitute up to 50% of the entire tumor mass, being  the 
most abundant immune population in the tumor [5] TAM are thought to arise from blood 
monocytes, and move within the tumor, attracted by several factors, such as CCL2, IL3 and CSF. 
This latter especially correlates with poor prognosis [85-88]. Herein  they can enhance metastasis 
supporting tumor progression [89]. Indeed, TAMs exhibit a typical M2 signature due to the absence 
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of pro-inflammatory stimuli within the mass which instead produces IL10, preventing the 
differentiation of DCs from monocytes and suppressing T cells activation [90, 91]. In fact they have 
been shown attracting Tregs upon release of CCL22, CCL17 and CCL18 [92, 93]. Moreover these 
cells produce neither NO nor inflammatory cytokines because of a defect in iNOS expression and 
Nf-kB activation respectively, but at the same time they up-regulate a variety of M2 genes, 
promoting angiogenesis, remodeling and repair, confirming their role as anti-inflammatory and 
suppressors of adaptive immunity-macrophages [94]. Indeed, TAMs are able to secrete mediators 
such as PDGF, TGF and VEGF which once released through the lymphatic stream support ex novo 
lymph angiogenesis and metastasis [95, 96]. Additionally, vascularization can also be promoted by 
TAMs through the secretion of chemokines like CCL2, CCL5, CXCL1, CXCL8, CXCL12 [97, 98] 
and it’s likely to be a consequence of the preferential localization of these macrophages in highly 
hypoxic areas of the tumor [99]. In turn, the production of some of these factors (particularly CCL5 
and VEGF) can lead to the activation of metalloproteinases like MMP9 capable of  disrupting the 
extracellular matrix once released, resulting in an increased invasiveness and metastatic potential 
[100, 101].   
For several tumor types, with the exception of some stomach and colorectal tumors [102, 103],  it 
has been proven that  the higher the TAMs infiltration, the poorer the prognosis [104, 105] and this 
evidence was also supported by experimental approaches including macrophages depletion and 
overexpression. 
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Fig.6. The role of TAMs in tumor development. The mediators produced by the tumor contribute 
in creating a microenvironment suitable for the differentiation of blood monocytes into tumor-
associated macrophages (TAM), which promote tumor growth and metastasis, impairing matrix 
deposition, remodeling and vascularization. 
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1.2. The tetraspanin family of proteins 
 
The tetraspanin (Tspan) family  includes thirty-three highly hydrophobic small (20-50 kDa) 
membrane glycoproteins  named by their structural characteristic of displaying four transmembrane 
domains, short cytoplasmic  N- and C-terminals, and two extracellular (EC) loops [106]. Their 
expression ranges from sponges to mammals, with each organism expressing a huge number of this 
family members [107]. Their involvement in several biological pathways such as cell signaling, 
adhesion, migration, proliferation, tumor metastasis, tissue differentiation, angiogenesis, cell-cell 
fusion [108-111] allocates them an essential biological role.  
Phylogenetic suggest the existence of sub-groups of tetraspanins based on the structural homology 
of their large extracellular loop (EC2) [112]. Establishing lateral interactions with several partners 
including integrins, C-type lectins, immunoglobulins and G-coupled receptors, tetraspanins can 
reorganize the plasma membrane generating characteristic tetraspanin-enriched microdomains 
(TEM) able to modulate a variety of processes [108, 109, 113, 114]  
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Fig.7. A phylogenetic tree of human tetraspanins Human tetraspanin amino-acid sequences were 
aligned and a phyologram was prepared using the ClustalW alignment program 
(www.ebi.ac.uk/custalw) to determine similarity between superfamily members. 
 
1.2.1. Tetraspanins structural characteristics   
 
The common features of tetraspanins family members are the presence of four transmembrane 
domains, a small extracellular loop (SEL), a large extracellular loop characterized by a conserved 
CCG motif and two or more Cys residues forming  a disulphide bond (LEL) and cytoplasmic 
amino- (NH2) and carboxy-termini (COOH) [112, 115].  
Min and colleagues  solved the tetraspanins crystal structure, revealing the folding of the EC2 on 
EC1 [116]. 
All the transmembrane domains except the second comprise a polar amino-acid with unknown 
function [109] and  membrane-proximal Cys residues undergoing  palmitoylation, essential for 
interactions between Tspan and mutations within these residues for some members led to 
diminished lateral associations  [117-119], although primary interactions are not influenced  by 
altered palmitoylation sites [113]. This post-translational modification seems to occur thanks to the 
palmitate transferase, DHHC2 localized within  the TEMs and its activity is crucial for Tspan 
interactions [120]. 
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Fig.8. The tetraspanin structure. The proteins share four transmembrane  (TM) helices (labelled 
1–4), one large extracellular loop of about 70–130 aa connecting TM3 and TM4 with a conserved 
helical region and a variable region (dark red) and a small extracellular loop (13–30 aa) linking 
TM1 and TM2. Tetraspanins typically present short N- and C-terminal cytoplasmic tails (6–19 aa) 
as well as a small inner loop (about 4 aa). Palmitoylation of membrane-proximal Cys (orange lines) 
allows  associations with other proteins within TEMs. Taken from Hemler, 2014 
 
1.2.1.1. The extracellular loops 
 
All is known about the small extracellular loop is that it seems to serve as a foothold for the large 
extracellular loop  [109], which is required for all the interactions involving these proteins and as 
already mentioned, its folding pattern represents a signature of the different Tspan subgroups. 
Moreover it shows a discrete variability among different members, suggesting it may be responsible 
for the different roles displayed by Tspan  in different cell types  [121].  
The LEL is  characterized by a constant region with  three α-helices named A, B and E and a 
variable region which allows interactions and can exhibit from one to three N-linked glycosylation 
sites, with the exception of CD81, which is not glycosylated at all [108, 109]. The levels of  
glycosylation within this region depend on cell type and tissue in which Tspan are expressed. 
 
1.2.1.2. The intracellular C and N- termini 
 
As anticipated before, both the termini in Tspan are cytoplasmic and although in the majority of the 
cases  a role hasn’t been described these regions,  a function has been attributed to CD63 C-
terminal. In fact, in some species,   the Tyr-based lysosomal targeting motif (G-Y-E-V-M) interacts 
with adaptor-protein-2 (AP-2) and AP-3 supporting  clathrin-mediated endocytic processes, and a 
similar motif can be found also in other members, such as CD82, CD151 and CD37 [113]. CD63 C-
terminal can also directly  interact with the PDZ domain-containing protein syntenin-1, being 
negatively regulate by it  in terms of internalization [122].  
Other proteins which demonstrated interact with Tspan at the C-terminal level are small G-proteins, 
phosphatidylinositol 4-kinase and protein kinase Cα [114, 123]. The role of the N-terminus has 
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been described only  with regard to ubiquitination, a modification that seems to take place in some 
Tspans at the level of N-terminal Lys residues, inducing their proteosomal degradation [124].   
 
1.2.1.3. Tetraspanin-enriched microdomains 
 
Tetraspanins are often referred as “web”, rather than single molecules, since they frequently 
localize within complexes where they develop self-associations and interactions with other 
membrane molecules [110] which may vary, depending on the biological environment [125]. These 
cell type specific platforms are commonly stated as tetraspanin-enriched microdomains and have 
been shown perform  as surface membrane  adaptors by modifying the availability of other 
receptors to signal.  
 
1.2.1.4. Tetraspanin-enriched microdomains vs lipid rafts 
 
The biological membrane presents several compartments made of glycerol-phospholipids, 
sphingolipids, cholesterol and proteins serving  as signaling platforms [126, 127]. The strong 
interaction of sphingolipids with each another and cholesterol leads to the isolation of these lipids 
into disconnected but highly organized membrane structures characterized by a gel-like phase, 
which differs from the rest of the fluid phase phospholipidic membrane [128]. These organized 
microdomains have been termed lipid rafts, and cover a key role during the activation of some cell 
types, particularly monocytes and macrophages [129-131]. 
Tetraspanin-enriched microdomains differ from lipid rafts basically in the composition of the 
compartments and in the fact that TEMs are not affected by temperature or cholesterol depletion but 
can be solubilized  by non-ionic detergents [127, 132]. So far only CD81 has been shown to 
translocate in lipid rafts upon binding of BCR and CD19/CD21/CD81 co-receptor complex[133] 
[134]. 
  
1.2.2.Tetraspanin interactions 
  
The potential tetraspanins partners range from adhesion molecules, membrane receptors, to signal 
transduction molecules [135].   
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These types of interactions may occur at three different levels, based on their strength and resistance 
to detergent disruption [108, 109]. 
The primary one is direct and preserved under stringent conditions (Triton X-100) and are stable 
upon  covalent cross-linking [108, 109, 114]. An example for this association is  the partnership 
CD151/ integrin α3β1 [136]. 
Secondary ones require a first interaction with others Tspan and can only resist in mild detergents 
(Brij97) [137]. 
Tertiary associations take place within large complexes and are only stable in very weak detergents 
such as CHAPS and Brij58 [108, 109].  
 
1.2.2.1. Interactions with integrins 
 
Integrins are transmembrane receptors that regulate a number of processes, from  adhesion to 
motility, angiogenesis  and invasion [138, 139]. 
 The main integrins associated with Tspan contain the β1 chain, generally combined with α3, α4 or 
α6 and only sporadically  α2 and α5 [123]. The β1 chain signals through the integrin-linked kinase  
(ILK), permitting  the connection with the extracellular matrix [140, 141]. 
Although the Tspan- integrins complex has a low affinity conformation, tetraspanins can affect the 
signaling mediated by integrins following binding of the ligand modifying actin polymerization, 
therefore affecting  migration and cell adhesion processes.  
The Tspan CD151 is expressed on epithelial and endothelial cells, Schwann cells, muscle cells, 
megakaryocytes and platelets [142] and by far represents the only direct interaction of a Tspan with 
an integrin [143] and was demonstrated affecting integrin-dependent adhesion and motility [144, 
145]. Mice lacking CD151  display a decreased  angiogenesis because of  altered integrin signaling 
and missing association with TEM [146]. CD151 interacts with  integrins α3β1 and α6β1 through a 
QRD (194-196) motif in the large extracellular loop [136] but also its cytoplasmic domain seems to 
play a role in the integrins internalization [147].  
The importance of this interaction is reflected also in clinic, since three patients baring a mutated 
form of CD151 lacking the large extracellular loop displayed  pretibial epidermolysis bullosa, and 
end-stage hereditary nephritis, confirming the pivotal role of  CD151-α3β1 and CD151-α6β1 
interactions  in the normal arrangement of the epidermal basement [148-150]. 
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1.2.2.2. Interactions with growth factors 
 
The only Tspan members reported to interact with this class of receptors are CD9 and CD82. 
The first one has been described  networking with the heparin-binding EGF-like growth factor 
tyrosine-kinase receptor (HB-EGF) and hepatocyte growth factor receptor (c-Met/HGF-R ) [151] 
implicated in epithelial-mesenchymal transition [152] and with the epithelial cell adhesion molecule 
(Ep-CAM) [114]. 
CD82 also has been shown to cooperate with c-Met activating a signaling via integrins, and this 
activation can be inhibited by the proximity of the ganglioside GM2 [153, 154] and can couple with 
EGFR, altering its activity and endocytosis depending on the Tspan expression level [109, 113]. 
CD82 tyrosine-based sorting motif (Y-S-K-V) in its C-terminal is responsible of its internalization 
of CD82 [113]. 
 
1.2.2.3. Interactions with membrane proteins 
 
The evidences of a crosstalk between Tspan and members of the HLA family (both II and I) 
suggests they might also be involved in the process of antigen presentation [151] [155]. 
CD9 was found supporting T cell activation interacting with HLA II on DC [156], while CD53, 
CD37 and CD81 seem to preferentially interact with MHC class I [157].  
Always CD81 together with CD82was able to interact also with the co-stimulatory molecules CD4 
and CD8 on T lymphocytes [158].   
 
1.2.3. Tetraspanins  signaling and functions 
 
It is well known that Tspan interact with a number of signaling molecules. However, considering 
they don’t resemble receptor proteins and up to date no ligands have been described for any of the 
members, it sounds unlikely Tspan can activate their own signaling cascade. More likely, they seem 
to both directly and indirectly regulate the signaling activity of their partners in the web [135] 
The use of monoclonal antibodies targeting Tspan led to several effects, such as calcium 
mobilization [159], direct interaction with type II phosphatidylinositol 4-kinase (PI 4K) [132, 160], 
protein kinase C activation and  integrin α3 phosphorylation [161-163], c-jun NH2-terminal kinase 
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(JNK) and c-Jun dependent transcription activation [164, 165], ERK1 and ERK2 induced 
proliferation [164], Dectin-1 mediated IL6 production down-regulation [166].  
 
1.2.3.1. Tetraspanins and immune system 
 
Although the function of most Tspan  has not been discovered yet , few exceptions shaded a light  
on their  role in a number of  immunological contexts.  
 
 
1.2.3.1.1. CD81 and BCR signaling 
 
The efforts to discover the role of CD81 revealed its involvement in a huge number of physiological 
processes, particularly regarding B and T cells signaling [167]. CD81 has been shown to interact 
with the BCR, enhancing its  signaling activity by decreasing the amount of Ag required for B-cell 
activation. [110][161].  Its role depends on the association with the CD19/CD21complex at the level 
of the lipid rafts compartments, at the B cells surface, where the BCR is sequestered and enabled to 
get in touch with key signaling molecules [133, 134].  the absence of CD81 indeed results in the 
non-re-localization of the complex within the rafts, and an impaired trafficking of CD19 to the 
membrane [133, 168].  
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Fig.9. Crosstalk between BCR and CD81. Recognition of the antigen by BCR and CD21 results 
in  in the palmitoylation of CD81 (b) stabilizing the complexes within the detergent-resistant 
micro domains (DRMs) (c), activating the signaling (d).  
The process is reversible, depending on the palmitoylation state (e). From Levy and Shoham, 2005. 
 
1.2.3.1.2. T-cells hyperproliferation in Tspan KO 
  
Several studies performed on different Tspan KO CD151, CD81, and CD37 concurred with 
evidences  of T lymphocytes hyperproliferation  upon TCR activation by anti CD3 antibodies. [169-
173]. 
This suggest Tspan may act as negative regulators of TCR signaling, either separating it  from 
activator kinases or associating it with inhibitory phosphatases within the TEMs, thus preventing 
the phosphorylation of the TCR ITAM and the cascade through Zap-70/Syk [174, 175]. 
 
 
1.2.3.2. Tetraspanins and infectious disease 
 
 1.2.3.2.1. HIV-1 
 
The human immunodeficiency virus-1 (HIV-1) infection  as well as the virus release occur  in 
macrophages, DC, epithelial  and T cells through the binding of  TEMs characterized by the 
presence of  CD63, CD9, CD81and CD82 [176]. After the virus was found trafficking through the 
endocytic system, CD63 became matter of study, and resulted  incorporated in the virions after the 
virus exits the host cell via late endosome-multivescicular bodies. However, the infectivity of the 
virus seems not to be impaired in  macrophages lacking CD63 [177] although a reduction in its 
expression results in a diminished viral particles output [178]. The same reduction in HIV release 
was found in the absence of CD81 in Molt T cells [179]. It definitely seems that tetraspanins may 
affect the virus accessibility and  infectivity in some cell types, although the process  may be 
supported by the cooperation with other molecules, and so far, they are unlikely to act as budding 
cofactors.   
Tetraspanins  rather seem to interfere with the fusogenicity of the virions, since it has been 
demonstrated that the incorporation of some of them (CD9, CD82, CD81, CD63, CD231) reduce 
26 
 
the Env induced membrane fusion, which would explain their down-regulation in chronically 
infected T cells [180]. 
 
1.2.3.2.2. HCV 
 
CD81, together with occluding and claudin1,  represents a co-receptor for Hepatitis C virus (HCV) 
and it has been acknowledged as one of the only two Tspan capable of directly interact in trans with 
a molecule (HCV envelope glycoprotein E2)  located on the surface of another cell [181, 182]. 
When missing, HCV infectivity drops, although is not totally abolished,  probably because of the 
viral particle is not able to bind the host cell with the same efficiency [183]. Opposite to HIV, 
infection of HCV does not require CD81 being localized within the TEMs compartments [184]. 
 
 
 
 
 
 
Fig.10. Function of CD81 in HCV. The dual recognition of HCV- E2 by BCR and CD81 prompts 
comparable effects as  those described above for opsonized antigens.  
 
 
 
27 
 
1.2.3.3. CD9, CD81 and oocyte fertilization  
 
CD9 has been shown playing a fundamental role in  reproductive biology. The absence of CD9 
leads to a dramatic change in the oocytes morphology and membrane proteins distribution,  that 
prevents their fusion with sperm  [185-188]. Recent data from CD81 KO mice revealed its 
involvement in sperm-egg fusion [189] and on the other hand, its over-expression restores fertility 
in CD9 KO eggs [190]. The high (45%) identity between these members may explain this 
compensatory effect.  
 
 
1.2.3.4. Tetraspanins and  cancer 
 
Most of the information about  tetraspanins expression derive from microarray data of human 
cancer samples and delineates recurrent patterns of Tspan expressions, allowing the identification of 
subgroups in diverse malignances. 
The very first evidences of Tspan as tumoral stage markers comes from B cells tumors, such as 
lymphomas and leukemia. 
Herein, the high expression of CD37 and CD53 or CD9 and CD81 correlates with lymphomas and 
mature-B cells leukemia or acute lymphocytic leukemia and clonal plasma cells, respectively and 
these differences permit the discrimination of different lymphomas in an single patient [191].  
A great peripheral blood and lymph node infiltration has been shown correlating with high 
positivity for CD53, known to protect the memory and mature lymphocytes  from apoptosis [164].  
In contrast, a higher bone marrow involvement has been associated with a lowered CD9 expression 
[192].  
 
These patterns of expression also recurred in other types of cancer other than B cell malignances, 
such as kidney cancer [193], and melanomas [194]. 
CD9 loss results in higher motility and metastatic capacity of melanomas [194], ovarian [195] lung 
[196], oral squamous cell [197], esophageal [198], cervical [199], and gastric [200]  carcinomas. Its 
association with TGFα leads to the induction of EGFR and cellular proliferation [201].  
CD63 was identified in melanomas and breast carcinomas, where its expression inversely relates 
with metastatic potential [202, 203]. 
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CD82 is up regulated in thyroid benign tumors but down regulated in carcinomas and almost absent 
in metastasis [204]. 
CD151 is mainly localized at the basal level of endothelial cells, [205] and up regulated in estrogen 
receptor 
 
negative tumors and breast cancer, where it correlates with high grade [137]. In this latter, 
CD151 together with CD9 and CD81 has been demonstrated to promote adhesion interacting 
transiently with the substrate before the formation of lamellipodia from the cell [206].  
 
 
 
 
 
Fig.11. Role of CD151 in tumor extravasation and invasion. CD151 induces MMP9 activation 
promoting matrix remodeling. The recruitment and rapid turnover of laminin-binding integrins from 
CD151 through exosomes  impairs the adhesion process. From Zoeller, Nature, 2009. 
 
These structures are in proximity with substrates of PKC, thus regulate migration through 
cytoskeleton reorganization [205]. In the skin, CD151 associates with laminin 5 [151, 207] 
contributing to the formation of hemi desmosomes [208]. Moreover, CD151 overexpression 
enhances motility, and metalloproteinase MMP-9 [209] while its knock-down results in motility 
loss in primary melanocytes [210], clearly implicating CD151 in the regulation of cell adhesion and 
tumor metastatization [211]. Also different types of prostate carcinomas show diverse expressions 
of CD151, CD9 and CD53 [212]. 
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1.3. MS4A protein family 
 
The membrane-spanning 4-domain, subfamily A (MS4A) includes highly hydrophobic proteins 
with four putative transmembrane domains with an overall amino acidic identity of 25-40%, that  
comprises at least 26 members in mouse and humans [7, 213]. 
The overall domain organization is consistent among the members, both at the transcript and at the 
protein level  with few exceptions, and they all include splice variants, usually generating truncated 
forms. All the boundaries exon/intron/exon show consensus splice-donor and –acceptor sequences, 
with recurrent exon/GTGAGT-intron-CAG/exon sequences [214]. 
These proteins share the secondary structure with tetraspanins although they present a different 
primary backbone [135].  Despite the noteworthy conservation of the first two transmembrane 
domains (VLGAIQIL sequence in the first transmembrane domain and GYPFWG in the second), 
the hydrophilic N- and C-termini (although in all the members they result rich in Pro residues) and 
the fourth transmembrane domains, probably the one involved in the interaction with other proteins, 
these molecules exhibit a higher degree of dissimilarity [215]. 
 
 
 
Fig. 12. Phylogenetic analysis for  MS4A family members. Tree construction performed 
following Higgins' method (Higgins et al., 1992). The percentages refer to the degree of identities. 
Adapted from Ishibashi, Gene, 2001. 
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The short intracellular loops between second and third transmembrane domains are also conserved 
and include phosphorylation sites for protein kinase A and C, covering  a hypothetical role in cell 
signaling. 
The members of this family are typically found in lymphoid tissues such as intestines, spleen and 
thymus and most of them are expressed in lymphoid and hematopoietic cells, therefore likely to 
play a relevant role in immune system although some clones do also exist in non-lymphoid tissues. 
At present, all the genes belonging to the MS4A family are linked on a 600Kb region on 
chromosome 11q12-13 in human and on chromosome 19 in mouse [216, 217], suggesting a cluster 
of related genes evolved from recent duplication events.  
 
 
 
 
Fig. 13. Structural organization of the human MS4A gene cluster on Chromosome 11q12. 
From Yinghua Liang, Immunogenetics (2001)  
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Most of the MS4A proteins are encoded by six exons except for MS4A2, MS4A5, and MS4A6E. 
The cytoplasmic N-terminal of MS4A2 is encoded by two exons, while MS4A5 and MS4A6E 
proteins lack in the  C-terminal domain. Moreover, the latter  exhibits  only two transmembrane 
domains, making it the smallest MS4A member (5060 bp). On the other hand,  MS4A4E results the 
longest gene with its 23,379 bp  [218]. 
Chromosome 11q13 is a genomic region linked to atopy and allergic disease, with nucleotide 
sequence polymorphisms in MS4A2 and MS4A3 correlating with disease susceptibility [219-222]. 
Whether sequence polymorphism recognized in the MS4A2 and MS4A6A genes equally combine 
with allergic disease hasn’t  yet been established [223, 224]. 
The same polymorphisms within Chr 11q12 are also recurrently found in some cancers such as 
renal oncocytomas [225], lung cancers [226, 227], ovarian tumors [228], and atopic allergies [220]. 
By the way only one mutation seems not to be enough to determine the onset of the disease. 
 
 
 
 
 
Fig.14.  Expression profile of  MS4A clones  by northern blot.  +++, highly expressed;++, 
moderately expressed; +, weakly expressed; +, very weakly expressed; -, not expressed; nt, not 
tested. From: Ishibashi, Gene, 2001 
 
The most well-known MS4A genes are MS4A1 (CD20), MS4A2 ( FcεRIβ) and MS4A3 (HTm4), 
although recently several new members have been described [229-231]. Despite the homology in 
structure and sequence, MS4A proteins present different regulation at the transcriptional level  and 
their functional properties may change within different cell types.  
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1.3.1. CD20/MS4A1 
 
CD20 is an activated-glycosylated phosphoprotein with a molecular weight of 35 kDa, long N- and 
C-terminal ends placed within the cytoplasm. It was first described by Tedder and Engel in 1994 as 
a  B-cell precursors and mature B cells specific marker  involved in the signaling and cell cycle 
progression of these lymphocytes [232].  
Its overexpression in fibroblasts resulted in the formation of a homo- or probably heterotetrameric 
receptor complex behaving as a Ca
++
 permeable-ligand independent-cation channel. It seems to 
constitutively co-localize with the B cell receptor, dissociating from it once this latter is engaged by 
its ligand [233-235]. CD20 oligomerization occurs within specific plasma membrane domains, 
called lipid rafts, promoting Ca++ conductance and the progression of the cell cycle and eventually 
apoptosis, once the molecule is activated. 
Several works speculated the CD20 membership to a wider transmembrane complex that includes 
BCR and CD40 [236-239]. These two proteins seem in fact to activate and down-regulate CD20 
respectively, with a mechanism that involves CD20 internalization [238, 239]. 
Since its expression is found from late pro-B cells to memory cells, but neither on early pro-B cells 
nor plasma blasts and plasma cells [233], mAb against CD20, in first place Rituximab, represent 
one of the most effective passive immunotherapeutic drugs for the cure of B-cell lymphomas, 
autoimmune disease [240, 241] and non-Hodgkin’s lymphoma [242-244].  
In the attempt to search co-expression and potential association of CD20 with other MS4A 
members in order to find  some alternative targets for therapy, 
MS4A4A, MS4A6A, MS4A7, MS4A8B and TMEM176A and TMEM176b expression was 
analyzed  in B cell lines. MS4A4A and MS4A8B and the two TMEM were not detected neither in 
normal nor in B cells lines, while MS46A and MS4A7 were only weakly expressed in terms of 
transcript, but undetectable in terms of proteins, pointing out that CD20 does not form oligomers 
with its cognates MS4A proteins [8].   
 
1.3.2. FcεRIβ/MS4A2  
 
FcεRIβ, together with  an IgE-binding α, β and two γ-chains constitute a tetrameric receptor 
complex [245] generally expressed on cells responsible of allergic responses, like basophils and 
mast cells where mediates interactions with IgE opsonized antigens mediating acute allergic 
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reactions [219, 246]. Although generally present ad a tetramer in humans, the complex may 
occasionally lack in the β-subunit [247, 248]. 
The signaling cascade activated by FcεRI upon ligand biding, leads to the issue of cytoplasmic 
mediators and the secretion of lipid mediators and cytokines. 
The major FcεRI β isoform mediates a strong enhancement of effector cells capability to mount an 
allergic response, while the truncated variant (βT) inhibits the expression of the receptor on the 
surface, dampening this effect and regulating the immune reaction.  
The genomic region baring the β-chain sequence has been described as linked to atopy and 
polymorphisms within this gene are associated with atopic syndromes, making it a putative marker 
for allergic diseases,  although a specific phenotype for this locus hasn’t been described yet.  
 
1.3.3. HTm4/MS4A3 
 
HTm4 is a protein of 214 amino acids, principally localized in the nuclear membrane, which 
.expression has been reported both in lymphoid and myeloid hematopoietic lineages, although it 
seems to be prevalent in basophils, and almost absent in monocytes, granulocytes, CD19+ B cells 
and naïve T cells [249]. The use of polyclonal antibodies revealed its presence in a variety of tissues 
such as hematopoietic cells of human fetal liver, adult lymph nodes, the lymphoblast in the cortical 
thymus, ovary, mammary epithelium, testis, pancreas, prostate, stomach and in the fetal brain 
ventricular zone.  
Kutok and colleagues, in 2005, considered that, given the high expression of the protein in fetal 
hematopoietic cells and in the thymus cortex, which contains the earliest lymphoid precursors, 
HTm4 might play an important role in hemato-lymphoid development. 
Also in some malignancies a weak staining revealed the presence of HTm4, specifically in 
endometrial, ovary, breast and prostate adenocarcinoma, but the meaning of its presence within the 
tumor microenvironment is not clear.  
Interestingly, as well as reported for FCERIβ, the TaqI polymorphisms (RFLP) within its introns 
also seem to correlate with atopic asthma. 
The evidence HTm4 expression levels drop upon late stage differentiation may suggest it may 
contribute to regulation of the  cell proliferation [213] and recent studies indeed  found HTm4 able 
of binding the cyclin-dependent kinase-associated (CDK-associated) phosphatase-CDK2 (KAP-
CDK2) complexes on its C-terminal region, promoting KAP phosphatase activity and determining 
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the cell cycle arrest at the G0/G1 phase. Recently it has been demonstrated how actually regulation 
by HTm4 occurs by interfering with cell cycle progression [250]. 
For what concerns murine models, a sturdy expression has been found in developing brain, with the 
strongest staining within the glial cells and fetal neurons, so called Cajal-Retzius and subplate-like 
cell, reinforcing a preexisting idea of HTm4 involvement in cortical organization [251] 
 
1.3.4. Other MS4A members 
 
 
1.3.4.1. MS4A4A  
 
This member presents an open reading frame containing 205 amino acids that include a consensus 
protein kinase C (PKC) phosphorylation site at the level of the intracellular loop. 
Liang and Tedder found MS4A4A being expressed in colon and small intestine in two bands of 
different sizes in mouse but couldn’t detect any positivity  in the same human samples.  
However, a strong positivity was found within all the human hematopoietic cell lines, which do all 
express the full length transcript, although a second smaller transcript seems also to be expressed 
from the B-cell line BJAB, in which almost half of the cDNA encodes the truncated protein. 
These splice variants generally excise the third  transmembrane-encoding exon, joining the first two 
transmembrane domains with the fourth one, and since this latter is  followed by a hydrophobic 
region barely long enough to pass the membrane [7], alternative splicing within this region may 
generate a protein with four transmembrane domains missing the second extracellular domain. 
Recently, in a gene expression profile study of classically and alternatively activated macrophages, 
MS4A4A was identified as an  IL-4 regulated gene, suggesting a potential role in orchestrating lipid 
metabolism, defense against ROS and basal expression of inflammation associated genes [252]. 
1.3.4.2. MS4A5 
 
The full length MS4A5 is a 200 amino acids protein characterized by a  protein kinase A  
phosphorylation site (KRKTT) in  its intracellular loop. 
The main splice variant is generated from the excision of the third transmembrane domain and the 
second extracellular loop encoding exons causing the fusion of the first/second transmembrane 
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domains with the fourth one and resulting in a three transmembrane domains isoform with an 
extracellular C-terminal. 
This member is mildly expressed in pancreas, heart, brain and testis in humans [213]. 
 
1.3.4.3. MS4A6A 
 
MS4A6A is 178 amino acid long and displays as well a protein kinase A and three protein kinase C  
phosphorylation site (KRLT) within  the intracellular loop.  
A 70 amino acid shorter variant  lacking the fourth transmembrane and cytoplasmic domains 
originates from the alternative splicing of the third transmembrane domain, generating the only 
known MS4A member without a C-terminal.  
Its expression has been found in heart , kidney, and small intestine and  its expression may be linked 
to development since no transcript is visible in human fetus samples [213]. 
 
1.3.4.4. MS4A7 
 
MS4A7 is characterized by 240 amino acids sequence with a n acknowledged protein kinase A and 
four protein kinase C phosphorylation sites (KKSS) at the C-terminal. Currently,  three splice 
variants are known, among which one shares high identity with MS4A6E. 
The expression of this member is restricted to the spleen in human, small intestine and colon in 
mouse [7]. 
 
1.3.4.5. MS4A9  
 
Its ORF has 226 amino acids and includes  a consensus tyrosine phosphorylation site 
(KNVPENVY) at the C-terminal, while the long hydrophilic N-terminal displays three protein 
kinase C phosphorylation sites. Expression was found in thymus, testis, lung, brain, and ovary 
[213]. 
 
1.3.4.6. MS4A10 
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Characterized by 726bp, its gene includes 6 exons with transcripts that result primarily expressed 
during oncogenesis or embryogenesis but are infrequent within normal tissues [213]. 
 
 
1.3.4.7. MS4A11  
 
Its ORF has 247 amino acids with a protein kinase A phosphorylation site (KKMT) and four protein 
kinase C phosphorylation sites at the intracellular loop.  
It IS expressed in colon, thymus, intestine, spleen, lung, heart  and testis [213]. 
 
1.3.5. MS4A in Alzheimer disease 
 
As cell membrane proteins, MS4A members were shown to take part in the regulation of calcium 
signaling, a process strictly connected with neurodegeneration [253]. 
 Alzheimer's disease (AD) is the most common human complex neurodegenerative pathology. 
Because of the constant increase in life expectancy, the incidence of AD is keeping on growing 
[254]. AD  causes a progressive brain neuronal loss, which normally ends up with the death of the 
patient and although its etiology is still not clear, genetic factors seem to play a pivotal role.  
Recently, several variants within the MS4A gene cluster, in particular the 
MS4A4/MS4A6E/MS4A6A locus, have been associated with the disease within recent serial 
genome-wide association studies (GWAS) [255]. 
Common variants located within highly expressed MS4A6A transcripts were significantly 
associated with Alzheimer. Further copies of the protective (minor) allele were associated with 
lower MS4A6A expression of each transcript and in heterozygous subjects, expression of the 
protective allele transcripts was lower. Regardless the genotype, MS4A6A transcripts were 
increased in blood from AD people and they were also widely expressed in tissues and cells. These 
evidences suggest that high levels of MS4A6A in Alzheimer’s disease are detrimental. Inhibiting 
the molecule may therefore promote a more neuroprotective activity, although further work is 
needed to establish whether this is actually the case [256]. 
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1.3.6. MS4A and cancer 
 
The fact most of  MS4A members seem to be involved in cell cycle regulation, implicates they play 
a significant role in tumor development, either promoting cell proliferation and supporting 
carcinogenesis, or acting like a marker of differentiation.  
Their presence has been described on both normal and neoplastic tissues, therefore the 
understanding of their role among different cell types and malignances, may represent a valid tool 
for the therapeutic exploitation of these molecules, as happened for the Rituximab target CD20. 
  
1.3.6.1. MS4A8 
 
MS4A8 ORF’s comprises 268 amino acids but no phosphorylation sites has been found for this 
member. 
Its putative function was first described in a murine model of malignant melanoma within a subset 
of tumor associated macrophages (TAMs) profiled as stabilin1-lyve1 f480 positive cells, induced by 
IL4, GC and tumor conditioned medium and regulated by an integration of the p38 MAPK and the 
glucocorticoid receptor (GR) pathways, therefore acknowledged as a marker of macrophage 
alternative polarization. Indeed, when transfected with the murine sequence for MS4A8B (Ms4a8a),  
RAW264.7 cells showed both up-regulation of the M2 marker arginase I (argI)  and a specific gene 
signature characterized by Tcfec, spink5, sla and sorl1, active in immune regulation. In the same 
study Ms4a8a+ RAW264.7 cells turned out supporting the tumor growth when transplanted in vivo, 
opposite to what happened with the transplantation of the same cells transfected with the control 
plasmid [229]. 
One year later, Michel et al. defined its expression as not restricted to hematopoietic cells, but 
extended in differentiated intestinal epithelium. Interestingly, MS4A8 expression was not detected 
in colon carcinoma and when overexpressed in carcinoma cell lines it led to a reduction in 
proliferation and migration rate and an overexpression of the intestinal differentiation marker 
cytokeratin 20, making MS4A8 a differentiation marker for colonic epithelial cells [257] 
Very recently, MS4A8B mRNA was detected by RT-PCR  in 13 types of  human normal and 
cancer  tissues, resulting  over-expressed specially in prostate cancer. Furthermore, the  
immunohistochemistry  performed for  MS4A8B and PCNA proteins  as diagnosis  index of 
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proliferative activity, revealed a  positive  association of both markers with the tumor severity in 
140 prostate cancer samples [258] 
In vitro, MS4A8B knockdown and overexpression  resulted in G1-S cell cycle arrest or accelerated 
S phase entry, respectively and it  was able to modulate  the expressions of Cyclin D1, Cyclin 
E1 and PCNA.  
Lentiviral infection of pancreatic tumor  cell lines  with sh-MS4A8B caused a reduced growth rate 
of the tumor mass when  injected subcutaneously in mice [258]. 
 
1.3.6.2. MS4A4B 
 
MS4A4B was first described by Venkatamaran in 2000, as selectively expressed in Th1 cells and 
both transcript and protein are down-regulated  during  T-cell differentiation under Th2 conditions 
[215, 259].  
It as well shows a differential expression  during immature thymic development, existing  in naive 
CD4+ and CD8+, NK cells, thymocytes at pre-commitment and at mature stages. It was also 
reported in myelo-monocitic lines, but disappeared upon stimulation with MCSF. 
MS4A4B is negatively regulated by IL4 via STAT6 signaling but  not affected by either  IL-12-  or  
IFN-gamma since its expression was found  in STAT4, STAT1 and INFɣ KO. 
It localizes at the cell  surface within  detergent-resistant membranes and migrates into lipid rafts 
upon activation of naive primary T cells [215]. 
Using it as baits in a yeast split-ubiquitin library screen for T regulatory cells,  MS4A4B has been 
demonstrated to interact with MS4A6B and with GITR, Orai1, and other surface receptors and in, 
more in detail, interaction of MS4A4B with GITR (a negative regulator for  Tregs and activator for 
effector T cells) augments GITR signaling and T cell IL-2 production in response to GITR 
stimulation. 
By making use of this innovative version of the more common yeast two hybrid assay, Howie 
provided  for the first time a process whereby MS4A proteins, may boost Ag signals  through the 
lateral association with co-stimulatory receptors.  
In other words, Ms4a4b enhances the sensitivity of GITR for its ligand, lowering the threshold for 
the amount of antigen needed to trigger  the response [230]. 
By far, MS4A4B expression was never reported in malignant cells. This is consistent with the 
evidence   that it actually works as survival modulator to preclude the overgrowth  of the activated 
cells.   
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Its inhibitory activity towards proliferation occurs by affecting the cell cycle progression enhancing 
the expression of  the cell cycle inhibitor subunits  p16
Ink4a
, p21
Cip1
 and p27
Kip1
, and diminishing 
cyclin A and B and Cdk2 activity and promoting de phosphorylation of Rb with  blockade of  
transcription and cell cycle arrest.  
Also the impact of MS4a4B on the intracellular Ca
++
 production that activates the Ca
2+
/CaM 
signaling pathway leading to the  up-regulation of Camk2a, promoting the transcription of Cdk 
inhibitors has to be taken into account. 
At the same time, the evidence ms4a4b is not expressed in apoptotic cells, points out  the potential 
protective role of  the molecule towards T cells, most likely prolonging their survival [215]. 
The selective expression of Ms4a4b on inflammatory T cells allowed the production of an antibody 
able to target these cells, that was successfully tested in  a model of experimental autoimmune 
encephalomyelitis (EEA) ameliorating the EEA severity, through  the suppression of ms4a4b 
bearing T cells [260]. 
More recently, ms4a4b has been shown to localize within ciliated airway epithelial cells and its loss 
correlates with epithelium loss during severe asthma. Its expression augmented during primary 
bronchial epithelial cells differentiation, decreased during rhinovirus infection, and BEAS cell line 
transfected with it shown inhibition of pro-inflammatory cytokines suggesting an important role in 
the maintenance of airway epithelial cells homeostasis [261]. 
 
1.3.6.3. MS4A12 
 
In contrast to the majority of members of the MS4A family, MS4A12 has never been described in  
cells of the hematopoietic or lymphatic lineage.  
MS4A12 stains specifically the apical membrane of epithelial cells within the colonic crypts and 
has been described as a novel colon-specific gene typically expressed in normal mucosa which is 
thought to support malignant transformation, being part of the store-operated Ca2+ (SOC) channel 
and thus able to promote proliferation and chemotaxis of colon cancer cells by modifying signaling 
through epidermal growth factor receptor (EGFR) [262].  
The rational for this very specific expression was given by Koslowsky, who discovered that  
MS4A12 activity is ruled by a homeobox transcription factor binding element on its promoter that 
recognizes the  intestine-specific endogenous transcription factors CDX2 [263].  
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These findings make MS4A12 suitable for becoming a novel candidate for therapeutic antibodies 
targeting.  
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1.4. C-type lectin receptors 
 
C-type lectin receptors were initially regarded as  proteins that recognize carbohydrates via a 
different fold in a calcium-dependent manner, through a carbohydrate recognition domain (CRD) 
[264]. The C-type lectin receptors family includes over 75 different transcripts of both classical and 
non-classical members, with 17 sub-groups based on the domain structure [264, 265]. ‘Classical’ C-
type lectins like DC-SIGN and langerin associate with the ligand in a calcium-dependent manner, 
while they are considered ‘non classical’ when the binding does not occur in the presence of Ca++ 
and in this case the domain is mentioned as a C-type lectin-like domain (CTLD) [264]. Some 
receptors belonging to this subgroup are dectin-1, CLEC-2 and CLEC9A.  
 
1.4.1. The C-type lectin-like receptors group V 
 
The non-classical C-type lectin-like receptors group V consist in a separate subfamily of proteins, 
(which includes the so called Dectin1 cluster members Dectin-1, CLEC-2, CLEC9A, AICL, CLEC-
1, LOX-1, and MICL) that are expressed in monocyte, dendritic and endothelial cells, in which they 
share the same domain structure, and are encoded within the same region on human chromosome 12 
and  murine chromosome 6 named natural killer (NK) gene complex [266]. These all are type II, 
single-pass transmembrane molecules with a single CTLD activated in a calcium-independent 
manner, a stalk region, a transmembrane region and a cytoplasmic end that usually consists in a 
signaling or internalization sequence consisting in a ITAM-like, ITIM and/or  tri-acidic sequences 
[267-269].  
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 Fig.15. The Dectin-1 cluster. A: The activatory receptors Dectin-1, CLEC-2 and CLEC-9A with 
ITAM-like and DED tri-acidic motifs, (except CLEC-9A).  B: The inhibitory receptors MICL and 
MAH with canonical ITIM motifs. C: CLEC-1 with its uncharacterized DED- Y-based motif  and 
the C-type lectin-like scavenger receptor LOX-1, with a DDL motif.  From Plato et al.2013 
 
1.4.1.1. Dectin-1  
 
Microorganisms display peculiar and highly conserved components on their surface called 
pathogen-associated molecular patterns (PAMP) that can be recognized by specific pattern-
recognition receptors (PRRs), like TLRs and the C-type lectins, expressed on antigen presenting 
cells [270, 271].  
Both human and murine hortologs are primarily expressed on myeloid cells including monocytes, 
DCs, neutrophils and macrophages as well as on some T cells subpopulations [272], human B cells, 
mast cells and eosinophils and, as recently reported, mice microglia [273-275]. Dectin1’s 
expression levels on these cell populations change among different tissues with the sites of 
pathogen entry (e.g. lungs, spleen and gut) showing the greatest levels and playing therefore an 
essential role in the immune responses against pathogens [272, 276]. The main two human isoforms 
are distinctly expressed in different cell types and so occurs  in different mouse strains [277]. 
Cytokines, chemokines or microbial factors can modulate Dectin1 expression [278, 279]. For 
instance, IL10, LPS and dexamethasone cause down-regulation of Dectin1  [278] while IL4, IL13 
and GM-CSF cause Dectin1 expression to be highly up-regulated. Furthermore, the systemic 
provision of both purified β-glucans and Candida albicans increases Dectin1 expression in 
leukocytes, opposite to what happens during polymicrobial sepsis  [279, 280]. It has also been 
proven that glycosylation promotes murine Dectin1 surface expression [281]. 
The importance of Dectin1 in host defense has recently been established by making use of knock 
out mice, which shown an impaired immune response to Pneumocystis carinii [282] and Candida 
albicans [283] fungal infections, although the latter work found Dectin-1 not being essential for the 
defense against Candida albicans, most likely because of the different paths of infection, fungal 
strains used and mice genetic background [284].  
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1.4.1.1. Expression and structure 
 
Dectin1 belongs to the so called dectin1 cluster,  within the natural killer gene complex on human 
chromosome 12 and mouse chromosome 6  [266, 285]. At least two isoforms of murine Dectin1 
exist that encode either the full length or the stalk-less version of the receptor through alternative 
splicing, (fig), therefore presenting differences in the capability to bind β-glucans and promote 
cellular responses [277]. Both these forms are N-glycosylated at two sites at the extracellular level 
[286]. 
 
 
 
Fig. 16. Human and Dectin1 isoforms.  Human (red) and murine (blue) Dectin1 isoforms. All the 
isoforms contain an extracellular CTL domain, a transmembrane domain and a cytoplasmic one. 
Both the murine  forms are N-glycosylated at two sites at the extracellular level (green), while only 
the human full length one presents one glycosylation site. 
 
In humans, eight isoforms derive from alternative splicing, of which only the main two are 
functional for the binding of β-glucan [273] and the major of which lacks the stalk region and has 
no glycosylation sites. The other one contains an N-glycosylation site in its stalk region instead 
[273, 287]. Not much is known about the other minor isoforms, except that one is kept in the 
cytoplasm and shows association with a Ran-binding protein, (RanBP) [288]. The functional 
importance of this interaction is still to be determined.  
As already mentioned, Dectin-1 C-type lectin-like domain has a binding site for β-glucan (which 
W221A/ H223A mutation impairs its binding activity), connected by a stalk to a transmembrane 
domain followed by a short cytoplasmic terminal [286]. Unlike many other lectins, the absence of 
Cys residues in Dectin1 stalk region, suggests it may operate as a monomer, rather than dimerizing.  
The signaling motif  within its cytoplasmic tail consists in a YXXL motif that undergoes 
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phosphorylation of the Tyr residue by Src family kinases, thus promoting signaling cascade through 
the phospholipase C (PLC) γ2 pathway [289, 290].  
 
1.4.1.1.2. The dectin-1 ligand, β-glucan 
 
Although several ligands have been described, Dectin1 is better known for its ability to recognize β-
glucans, polymers of D-glucose, the major component of fungal cell walls. It is indeed estimated 
that more than 50% of the cell wall of Saccharmoyces cerevisiae is made up of β-glucan polymers 
[291]. Some of the Dectin-1 ligands, like Curdlan and Zymosan, are commonly used to explore the 
role of this receptor in in vitro and in vivo. Curdlan is purified from Alcaligenes faecalis and is 
made of polymers of linear glucan, while Zymosan is purified from Saccharmoyces cerevisiae, and 
since it contains mannan, chitin and other proteins, it can activate other receptors besides Dectin-1 
[292]. Dectin1 was initially described as a DC specific receptor that modifies T cell function 
recognizing an unidentified ligand on their surface [293, 294]. It was first acknowledged as a β-
glucans receptor after  a screen of a murine macrophage cDNA expression library with Zymosan 
[295]. Dectin1 specificity for β-glucans was then further tested using oligosaccharides microarray 
technology, confirming that actually the receptor binds β (1-3)-linked oligomers of glucose in a 
metal  ion dependent manner [294] and that at least a branch of heptasaccharides is required for the 
binding to occur [296]. The Ca
++
 dependent mechanism behind this process  is not fully understood 
yet, however at least two residues flanking a superficial groove on the protein surface, Trp221 and 
His 223, have been associated with the binding [286]. and the glucan polymers helical structure 
may itself support this interaction[296]. Thanks to its β-glucan specificity D ectin1 resulted 
recognizing various fungal species including Candida, Pneumocystis, Saccharomyces, Aspergillus, 
Coccidoides and Penicillum [9, 282, 283, 297-302] and, more recently, some members of 
Mycobacterium family [303], although the specific ligand on these microorganisms remains 
unknown [303-305]. Studies on cell lines showed that Dectin1 can also  interact with an 
endogenous ligand on apoptotic cells [306].  
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1.4.1.1.3. Signaling pathways 
 
The interaction between β-glucan and Dectin-1 induces the secretion of several cytokines and 
chemokine, such as IL -6, IL -12,IL-10, IL-23, IL-2, TNFα and CXCL2, regulates ligand uptake via 
phagocytosis and endocytosis and activates the respiratory burst and the synthesis of arachidonic 
acid metabolites [270, 271], covering a fundamental role in managing fungal infections.  
Dectin1 signaling occurs through an short N-terminal  immune-receptor tyrosine-based activation 
(ITAM)-like (also called hemi-ITAM) and tri-acidic [DED] motifs  in its cytoplasmic tail and can 
activate either a Syk dependent , leading to both  canonical and  non-canonical NF-kB activation, or 
a Syk independent signaling pathway (Fig.17). The typical ITAM motif exhibited by all the B cells, 
T cells and Fc receptors, includes a consensus sequence with two tyrosine residues, 10-12 AA apart: 
YxxI/Lx YxxI/L [51, 267, 307-309]. Once the receptor is bound with its ligand, the Tyr are 
phosphorylated  by Src  kinases, allowing Syk kinases recruiting through their SH2 domains [310, 
311]. However, opposite to the more common ITAM receptors where the  phosphorylation of both 
Tyr is  required for Syk engagement, one phosphorylated Tyr is enough for Syk to associate with 
Dectin1, although both SH2 domains are needed [289, 312].  
 
Canonical NF-kB activation 
As demonstrated in DCs challenged with Candida albicans or Zymosan, the association of Dectin1 
with the spleen tyrosine kinase Syk kinase leads to the activation of the phospholipase Cɣ2 (PLCɣ2) 
which in turn results in the recruitment of the caspase-recruitment domain containing protein 
(CARD9), the adaptor protein B-cell lymphoma leukemia 10 (Bcl-10) and the mucosa associated 
lymphoid tissue lymphoma translocation protein 1 (MALT1) complex, that activates the canonical 
p65/c-Rel/NF-κB pathway [313, 314]. CARD9 seems to play an intermediary role in connecting 
Dectin-1 signaling to NF-κB activation and it takes part to the secretion of IL-12 [313, 315]. 
Moreover, mice KO for CARD9 display lower survival rate following Candida albicans infection  
compared to the WT mice [313]. The mechanism by which CARD9 is recruited by PLCɣ2 and 
initiates the downstream cascade seems to involve the PKCδ isoform [316].  
 
Also Dectin1- mediated IFN-β production upon C. albicans infection resulted from Syk/ Card9-
driven signaling but relies on the transcription factor IRF5 recruitment [317]. 
Despite its important role, not all the cellular responses regulated by Dectin1/Syk pathway depend 
on CARD9 (e.g. the MAP kinase ERK) [318]. 
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Non canonical NF-kB activation 
Other than  the canonical one described above, Dectin-1 can mediate a non-canonical NF-kB 
activation pathway exploiting NF-κB-inducing kinase (NIK) through Syk  dependent activation, 
leading to the assembly of p52 dimers and RelB [319].  
 
Syk independent pathway 
Furthermore, a Syk-independent pathway involving Ras and the serine-threonine kinase Raf-1 
activation can be triggered by Dectin-1, integrating with the Syk cascade at the level of NF-kB 
activation. In fact, the Raf-1- phosphorylated p65 generates a p65-RelB dimer, thus isolating RelB, 
preventing its association with DNA, in favor of Raf-1-dependent IL-12p70 as well as many others 
pro-inflammatory cytokines production required for the differentiation of TH1 cells. 
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Fig. 17. Dectin-1 signaling network. Recruitment of  Syk upon interaction with the ligand  
activates PLCγ 2/Ca2+ mediated signaling triggering PKCδ that phosphorylates CARD9-Bcl10-
Malt1 and controls calcineurin/NFAT and ROS/NLRP3 inflammasome. CARD9 complex activates 
NF-κB and c-Rel, promoting transcription. Syk can also initiate a non-canonical NIK pathway, 
mediating  the activation of RelB and p52, which can be however inhibited by the Raf-1-mediated 
pathway that phosphorylates  p65. This can in turn sequestrate RelB, preventing its interaction with 
the NF-κB complex.  
 
 
Dectin1 can also signal via calcineurin/ NFAT through the PLCγ activated by Syk, inducing as 
ultimate effect the expression of IL-2 and IL-10 and  the fate regulation of Tregs and other 
lymphocytes populations [320].   
The complexity of the Dectin1 signaling pathway clearly reflects the importance of this receptor in 
tuning and finely regulating the immune response. 
 
 
Dectin1 is also uniquely able to elicit mediators of adaptive immunity without coupling with TLR, 
resulting for instance in the induction of  Th1 and  Th17 CD4+T cells following C. albicans and M. 
tuberculosis infection of DCs [314, 321]. Moreover it can also switch specific Tregs populations 
into IL17 producing  non Th17/non regulatory  T cells with intermediate phenotype through DCs 
activation (Osorio 2008). Dectin1 has also been implicated , along with TLRs, in the enhanced 
functionality of CD4(+)CD25(+) T regs in Zymosan treated Type 1 Diabetes murine models [322].  
Finally, other than CD4+ cells, Dectin1 antibody mediated targeting can determine CD8+ T cells 
differentiation into cytotoxic T-lymphocyte [323, 324].  
Noteworthy, all the responses mediated by dectin1 turned out being cell-type specific [325, 326].  
 
1.4.1.1.4. Dectin1 and other receptors 
 
Always more evidences have been given, proving that multiple PRRs need to be primed by 
microbes in order to be able to induce an efficient  immune response. Association of Dectin1 with 
MyD88 coupled TLRs is for instance required for a proper induction of the cytokine repertoire 
(especially for TNFα in macrophages), [327], phagocytosis and for  boosting the respiratory burst 
[328, 329] . On the contrary, TNF and IL10 do not require Dectin1-TLRs interaction for being 
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produced in DCs  [314, 328] and in the same cells, the administration of Dectin1’s ligands and/or 
TLR2 ligands  results in the down-regulation of IL12 in favor of a higher expression of IL23, 
orchestrating in this way the Th17 responses [330]. 
Dectin1 can also interact with other pattern recognition receptors, like DC-SIGN , initiating the  
arachidonic acid metabolites pathway in human DCs [331] and promoting the fungal recognition by  
murine macrophages through the mouse hortolog SIGNR1 [332].  
 
1.4.1.1.5. Dectin1 and tetraspanins 
 
Other than PRRs, Dectin1 generates several interactions with tetraspanins within the TEMs located 
within the plasma  membrane [159]. Mantegazza and colleagues beautifully described its 
association with CD63 showing the internalization of both molecules upon  challenging with yeast 
particles by DCs, that was inhibited when  soluble β-glucan  laminarin was added to the cell culture. 
On the other hand, no internalization occur when DCs were given with the mannose receptor 
(MMR) ligand Dextran, indicating the specificity of the interaction during the phagocytic process, 
although  its functional significance hasn’t been elucidated yet [333]. 
Also the leukocyte-specific tetraspanin CD37 seems to interact dectin-1, since CD37 KO 
macrophages  show higher Dectin1 induced IL-6 production despite the reduced dectin-1 surface 
expression and along with these findings, RAW264.7 cells show up-regulation of Dectin1 when 
transfected with CD37 cDNA. Also the co-immunoprecipitation of dectin-1 and CD37 performed 
by the same group in  transfected HEK293T confirmed the former  results [166]. It has been 
speculated that CD37 stabilizes Dectin1 at the membrane level, somehow down-regulating Dectin-1 
signaling. Consecutive to these findings, van Spriel and colleagues confirmed in vivo that CD37 
KO mice are better protected  from Candida albicans infections, as they secrete more IL-6 and 
immunoglobulin (Ig) A compared to WT, [334]. 
 
1.4.1.1.6. Dectin1 and cancer 
 
Being expressed on the surface of several APCs, Dectin1 recently became of significant interest in 
the context  of anti-tumor innate immunity. 
Human breast cancer development is sustained by the production of IL13 from anti-inflammatory 
Th2 cells due to the tumor driven induction of CD134L expression from DCs. In the attempt of 
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reprogramming Th2  into T cells with a pro-inflammatory phenotype (Th1), Wu and colleagues 
demonstrated how targeting the tumor associated DCs with the Dectin1 ligand β-glucan in vivo 
inhibits STAT6 phosphorylation leading to a down-regulation of CD134L. At the same time, the 
activation of Dectin1 by  β-glucan in the presence of breast cancer supernatant, promotes IL12/p70 
secretion expanding Th1 and CD8+CTL populations at the expense of Th2, inducing tumor necrosis 
[335]. 
NK-mediated killing of tumor cells is partially orchestrated by Dectin-1 expressed on DCs and 
macrophages [336, 337]. As previously described, in fact, Dectin1 is able to activate the 
transcription factor IRF5 leading to IFNβ production and thus modulating NK cells responses and 
the receptor is mandatory for the NK tumoricidal activity in vitro, as observed in Dectin1 deficient 
mice. 
Moreover, Dectin1 is capable of directly binding N-glycan structures expressed on the surface of 
malignant melanoma, lung carcinoma, lymphoma and fibrosarcoma cell lines and these cells are 
more vulnerable to Dectin1 dependent-NK cell-mediated killing [338].
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1.4.1.2. CLEC-2 
 
1.4.1.2.1. CLEC-2 expression pattern 
 
CLEC-2 has been initially discovered in a screening for NK receptors, and resulted later on 
expressed  on DCs, monocytes, granulocytes, and especially on platelets [339, 340]. In two out of 
tree splice variants of the murine homolog the transmembrane region is missing, thus confining 
them within the cytoplasm [288, 341] the hemi-ITAM (YxxL) is also present on this member and 
seems to cover a main role in platelets signaling in response to rhodocytin (Suzuki-Inoue et al., 
2006), a component of the venom of the snake Calloselasma rhodostoma, that determines platelet 
activation and blood coagulation [339].  
It has been described that rhodocytin can interact with the collagen binding integrin 
α2β1/GPIb/IX/V complex [342], although mice lacking both the integrin and the GPIb subunit can 
still mount a response to rhodocytin [343], suggesting the presence and activation of another 
receptor on platelets subsequent to rhodocytin stimulation.  
More recently ,CLEC-2 has been found a peripheral blood neutrophils activation receptor 
promoting the secretion of  pro-inflammatory cytokines, particularly TNFα, and phagocytosis of 
Ab-coated beads but without triggering the respiratory burst [344]. 
 
1.4.1.2.2. CLEC-2 structure and signaling 
 
As well as the other members of the CTLR, also CLEC2 requires Syk activation to induce cellular 
responses [312, 339, 345, 346] through  its highly conserved tri acidic DED motif upstream the 
YXXL motif enabling an HemITAM-independent tyrosine-based signaling that, opposite to the 
ITAM-based receptors, is preceded by a Src mediated SH2-Syk binding of the ITAM-like sequence, 
phosphorylating it and leading to its activation [347]. CLEC2 phosphorylation seems to depend 
basically on its association with lipid rafts and, indirectly, on actin polymerization, and induce a 
signaling cascade activated by Rac1 and, subsequently PLCɣ 2 [348]. 
The receptor seems to exist as a dimer as a dimer in resting platelets and switches to larger 
complexes following activation [349, 350] sometimes coupling with TLRs activity upon exposure 
to LPS, also increasing IL10 production in myeloid cells [351]. 
 
51 
 
 
 
 
Fig. 18. ITAM-like-bearing CTLRs within the Dectin-1 cluster. As well as Dectin-1, there are 
two additional receptors that contain ITAM-like motifs. These receptors share Syk as a primary 
downstream signaling kinase; however, the lack of a tri-acidic in CLEC-9A and the presence of 
an isoleucine prevent the endocytic and activation functions of this receptor. CLEC-2 utilizes its 
tri-acidic motif to complement activation through Syk resulting in adhesion and clot formation in 
platelets. Dashed arrows represent a pathway that has yet to be fully defined. 
 
1.4.1.2.3. CLEC-2 in hemostasis and thrombosis 
 
In 2009 May and colleagues demonstrated a fundamental role for CLEC2 in platelets aggregation, 
making use of an antibody mediated depletion of the receptor in vivo, showing how although the 
CLEC-2-deficient platelets exhibited normal adhesion under flow, their ability to coagulate was 
impaired, as resulted from the increased bleeding times and diminished occlusive thrombus 
formation [352] 
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1.4.1.2.4. The CLEC-2 ligand, podoplanin 
 
Another ligand proposed for CLEC2 is the endogenous transmembrane sialoglycoprotein  
podoplanin expressed on type I lung alveolar cells, tumor cells, kidney podocytes and lymphatic 
endothelial cells [353-356]. Podoplanin-induced platelet aggregation depends on Src family kinases 
and PLCγ2, as confirmed by podoplanin expressing-HEK293T cells, which are able to activate 
platelets [312, 339] and to bind CLEC2 expressing cells through a podoplanin mediated recognition 
[355] suggesting a mechanism by which tumor cells may approach and bind platelets to promote 
tumor growth, given the huge number of growth factors produced by these cells.  
 
1.4.1.2.5. CLEC-2 and HIV-1 
 
As well as its cognate molecule DC-SIGN, CLEC-2 seems to promote the binding of HIV-1 both by 
platelets and CLEC-2-transfected cells through its ectodomain [357]. Since the binding seems to 
take place during the viral budding process, it has been postulated the host protein involved in the 
recognition by CLEC2 is actually podoplanin [340]. 
 
 
1.4.1.3. CLEC9A 
 
The  first report about CLEC9A dates back to 2008, when Huysamen first  identified it as  C-type 
lectin-like activation receptor [267].  It shares similar features with the other members of the 
Dectin1 cluster, including multiple splice variants, of which the main one is expressed on 
plasmacytoid dendritic cells where it recognizes its F-actin ligand express indistinctively on the 
surface of all necrotic cells [307, 358-360] priming the activation of CTL [361, 362] via an internal 
cross-presentation pathway, therefore just cross-presenting without inducing cytokine production 
[363]. 
Similarly to Dectin-1 and CLEC-2, CLEC9A signals via Syk through  a YXXL motif within its 
cytoplasmic tail  [267, 307]. A crucial difference is that human CLEC9A has been shown to be 
expressed as a disulphide-linked glycosylated dimers [267].  
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2. AIM OF THE STUDY 
 
This thesis is focused on the characterization of the regulation and function of the tetraspanin like 
molecule MS4A4A in alternatively activated macrophages. 
In the first part we describe the regulation of the molecule by M2 stimuli, particularly GC. 
In the second one we explore its association with tumor associated macrophages in human 
lymphoma samples and we describe the development of a MS4A4A targeting human anti human 
monoclonal antibody. 
Finally in the third part we investigated the relationship between MS4A4A with the β–glucan 
receptor Dectn1 in vitro and in vivo. 
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3. MATERIALS AND METHODS 
 
 
Chemicals and antibodies 
 
Poly-L-lysine and Cycloheximide were from Sigma-Aldrich (St. Louis, Missouri, US). Sodium 
azide (NaN3), paraformaldehyde (PFA), Triton X-100, glycine, Tween 20, phenylmethylsulfonyl 
fluoride (PMSF), EDTA and chemicals for lysis buffer, Phosphate Buffered Saline (PBS) and 
reducing sample buffer were from Merck Chemicals (Darmstadt, Germany). Lipofectamine 2000 
was from Invitrogen (Life Technologies Ltd, Paisley, UK). Normal goat serum (NGS) was provided 
by Dako (Glostrup, Germany). Vibrant Lipid Raft Cholera Toxin B 594 was purchased from 
Molecular Probes (Life Technologies Ltd). 
Recombinant murine chemokines were from R&D Systems (Minneapolis, Minnesota, US); 
recombinant human ones from Miltenyi Biotec (Bergisch Gladbach, Germany)  
For Western blot and co-immunoprecipitation, antibodies for goat anti-human Dectin1 and rabbit 
anti human CD9 were from R&D, rabbit anti human CD63 was from SIGMA Aldrich, goat anti 
beta actin was from Santa Cruz. Mouse anti MS4A4A was from Abcam (Cambridge, England).    
Anti-rabbit and anti-mouse IgG-horseradish peroxidase conjugated secondary antibodies were 
provided by Ge Healthcare GmbH (Freiburg, Germany).  Anti-goat IgG-horseradish peroxidase 
conjugated secondary antibody was from Santa Cruz. 
For confocal microscopy analysis and flow cytometry,  anti-human MS4A4A monoclonal antibody 
and mouse IgG2a isotype control were from R&D Systems. Antibodies for human Dectin1-PerCP, 
CD206-FITC, CD163 AF700 and mouse IgG2a isotype control were from BD Biosciences (San 
Jose, California, US). Alexa Fluor-conjugated secondary antibodies, CellRox Deep Red Reagent, 
fluorescein conjugate Zymosan BioParticles, Hoechst-33342 and 4',6-diamidino-2-phenylindole 
(DAPI) were purchased from Molecular Probes.  
Non conjugated-endotoxin free Zymosan was from Invivogen (San Diego, California). 
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Plasmids 
 
Human MS4A4A, MS4A6A, MS4A7, Dectin1, CD63 were expressed with pcDNA3.1 vector 
(Invitrogen), pEGFP-N1 or pmCherry-N1 vectors (Clontech, Mountain View, California, US), 
amplifying the codifying sequences with primers with the restriction sites for BamHI and XhoI or 
KpnI in order to have the CDS sequences without stop codon and in frame with the reporter genes, 
where present.  
 
Cells 
 
Authentication of cell lines was assured by regular morphology checks and growth curve analyses. 
Cells were regularly tested for mycoplasma infection by PCR. 
 
Cell culture and transfection 
 
Chinese hamster ovary (CHO-K1) cell line wild type or stably expressing the human MS4A 
members, Dectin1, CD9 and CD63 (untagged or Pegfp/mCherry-tagged) and human embryonic 
kidney (HEK293 and HEK293T) cell lines wild type or stably expressing human MS4A4A were 
grown in DMEM (Lonza, Basel, Switzerland) completed by adding 10% fetal bovine serum (FBS) 
(Euroclone, Milan, Italy), 100 U/ml of penicillin/streptomycin (P/S) (Lonza), 25 mM HEPES 
(Gibco, Life Technologies Ltd). Transfectants were obtained by lipofection with the indicated 
plasmids, according to Lipofectamine 2000 manufacturer's instructions and selected with 650 µg/ml 
G418 (Invitrogen, Life Technologies Ltd). 
 
Human macrophage preparation and culture 
 
Macrophages were generated differentiating  blood monocytes obtained from buffy coats from 
healthy donors by Ficoll-Hypaque (Ficoll, Biochrom) gradient centrifugation. In order to induce 
their differentiation into macrophages, monocytes (1x106/ml ) were cultured for seven days in 
56 
 
Petriperm culture dishes in Iscove's Modified Dulbecco's Medium (Lonza) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS) and 100 ng/ml M-CSF (MACS, Miltenyi Biotec) (M0).  
For M1 polarization, macrophages were resuspended in medium containing 0.1 μg/mL LPS (E. coli 
strain 055:B5, Sigma) and 20ng/mL IFNγ (R&D) for 24 h. For M2 polarization, macrophages were 
incubated for 18 h with 20 ng/ml IL-4 and/or Dexamethasone (10-6M) (Sigma), 10 ng/ml TGF-β 
(Peprotech) or 20 ng/ml IL-10. In all experiments comparing M0, M1 and M2 macrophages, the 
cells were generated in parallel from the same donor’s monocytes.  
 
In vitro stimulation with opsonized particles  
 
LPS and Mannan-coated latex beads were prepared by passive adsorption. Approximately 2 × 10^9 
polystyrene latex beads (Sigma-Aldrich), 3 μm in diameter, were washed twice (10,000 g for 10 
min) in 0.1 M of carbonate-bicarbonate buffer, pH 9.6, and incubated with 500 μg of Mannan from 
Saccharomyces cerevisiae or LPS from E.coli (Sigma-Aldrich) in 500 ml of the carbonate-
bicarbonate buffer for 1 h at 37°C. The beads were then washed twice with HBSS (Invitrogen), 
incubated in 5% BSA for 2 h at 37°C to block nonspecific binding sites, washed again, re-
suspended in HBSS, and stored at 4°C before use. Macrophages were then treated for 2h in 
complete medium at 37°C, 5% CO2. Excess of beads was then washed and cells were prepared for 
mRNA extraction, FACS or immunofluorescence. 
 
Co-Immunoprecipitation and Western blotting. 
 
Macrophages were cultured as previously described. Before stimulation, the cells were washed with 
PBS and cultured in fresh DMEM with 10% FBS and then challenged with 100μg/mL of  Zymosan. 
PBS alone was also used as a control. After incubation for 2h at 37°C, cells were rinsed once in ice-
cold PBS and lysed with lysis buffer (50 mM Tris HCl pH 8 + 150 mM NaCl + 5 mM EDTA + 
5mM EGTA + 1% NP-40 + 10% glycerol) freshly prepared and supplemented with protease 
inhibitors EDTA-free (Roche, Basel, Switzerland) and 100 µg/ml PMSF and lysed for 30 minutes at 
4°C in agitation. 
After 20 min centrifugation at 13000 rpm at 4°C, cell supernatants were quantified by DC Protein 
Assay (Bio-Rad, Hercules, CA).   
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For co-immunoprecipitation, 200μg of protein were pre-cleared from cell lysates with 30 μl of 
protein G–agarose–Sepharose beads (GE Healthcare) for 1h at 4°C. The pre-cleared lysates were 
then incubated without (control) or with 5 μg of goat anti Dectin1 (R&D), rabbit anti CD63 or 
rabbit anti CD9 (Sigma) over night at 4°C, followed by incubation with 30 μl of the protein G beads 
for 3h at 4°C. The beads were washed four times in lysis buffer, resuspended in 30μl Laemmli 
Sample Buffer (Bio-Rad), containing 0.71 M β-mercaptoethanol, heated at 95°C for 5 minutes and 
applied to 12% SDS-PAGE and blotted to nitrocellulose membranes (Bio-Rad). Membranes were 
blocked in 3% non-fat dry milk (Nestlé, Vevey, Switzerland) 1% BSA (Sigma Aldrich) in PBS over 
night at 4°C, rinsed three times with PBS-T for 5 min and then incubated overnight at 4°C with 
1:500 dilution in PBS + 5% BSA of the indicated primary antibody. MS4A4A was detected by 
immunoblotting using mouse anti-MS4A4A antibody (Abcam). Membranes were washed 5 times 
for 5 min with PBS 0.1% Tween (PBS-T) and incubated for 1 hour at RT with 1:5000 dilution in 
PBS-T + 5% BSA of anti-mouse/goat IgG-horseradish peroxidase conjugated secondary antibody. 
Membranes were washed 5 times for 5 min with PBS-T and incubated with chemiluminescent HRP 
substrate Immobilon Western (Millipore, Billerica, Massachusetts, US). Blots were acquired by 
ChemiDoc XRS Imaging System (Bio-Rad).  
Bands were detected as approximately 50 kDa (b-actin), 25kDa (Dectin1, MS4A4A, CD9), 70kDa 
(CD63). 
 
Mice 
 
All knockout mice are backcrossed to C57BL/6J background and housed under specific pathogen-
free 
conditions. Mice in each group were littermate controlled and used at 6 to 12 weeks of age. All 
procedures with the animals were in accordance with institutional guidelines and with national (DL 
116, Gazzetta Ufficiale della Repubblica Italiana, supplement 40, 18-2-1992) and international law 
and policies (European Economic Community Council, 1987, Directive 86/609, Official Journal of 
European Communites L 358,1; and Institute of Laboratory Animal Resources, Committee on Life 
Sciences, National Research Council, 1996, Guide for the Care and Use of Laboratory Animals). 
Animal procedures were also reviewed and approved by the Institutional Ethical Committee at 
Humanitas Clinical and Research Center. 
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Generation of Ms4a4a loxP/loxP and conditional Ms4a4a KO mice.  
 
Mice heterozygous for Ms4a4a-loxP were generated by Ozgene (Bentley, WA). The Ms4a4a loxP 
allele was created by inserting loxP sites within the exon 3 of the Ms4a4a gene, flanking exon 3. 
Overview of this construct is shown (Fig). Ms4a4a-loxP mice were interbred with LysM-cre mice 
to generate the desired conditional knockout genotype (Ms4a4a-loxP/loxP; Cre +/+ ). Mice 
homozygous for Cre recombinase linked to the Lysozyme M (LysM) promoter are commercially 
available from Jackson Laboratories.  
Transgenic mice used for experiments were confirmed to be desired genotype via standard 
genotyping techniques, using the primers identified using MacVector and the Primer3 algorithm 
(see below). Control mice used in this study were Ms4a4a-loxP/loxP; Cre -/- mice (WT).  
. 
 
primer_01F WT CCCCTTCTTCAGTGTACATAGGAT 
primer_02R conKO GGATAGCTAGAGCAGAGAAATACC 
 
 
 
 
 
 
 
Fig1. Knock-out construct and primers used for the flox genotyping. 
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BMDM, PEC, splenic and blood macrophages isolation 
 
Peritoneal elicited macrophages (PEC) derived from mice intraperitoneally (i.p.) injected with 1 ml 
of the exudate-inducing compound thioglycollate (3% thioglycollate medium w/o dextrose, BD; 
Franklin Lakes, NJ) and collected after 4 days by peritoneal lavage with sterile phosphate-buffered 
saline and plated  in 10% fetal calf serum (FCS)-RPMI 1640 medium for 24 h before treatment.  
Mouse resident peritoneal macrophages were obtained by washing the peritoneal cavity with 5 ml 
of ice-cold sterile RPMI 1640 medium, and cultured in a humidified incubator containing 5% CO2 
at 37°C in 10% fetal calf serum (FCS)-RPMI 1640 medium for 24 h before treatment.    
BM cells were obtained from femurs of B6 WT and Ms4a4a−/− mice and incubated overnight at 
37°C with complete medium. Non adherent cells were then cultured in DMEM containing 10% 
FCS and 30 ng/mL mM-CSF (Miltenyi Biotec) for 7 days in ultra-low attachment plates (Corning 
Life Sciences). 
After incubation, the non-adherent cells were removed by washing with serum-free medium and the 
adherent cells were incubated in 10% FCS-RPMI 1640 medium. For M1 polarization, macrophages 
were incubated with 100ng/mL LPS (E. coli strain 055:B5, Sigma) and 20ng/mL m-IFNγ (R&D). 
For M2 polarization, macrophages were incubated with 20 ng/ml m-IL-4 (Miltenyi Biotec) and/or 
Dexamethasone (10-6M) (Sigma). 
Splenic macrophages were obtained  by removing the spleen by lifting it at one end and cutting 
away from the body and placing it on a sterile mesh. Through a sterile syringe plunger the organ 
was  mashed and  the cells were collected in a petri dish containing 5 ml of cold RPMI 1640. The 
cell suspension was 5 times with RPMI 1640 by pelleting cells at 300 g for 15 minutes at 4°C and 
the the cell pellets was resuspended in 5 ml HBSS for separation by Percoll (280-320 mOsm/kg 
H2O and 1.070 g/ml density) density gradient centrifugation. Cells were layered on top of the 
gradient and span at 400 g for 30 minutes at 4°C without brake. The isolated cells were extensively 
washed in HBSS and plated.  
For blood derived macrophages, blood from cardiac puncture was isolated and layered on a  Ficoll 
gradient to obtain PBMC. Cells were extensively washed in PBS and plated in complete RPMI in 
the presence of mM-CSF for 6 days for differentiation. 
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TAM isolation from RCC xenograft  
 
TAM were obtained from a xenograft  model of human  renal cell carcinoma (RCC) in SCID mice. 
Solid fresh cancer was disaggregated  with collagenase cocktail and red blood cells were lysed with 
ACK buffer.  Tumor cells were isolated  using a cocktail of anti-CD15 and anti-CD33 antibody-
conjugated magnetic beads and MACS columns (Miltenyi Biotec) positive selection. TAM in the 
negative fraction were eventually purified  by positive selection using anti-CD11b antibody-
conjugated magnetic beads and MACS columns (Miltenyi Biotec).  
 
Enzyme-Linked Immunosorbant Assay (ELISA) 
 
PEC and BMDM were seeded into 12-well plates (7 x 10
5
 cells/well) and grown under normal 
conditions for 24 h. The medium was replaced by complete DMEM alone or with 25ug/mL 
Zymosan particles. Supernatants were collected after 24 h and mIL6, mIL10 andmTNFa were 
measured using sandwich ELISA (R&D Systems). The optical density (O.D.) of each well  were 
analyzed at  450 nm by SoftMaxPro 5.3 software. 
 
Reverse-transcriptase and Real Time polymerase chain reaction 
 
Total RNA was obtained using Trizol (Invitrogen, Carlsbad, CA). Reverse transcription was 
performed on 1µg RNA template using High Capacity cDNA Reverse Trascription Kit (Applied 
Biosystems). Quantitative PCR was performed with Sybergreen Master Mix (Applied Biosystem) 
and 500 nM primers in 50 μl total volume  in a ViiA™ 7 Real-Time PCR System (Applied 
Biosystems).  
All Primers used are listed in Table...  
Each sample was amplified with 1 cycle at 95°C for 10 min and 39 cycles at 95°C for 15 sec and 
60°C for 1 min.  
Results are expressed as the fold of increase in mRNA expression with respect to the control cells 
(M0), and normalized on the housekeeping gene GAPDH. 
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target gene  primer F (5’-3’)  primer F (5’-3’)  
hMS4A4A CTGGGAAACATGGCTGTCATA  CTCATCAGGGCAGTCAGAATC  
mMs4a4a CTGCATAGGAGTATCCCTCTCT GTCTCTGCCTTGGTAGGATTTG 
hMS4A6A CTGGTGGGTTTCATTATCCT CAGACTGGCTTTGGCTGTAT 
mMs4a4B GTCTCCGGATCCCTGTCC TTCAGAGTTAGACTGGCAACGA 
mMs4a4c CTGTTGTAACTCCAGCGAGGT ATGGTTGAAGCGTCACAGG 
mMs4a4D CCCACAAATAGAGTCCCACATC GGGCAGCAGAAACAGTATCC 
hCD163 GGGATGTCCAACTGCTATCAA  GACTCATTCCCACGACAAGAA 
mcd163 CAGACTGGTTGGAGGAGAAATC CAGCTTCCAGAGACAAGTCAA 
hCD206 GGAGTGATGGTTCTCCTGTTTC CCTTTCAGCTCACCACAGTATT 
hCD9 CTGTTCTTCGGCTTCCTCTT CTCCTGGACTTCCTTAATCACC 
hCD63 TACTGTGGGCTGTGGGATTA CAGCTACCACCAGCACATTT 
hDectin1 CCTGGGTACCATGGCTATTT GGGTTGACTGTGGTTCTCTT 
mDectin1 CTCAGCCTTGCCTTCCTAAT AGCAGTGTCTCTTACTTCCATACAC 
GAPDH TCCACTGGCGTCTTCACC GGCAGAGATGATGACCCTTTT 
mGAPDH AACAGCAACTCCCACTCTTC CCTGTTGCTGTAGCCGTATT 
mIL6 GGATACCACTCCCAACAGACCT GCCATTGCACAACTCTTTTCTC 
mIL10 GGTTGCCAAGCCTTATCGGA ACCTGCTCCACTGCCTTGCT 
mTNF GAAAAGCAAGCAGCCAACCA CGGATCATGCTTTCTGTGCTC 
mIL12 GGAAGCACGGCAGCAGAATA AACTTGAGGGAGAAGTAGGAATGG 
 
 
Table.1.  Primers used for qPCR. 
 
 
Flow cytometry  
 
Flow cytometry was performed using a BD LSRFortessa™  flow cytometer and analysis run with 
FACSDiva 6.1.1 software (BD Biosciences) or Flowjo (Treestar).  
Cells were stained with anti-human: MS4A4A-PE (R&D), CD3-APCH7, CD20-APC, CD14-FITC, 
CD14-PE, CD206-FITC, Dectin1-PerCP (BD Biosciences) and CD163- Alexa700 (BioLegend). 
Intracellular staining was performed using Cytofix/Cytoperm KIT (BD Biosciences). Dead cells 
were excluded by LIVE/DEAD Fixable Cell Stain Kit (Invitrogen).  
 
62 
 
Immunohistochemistry 
 
Patient selection 
12 female and 24 males with a median age of 50 years (range 29-86 years)  were enrolled in this 
study. Lymph nodes surgically isolated from 26 patients with lymph proliferative diseases (19 
nodular sclerosis HL, 3 mixed cellularity HL, 4 non-classic HL) and from  8 patients with non-
proliferative disease (1 dermatopathic lymphadenopathy, 2 non-necrotizing granulomatous 
lymphadenopathy, 5 chronic lymphadenopathy) from  January 1997 and June  2014. This study was 
conducted in accordance with the Declaration of Helsinki. 
 
From each patient enrolled in the study, 2-mm  thick tissue slides from formalin-processed and 
paraffin- embedded tumor sections were processed for immunohistochemistry. After 
deparaffinization and rehydration sections were immersed in Diva Decloaker antigen retrieval 
(Biocare Medical) bath for 15 minutes, then incubated with 3% H2O2 for 20 minutes to block 
endogenous peroxidases. Slides were stained with primary antibodies raised against MS4A4A 
(HPA029323, Sigma Aldrich) and CD68 (clone KP1, Dako) for one hour at room temperature. 30 
minutes incubation with the MACH 4 Universal HRP-Polymer kit (Biocare) followed. 
Diaminobenzidine tetrahydrochloride (Dako) was used as chromogen. Nuclei were lightly 
counterstained with a freshly made hematoxylin solution (Medite). The sections were further 
washed in water, mounted, and analyzed under an optical microscopy.  
Slides were digitized using the Olympus dotSlide computer-aided image analysis system (Olympus 
Hamburg, Germany). Acquired digital images representing whole-tissue sections were evaluated for 
image quality and subsequently segmented based on RGB scale. Immunoreactive surface was 
expressed as percentage.  
 
Confocal microscopy 
 
Macrophages were seeded on poly-L-lysine coated 14 mm diameter glass glasses  (Menzel-Gläser, 
Thermo Fisher Scientific, Waltham, Massachusetts, US) in 24 wells plate, treated as described 
above and fixed with 4% paraformaldehyde (Euromedex). Cells were washed with Ca2+/Mg2+ 
PBS and maintained in Ca2+/Mg2+ PBS or permeabilized with 0.05% Triton X-100 in Ca2+/Mg2+ 
PBS for 5 minutes. Nonspecific ligands were blocked with 5% goat serum (Dako) in Ca2+/Mg2+ 
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PBS containing 2% bovine serum albumin and 0.1% glycine for 1 hour at room temperature. Cells 
were then incubated with the following primary antibodies: mouse anti–human MS4A4A mAb 
(R&D Systems), rabbit anti-human Dectin1, rabbit anti-human CD63 and rabbit anti-human CD9  
(SIGMA Aldrich). Irrelevant immunoglobulins G (IgGs) were used as the isotypic control. After 
incubation over night at 4°C, cells were washed and incubated with 1 μg/mL of Alexa Fluor 488–
conjugated goat anti–mouse IgG and Alexa Fluor 647–conjugated goat anti–rabbit IgG (Invitrogen) 
for 1 hour at room temperature. 4′,6-diamidino-2-phenylindole (DAPI; Invitrogen) or Hoechst 
33342, Trihydrochloride, Trihydrate (Molecular Probes) were used to stain DNA. After each step, 
cells were extensively washed with Ca2+/Mg2+ PBS + or Ca2+/Mg2+ PBS + 0.05% Tween 20 
(Merck). Specimens were finally mounted on glass slide (Menzel-Gläser) with 20 µl FluoSave 
reagent (Calbiochem, Merck4Biosciences, Darmstadt, Germany) and kept in dark at RT for 24 
hours.  High-resolution images (1024 x 1024 pixels) were acquired sequentially with a 60X 1.4 
N.A. Plan-Apochromat oil immersion objective by using a FV1000 laser scanning confocal 
microscope (Olympus; Hamburg, Germany). Differential Interference Contrast (DIC- Nomarski 
technique) was also used. Images were assembled, cropped by ImageJ software (NIH). Quantitative 
colocalization and statistical analysis were performed by Imaris Coloc 4.2 (Bitplane AG, Zurich, 
Switzerland) software and FV1000 1.6 colocalization software (Olympus). Quantification of 
Pearson’s Coefficient of Correlation (PCC) was performed inside a selected region of interest per 
image, representative of the analyzed cell. For statistic, colocalization analysis was performed on at 
least 50 cells representative of each experimental condition/donor.  
 
ROS production detection 
 
In order to measure the generation of reactive oxygen species (ROS), CellROX Deep Red reagent 
(Life Technologies C10422) was used according to the manufacturer's instructions. Briefly, 2.5 × 
10
5
/ well PECs or BMDMs cells were seeded in a 24 well plate in complete medium and incubated 
for 30’ with CellROX Deep Red reagent along with Hoechst 3334 dye (1 μg/mL) to discriminate 
the nuclei. Cells were left untreated or treated with 20ug/mL Zymosan for 2 hours at 37°C. 
Fluorescence was monitored at 350ex/461em (Hoechst) and 640ex/665em (CellROX) and analysis 
was performed for each ROI using Xcellence-rt software (Olympus)  Live-cell confocal microscopy 
was performed with an Olympus Cell-R epi-fluorescence microscope. 
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Split-ubiquitin screening with GC treated macrophages library 
 
Split-ubiquitin NubG-X library from glucocorticoids polarized macrophages was constructed by 
Hybrigenics Services.   
MS4A4A cDNA was cut from pcDNA3 plasmid and directionally cloned into the bait construct 
pBT3-N in which LexA-VP16-Cub cassette (supplied by Dualsystems Biotech), is fused to the N-
terminus of the bait protein.  The bait construct was transformed into the S. cerevisiae strain 
NMY51 (MATa his3Δ200 trp1–901 leu2–3,112 ade2 LYS2::(lexAop)4-HIS3 ura3::(lexAop)8-
LacZ ade2::(lexAop)8-ADE2 GAL4) using standard procedures [364]. For two-hybrid screens, 
transformants were grown on selective medium lacking leucine, tryptophan, histidine, and adenine, 
with addition of 20 mM 3-amino-1,2,4-triazole (3-AT). Positive clones were sequenced by colony 
PCR using the primer set pPR3N-FOR: 5’-GTCGAAAATTCAAGACAAGG-3’ and pPR3N-REV 
5’-AAGCGT GACATAACTAATTAC-3’. Library plasmids were isolated from positive clones and 
retransformed into NMY51 to test bait dependency. Only preys activating the histidine and adenine 
reporters in the presence of MS4A4A and not pCCW-Alg5 or pBT3STE were considered true 
interactors. 
 
 
 
 
Fig.2. The Split-ubiquitin yeast two hybrid principle. The  bait is in frame with  the C-terminal 
of ubiquitin (Cub) and a transcription factor (LexA-VP16) and a TF. When the prey fused with  the 
N-terminal half of ubiquitin (NubG) interacts with the bait, split-ubiquitin is reconstituted  and  
cleaved by proteases, releasing the TF, which enters the nucleus activating the reporter genes and 
allowing the growth of the yeast carrying the interaction. 
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The system is based on the reconstitution of ubiquitin, a highly conserved protein which labels other 
proteins for degradation [365]. Once the target is ubiquitinated, it moves to the  
26S proteasome, where it is degraded. The poly-ubiquitin chain can then be cleaved off the target 
and recycled. This process is dependent on ubiquitin specific proteases (UBPs) which recognize 
folded ubiquitin and detach the polypeptide chain next to the last residues (a Gly-Gly motif).  
Nils Johnsson and Alexander Varshavsky, discovered  that yeast ubiquitin can  be split into two 
parts, the  N-terminal ubiquitin and  C-terminal ubiquitin becoming not recognizable by the UBPs 
[366]. Whenever they are co-expressed  from the same cell, they reassemble and become ready to 
be cleaved. 
The strong affinity is mediated by the isoleucine at position 3. When this is mutated with a glycine 
(NubG), it loses affinity for Cub when co-expressed. Johnsson and Varshavsky exploited these 
findings to create a protein complementation assay by fusing a protein X to Cub and a second 
protein Y to NubG. An interaction between X and Y brings the two halves in close proximity, 
reconstituting the ubiquitin, that can be now recognized and cleaved by UBPs. As outcome, 
whenever an artificial TF is cloned in frame with Cub it will be cleaved off from the membrane and  
able to translocate into the nucleus where it will bind the promoter  located  upstream of a reporter 
gene via its DNA binding domain. The reporter genes used in the DUALmembrane system are two 
auxotrophic growth markers (HIS3 and ADE2), whose activation allows the yeast to grow on 
selective minimal medium lacking histidine or adenine, and  lacZ, encoding the enzyme β-
galactosidase. The interaction between two proteins at the membrane level  will result into a 
transcriptional activation,  growth of yeast and color development in a β-galactosidase assay. 
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FLIM-FRET 
 
The Physical Phenomenon of Fluorescence  
 
Interaction between light and matter is described by the Einstein theory (Einstein A., Zur 
Quantentheorie der Strahlung, 1917. Physikalische Zeitschrift 18: 121–128). Three types of 
interaction are possible: 
 Absorbtion, when a photon interacts with a molecule and is absorbed; the photon’s energy 
is transferred to the electron and stored as potential energy, allowing a jump from a state Em 
to a state En. This is a very quick process, happening in femtoseconds 
 Spontaneous emission, when an electron in an excited state En can return to a fundamental 
state. In this process a photon of energy En - E0 = hν is emitted 
 Stimulated emission is a process that occurs in presence of an external electromagnetic 
radiation. An electron in excited state En can interact with a photon of energy hν and release 
another photon with same frequency and phase. 
 
 
 
Figure . Fluorescence principle. Schematic representation of  fluorescence according to the classical Bohr 
model. Absorption of a light quantum (blue) set off  an  electron to move to a higher energy orbit. After 
existing  in this excited state for a  certain time (the fluorescence lifetime), the electron drops back to its 
former orbit and the  fluorochrome disperses the excess energy by emitting a photon (green). From 
Ishikawa-Ankerhold, 2012 
 
Here we focus on luminescence, which is a spontaneous emission from an excited state (Lakowicz 
J. 2006). 
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Luminescence is commonly divided in fluorescence and phosphorescence, according to the type of 
excited state. Fluorescence is the transition from a singlet state S
1
 to the ground state; this is a quite 
quick process – happening in nanoseconds – with an opposite spin electron in the ground state. It’s 
a permitted transition so it possesses very high emission intensity. Transition from a triplet state T
1
 
to the ground state occurs between two electrons with same spin; this transition is not permitted by 
selection rules and the emission intensity is much lower. 
Almost all fluorophores follows three general rules: 
 Fluorescence is emitted at a lower energy than excitation, i.e. at longer wavelength (Stokes 
Shift) 
 Emission spectra are usually irrespective of excitation wavelength (Kasha’s rule), because  
energy is first dissipated through vibrational relaxation 
 Absorption and emission spectra are generally symmetric. This is called Mirror rule and is 
due to fluorophores having similar vibrational states in the electronic ground and excited 
states.  
Lifetime of a fluorophore τ is the average time of the decay process from an excited state to the 
ground state. Fluorescence lifetimes are usually short (order of magnitude 1-10ns), while 
phosphorescence lifetimes are much longer (order of magnitude 1-10
3
 ms, but in some cases can be 
even longer). 
Absorption and radiative emission can be described with a Jablonski diagram. Transitions from 
each state are shown as vertical lines between states, because transition times fall in the order of 
magnitude of 10
-15
 s. 
After absorption, fluorophores relax to the ground vibrational state. This is still an electronically 
excited state. At this point, one of these types of decay can occur: 
 Fluorescence, if the electron falls from a singlet state to the ground state. 
 Quenching, when the fluorophore relaxes in a non-radiative way (mainly heat), due to the 
interaction between the fluorophore and molecules from the solvent . Most frequent case is 
the presence of O2 
 Intersystem crossing, the fluorophore shifts from a singlet state to a triplet state. According 
to selection rules, transitions from this state to ground state are avoided so the fluorophore 
undergoes phosphorescence. The fluorophore can even return to a singlet state (in 
milliseconds) and then relax with radiative emission of fluorescence. 
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 Resonance energy transfer. Energy can be transferred non-radiatively between two 
fluorophores via dipole-dipole interactions, if the distance between two fluorophores is in 
the range of tens of nanometers. 
 
Resonance energy transfer (RET) 
 
Resonance energy transfer is a process in which a fluorochrome in excited state (donor), transfers 
energy to another non-excited fluorophore (acceptor) and occurs when the emission spectrum of the 
former overlaps with the excitation spectrum of the latter. The efficiency of energy transfer is 
proportional to spectral overlap and is described in terms of Forster distance (R0). 
The rate of energy transfer kT(r) is given by 
 
 
 
where r is the distance between the donor (D) and acceptor (A)  and  τD is  the  lifetime  of  the  
donor  in  the  absence  of energy transfer. The efficiency of energy transfer (E) is the fraction of 
photons absorbed by the donor which are transferred to the acceptor 
 
 
 
By substituting the previous equation, last one can be rewritten as 
 
 
 
Efficiency is normally calculated as the relative variation of fluorescence intensity of the donor in 
presence FDA and absence FD of the acceptor, as in 
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Fluorescence Lifetime Imaging Microscopy (FLIM) FRET 
 
The interpretation of intensity-based FRET measurements is often  limited by experimental 
conditions and may originate artefacts, such as  concentration and efficiency of the fluorochromes,  
signal cross-contamination, variations in excitation intensity and exposure duration, and 
photobleaching. The fluorescence lifetime τ is affected by energy transfer, but basically unaffected 
by the above-mentioned limitations. Therefore, measuring the lifetime via FLIM provides essential 
information on FRET and improves many limitations related to intensity-based FRET.  
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Figure.  The FRET photo physical process. FRET depends on the  proximity of donors and 
acceptors fluorescent molecules and their  spectral overlapping. Whenever the donor is excited but 
the acceptor  is too far away  from it, only the donor fluorescence can be detected. However, when 
the acceptor is closer, FRET phenomenon occur. The more the donor  intensity  emission decreases, 
the better the  acceptor emission will be detected. From  Ishikawa-Ankerhold, 2012 
 
 
FLIM is a technique that maps the spatial distribution of the lifetimes which does not change upon 
intensity variations as long as sufficient signal is available to be detected. Additionally, lifetime 
values are not dependent on the  fluorochromes concentration, the excitation light intensity, or on 
the fluorescence detection  efficiency (Lakowicz 1992) and are normally indifferent to moderate 
levels of photobleaching (Van Munster 2004).  
In FLIM-FRET,  the acceptor presence causes energy transfer and loss of donor’s excited state 
faster than in its absence. Consequently, the donor fluorescence lifetime drops.  
In case of FLIM-FRET, efficiency (EFRET) may be calculated according to:  
 
 
 
where τDA and τD are the excited-state lifetimes of the donor in the presence and absence of the  
acceptor, respectively. 
  
CHO-K1 cells (1x106 cells in a 6 well plate, in DMEM without P/S) were transiently co-transfected 
using Lipofectamine2000 with the plasmids described above and tested for interaction by FLIM-
FRET using a two photon microscope (Trimscope II, LaVision Biotec, Bielefeld, Germany), based 
on Olympus BXW51 upright microscope with 60x objective (LUMFL60x Olympus, Japan). 
Light was separated using a IR700 long pass filter and detected with a FLIM X16 module 
(LaVision Biotec, Bielefeld, Germany). 
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Figure. EGFP-mCherry couple photophysical properties. Spectra of the reporters chosen to 
detect interaction between molecules. 
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Humanized anti-MS4A4A antibody generation by Phage Display 
Library 
 
Anti-MS4A4A antibodies were isolated from HX02 human Fab phage display library (Humanyx 
Pte Ltd, Singapore) via in vitro selection.  
The library was derived from 22 anonymous donors’ blood and tissues after informed consent and 
consists of 3 × 10^
10
 M13 phagemids, each one encoding and presenting one different antibody in a 
Fab format. DNA fragments encoding  Heavy Chains (HC), Light Chains (LC), and the linker were 
amplified from reverse-transcribed mRNA by PCR and ligated into pComb3X  phagemid vector. 
Amplified products were purified from agarose gel with QIAquick Gel Extraction Kit (Quiagen) 
and transformed  into competent TG1 bacteria, subsequently infected with the M13KO7 helper 
phage so that the phage-displayed antibodies can be selected on immobilized antigen. 
The library was panned against transiently transfected HEK 293T  expressing MS4A4A.  
The amount of protein expressed at the surface level by the transfectants was tested by Flow 
cytometry and epifluorescence microscopy on HEK 293T cells expressing MS4A4A in frame with 
a GFP reporter. 
In the first round of panning 10^
13 
CFU/mL  phages were mixed with 5x10^
6
 non transfected HEK 
293T cells for depletion in DMEM+1%FBS media for 1h at 4°C on a rotor. After centrifugation, the 
supernatant was mixed with HEK293T expressing MS4A4A-eGFP FOR 1h at 4°C in agitation. 
Cells were washed 6 times with complete media (DMEM+ 1%FBS) and once with PBS. Phage 
elution was performed using a Glycine buffer pH 2.2 for 10 min followed by neutralization with 
Tris buffer pH 8 and centrifugation of the cells. Supernatant was incubated with E. coli TG1 
bacteria (Stratagene) for  amplification. The output of this round was determined to be 3,2x10^
5
 
phages.  
The second round of panning was done similarly using 2x10^
12 
phages as an input and 10^
6
 phages 
as output. 
For the third round CHO cell line was used together with HEK 293T. 2x10^
12
 phages were used as 
input as above. After acidic elution, the eluted phage were mixed with non-transfected CHO 
followed MS4A4A-EGFP transfected CHO as a back-to-back panning with HEK 293T. After 
elution for MS4A4A-EGFP transfected CHO, the output was determine to be 3000 clones. 
192 colonies were picked for screening. Phage was rescued for each colony and supernatants were 
incubated on non-transfected and MS4A4A transfected HEK 293T cells in 96 well-plates for phage 
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ELISA screening. Binding was detected by HRP-conjugated anti-m13 phage antibodies (Amersham 
Bioscience).  
Binding  phages were eluted by washing the cells with cold glycine buffer (50 mM glycine, 150 
mM NaCl, 200 mM urea, 2 mg/ml polyvinylpyrrolydone, pH 2.8) at 4°. 
The positive Fabs were then converted into full-length IgG1 molecules. VH and VL chain genes 
were amplified by PCR using primers for the human framework with the addition of restriction sites 
and cloned into eukaryotic expression vectors with constant antibody domains. IgG1 was expressed 
by transient transfection of mammalian cells in serum-free medium and purified on protein A 
affinity columns. The concentration of purified antibodies was measured by optical absorbance at 
280 nm. 
 
Affinities of 4 IgG clones for human MS4A4A and mouse Ms4a4a. 
 
HEK-293T cells were transiently transfected with a hMS4A4A-coding pcDNA3  or mMs4a4a-
coding pcDNA3plasmid by lipofection and stained with increasing concentrations of each IgG for 1 
h on ice. Anti-human IgG A488-coupled secondary antibody was used at 1:4000 dilution followed 
by PBS washes. Fluorescence was read in a EnVision Multilabel plate reader (PerkinElmer).  
 
Peptide competition assay for D1 antibody. 
 
D1 antibody was coupled with a PECy7 fluorochrome with PE/Cy7Lightning-Link, (Innova 
Biosciences), following the manufacturer instructions.  A peptide corresponding to MS4A4A’s 
second extracellular loop was incubated at indicated concentrations together with 1ug/ml 
concentration of  D1-PECy7 coupled antibody () at room temperature for 30 min. HEK cells 
transfected with MS4A4A were then added to the mix and incubated for another 30 min. Antibody 
staining was quantified by flow cytometry. 
 
Epitope mapping  
 
Based on sequence D1 antibody is able to bind,  6 residues were mutated in the second extracellular 
loop. Mutations were generated from the hMS4A4A-GFP construct using QuickChange kit 
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(Agilent), according to manufactures instructions. Each mutant was transfected HEK 293T cells and 
after 48h hours cells were harvested for FACS staining using either D1 or H10 biotinylated 
antibodies at 1mg/ml concentration followed by Streptavidin PE-coupled secondary staining. 
 
Antibody-dependent cytotoxicity assay. 
 
48 h after transfection, HEK-293T cells were loaded with 10 mM of the calcein-AM dye (Life 
Technologies) for 1 h at 37°C followed by 3 washes with complete medium. Human NK cells were 
isolated on the same day using a human NK cell isolation kit (Macs Miltenyi). 10^
4
 HEK-293T 
cells were first incubated with increasing concentrations of antibodies in a round bottom 96-well 
plate for  1h at RT. 10^
5
 NK cells were then added to each  well (1:10 ratio), spun down, and 
incubated for 4 h at 37°C. Plates were then centrifuged and 70 µL of supernatant was transferred in 
a black plate for fluorescence reading.  Samples were measured using a Spectramax Gemini dual-
scanning microplate spectrofluorimeter (Molecular Devices, Sunnyvale, Calif.) . Percent lysis was 
calculated as: 
(Test release - spontaneous release/maximum release - spontaneous release) x 100 
H1L1 clone was used as control antibody as well as non-transfected cells were. 
 
Statistical analysis 
 
GraphPad 6 Prism software was used to perform Student’s t-test or ANOVA using Bonferroni 
algorithm. A p-value < 0.05 was regarded as statistically significant. Level of significance was 
indicated by asterisks (***p < 0.001; **p < 0.01; and *p < 0.05). Error bars show SEM, if not other 
indicated, of each experiment. Experiments were performed at least in triplicate. 
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4. RESULTS 
 
4.1. MS4A4A expression, regulation and structure 
 
4.1.1. Selective MS4A4A mRNA Expression in hematopoietic cells and 
alternative macrophages  
 
In a previous study performed in our lab, the analysis of the transcriptional profile associated with 
human macrophage M1 and M2 polarization led to the identification of a subset of tetraspanin-like 
genes, MS4A (membrane-spanning 4-domain family, subfamily A), selectively expressed in 
polarized macrophages. The evaluation of these molecules expression in several cell lines and 
primary culture, revealed the specific association of one of these candidates, MS4A4A, with a 
number of tissues, all somehow related to immune functions. 
The microarray analysis and the following validation by q-PCR  confirmed  MS4A4A being almost 
mutually expressed  in alternatively activated macrophages (M2) (Fig.1 A and B). 
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Fig.1. Expression of MS4A4A in tissues, cells and polarized macrophages. A. . Microarray 
analysis highlighting the expression of  MS4A4A in M2 polarized human macrophages (reported in 
Martinez et al. J Immunol., 2006). Mo: Monocytes; Mo-d3: monocytes after 3 days of culture with 
M-CSF; MQ: monocyte-derived macrophages; M1: classical macrophages; M2: alternative 
macrophages. B. Validation of microarray data by qPCR. C. .MS4A4A expression profiling in 
tissues and primary cells.  
 
4.1.2. MS4A4A is a four-transmembrane domain protein expressed on 
the cell surface 
 
 
The open reading frame of MS4A4A encodes a protein of 239 aminoacid residues. The 
computational analysis performed with the TMHMM program  for prediction of transmembrane 
helices based on hidden Markov model showed four hydro phobic, putative transmembrane regions, 
(65-85aa, 99-119aa, 138-158aa, 180-200aa ) (Fig.2B ) forming a smaller and a larger extracellular 
loops, with a long intracellular amino- and a short intracellular carboxy-terminals (Fig.2B and C ), 
resembling the  tetraspanins structure. According to the sequence, the molecule is lacking an N-
terminal signal peptide. 
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 In order to determine whether MS4A4A was indeed a cell-surface molecule, we generated a 
mammalian expression vector encoding MS4A4A  in frame with a C-terminal GFP tag. HEK 293 
cells were transiently transfected by lipofection with the MS4A4A and the mock GFP plasmids for 
24h. Total internal reflection fluorescence (TIRF) imaging demonstrated  the cell-surface 
expression of MS4A4A characterized by a punctate distribution,  in contrast with the HEK293 cells 
transfected with the GFP control vector which show the spread staining pattern with green 
fluorescence in the cytoplasm(Fig.2D). These results indicated that MS4A4A is indeed  a 
transmembrane protein. 
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Fig.2.  Molecular characterization of MS4A4A. (A). Aminoacid sequence of MS4A4A with the 
predicted cytoplasmic (cyan), transmembrane (red) and extracellular regions (yellow). The 
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sequence is available on the  NCBI website, Reference Sequence: NP_683876.1. (B) Computational 
analysis of the amino acid sequences of MS4A4A, using the TMHMM program 
(http://genome.cbs.dtu.dk/services/ TMHMM/), predicting four-transmembrane hydrophobic 
domains. (C) Schematic illustration of the tetraspanin-like structure of MS4A4A. Amino (NH2) and 
carboxyl (COOH) termini are indicated. (C). Membrane localization was further analyzed by TIRF 
microscopy. 293T cells were transfected with the mock and MS4A4A-GFP plasmid and analyzed 
with a 60x oil immersion objective. 
 
4.1.3. MS4A4A is induced in macrophages by anti-inflammatory 
mediators  
 
Given that the alternative phenotype can be induced  in macrophages by different stimuli, MS4A4A 
expression was validated upon several anti-inflammatory  treatments. 
As reported in Materials and Methods,  monocytes were isolated from healthy donors’ buffy coat 
and cultured for 7 days with 100 ng/ml M-CSF and eventually polarized for 18 h with different 
alternative stimuli: 20 ng/ml IL-4, 20 ng/ml IL-10, 10 ng/ml TGF-β, or dexamethasone (Dex) 10-
6M. Since Schmieder and colleagues described the synergistic induction of the CD20 homolog 
Ms4a8a expression in BMDMs by the combination of LPS and M2 mediators (Schmieder 2011), 
cells were also treated with combinations of IL4 and Dex or IL4/Dex and LPS in order to figure out 
whether MS4A4A is also responding to  the same arrangement of stimuli. 
After the treatment, MS4A4A expression was assessed both at the transcriptional level by q-PCR 
and at the protein level by flow cytometry. 
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Fig.3. MS4A4A is up-regulated by Dex and IL4 and down-regulated by LPS. A. q-PCR from 
macrophages treated with different M2 and M1 stimuli and their combinations. Expression is 
indicated as fold increase respect to mature macrophages (M0). B. Mean fluorescence intensity 
(MFI) of the expression of MS4A4A at the membrane level, normalized on the isotype control . 
Results are expressed as mean ± SD of 8 different experiments. (*p < 0.05). C. 
Immunofluorescence of resting human macrophages (M0), stimulated 18h with 20ng/mL  
IFNɣ+100ng/mL LPS (M1) or 10-6M Dex (M2).  
 
As shown in Fig.3, MS4A4A is mainly induced by dexamethasone both at the transcript and at the 
protein level. A little induction in the mRNA can be achieved also upon  IL4, TGfb and the 
combination of IL4/Dex/LPS, although the levels are not comparable with the glucocorticoid (GC) 
alone.  
The FACS analysis confirmed the MS4A4A dependence on IL4 and Dex, underlying the down-
regulatory effect of LPS in the expression of the molecule, classifying MS4A4A as a marker of  
macrophage anti-inflammatory phenotype.  
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Human macrophages (M0) were also polarized into M1 (LPS/IFNɣ) and M2 (Dex), fixed in 
4%PFA and permeabilized in 0.05% Triton-X  before assembling the coverslips with the mounting 
medium for the confocal analysis of the protein localization.  
The confocal analysis corroborated once again the membrane topology of the molecule, which is 
consistent in primary cells (Fig.3C). 
Despite the absence of MS4A4A induction by the combination of Dex/IL4/LPS, a synergistic effect 
on MS4A4A expression was given by the combination of Dex/IL4 compared to the single 
treatments.  
 
4.1.4. MS4A4A is co-expressed with M2 polarization markers 
 
To test whether MS4A4A+  macrophages can be considered bona fide M2 macrophages, a staining 
with two widely acknowledged M2 markers such as the macrophage mannose receptor (CD206) 
and the scavenger receptor A (CD36) was performed and MS4A4A expression analyzed by flow 
cytometry (Fig.4).  The cells were differentiated from healthy donors buffy coats and polarized 
either with IFNɣ (20gn/mL)/LPS (100ng/mL) to acquire the M1, or with Dex (10-6M) /IL4 
(20ng/mL) for the M2 phenotype, or left untreated (M0). After 24h the cells were stained with 
CD206, CD36 and MS4A4A. In the M2 condition, almost half of the cells acquired a triple 
positivity, and an average of 60% of the cells expressing either CD206 or CD36 or both was also 
MS4A4A+,  while the cells negative for both the M2 markers were also negative for MS4A4A. 
Also in resting conditions, 16% of the cells positives for at least one of the two M2 markers, is also 
MS4A4A  positive,  indicating that MS4A4A+ cells can be acknowledged as M2 macrophages.  
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Fig.4. MS4A4A+ population is co-expressed with others M2 markers. FACS analysis of 
MS4A4A+ macrophages (red population) and their profile with regard to CD206 and CD36 in M1 
and M2 polarizations. 
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4.1.5. Induction of MS4A4A expression in macrophages by M2 
mediators is mainly regulated by GR signaling 
 
Glucocorticoids are powerful anti-inflammatory compounds capable of inhibiting all stages of 
inflammation as well as playing a pivotal role in cell metabolism. 
All the cellular responses to GC is attributed to their binding to the intracellular GR (Glucocorticoid 
Receptor) [367]. The GC hormone crosses the plasma membrane and moves into the cytoplasm 
where it binds to the high-affinity GR, releasing it from the interaction with the inhibitory complex 
it is associated with,, thus unmasking  the GR nuclear localization signal. Upon activation, GR  
traslocates into the nucleus, dimerizes,  and binds to DNA through its central domain characterized 
by a DNA binding motif by targeting specific nucleotide palindromic sequences called GRE 
(Glucocorticoid Response Elements) or nGRE (Negative GRE) [368]. 
The dependency of MS4A4A  expression on glucocorticoid receptor  activation was confirmed  
challenging the cells with two different  concentrations (1ug/mL and 100ng/mL) of the GR 
competitor antagonist Mifepristone (Mf). Cells were treated with the IL4, Dex or Dex/IL4 alone, or 
together with the antagonist  for 18h and  a significant inhibition of both Dex and Dex/IL4 treated 
macrophages expression  occurred  in a dose dependent manner, at both the transcript and the 
protein level (Fig.5A ). The same behavior was exhibited by another M2 marker, the scavenger 
receptor for  the hemoglobin-haptoglobin complex, CD163, which expression is well known  being 
regulated by GC (Sulahian 2000, Tang 2013). 
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Fig.5. MS4A4A overexpression is found upon GC treatment and is blocked by Mifepristone. 
(A) MS4A4A and CD163 expressions in human macrophages was analyzed in the presence of 
increasing concentrations of the glucocorticoid receptor  antagonist Mifepristone. MS4A4A (left)  
and CD163 (right) expressions were determined by qRT-PCR and  FACS  analysis.  
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Fig.7. Dexamethasone kinetic and schematic representation of the putative promoter elements 
regulating MS4A4A. A. Time course of MS4A4A expression in Dex treated macrophages for the 
indicated time points at the transcript (left) and protein (right) level. Results are  shown as mean and 
SEM of n = 6 and are representative of two  independent experiments. The p-value was (*p < 0.05) 
according to ANOVA with Bonferroni algorithm. Values represent the relative induction of 
MS4A4A normalized to the housekeeping gene GAPDH for qPCR and isotype for FACS  and are 
given as the fold-induction over M0 or T0 set at 1. In the time point  graph the relative MFIs are 
normalized only on the isotype control. B. The black rectangles at the 5’ of MS4A4A represent the 
highly conserved H3K4me3 regions, containing several GRE each, that are likely to regulate 
MS4A4A expression. Also the C-EBP and STAT-3 binding sites found in this region can be bound 
by the GR. 
 
The analysis performed with the T.Tsunoda, and T.Takagi software TRANSFAC R.3.4. revealed 
that both these regions were characterized by a huge number of  C/EBP, STAT1, STAT3  but no 
STAT6 transcription factors binding sites. Particularly,  more than 30  palindromic glucocorticoid 
responsive element (GRE) sequences were identified within this region. Interactions and also co-
stimulatory effects has been demonstrated for the GR with both C/EBP and STAT3.  
Indeed, IL6 activated -STAT3 has been described acting as a co-activator of  the Glucocorticoid 
Receptor Signaling, arranging a  trans-activating/signaling complex that can be both dependent or 
independent on IL6 responsive element [369].  
On the other hand, GC have also been acknowledged  playing a role as ligand in the nuclear  
receptor  PPARɣ expression regulation through C/EBP interaction  [370]. 
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Grave’s syndrome is a very common form of autoimmune hyperthyroidism to which 
glucocorticoids represent the most effective treatment. In order to understand  the in vivo effect of 
glucocorticoids on MS4A4A expression, monocyte were isolated from  three Graves’s patients 
before and after glucocorticoids administration  (1mg/patient) and RNA was extracted to perform q-
PCR analysis (Fig.8). MS4A4A expression was up-regulated in all samples upon GC treatment. 
Particularly, patient1 and 3 were at their first GC injection, while patient2 was at  his 5th injection, 
justifying the apparently lower induction with a higher basal level of MS4A4A due to the chronic 
GC treatment . 
 
 
 
 
Fig.8. MS4A4A expression after Dex treatment in vivo. MS4A4A mRNA expression from 
Grave’s syndrome patients monocytes before and after treatment with 1mg Dexamethasone. 
Expression is indicated as fold increase respect pre-treatment. 
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4.2. MS4A4A and tumor associated macrophages  
 
4.2.1. MS4A4A is overexpressed in TAM in vivo but not in vitro 
 
TAM mainly  consist of M2-like macrophages displaying almost  no cytotoxicity for the  tumor 
cells because of their very low production of  pro-inflammatory cytokines and their poor antigen 
presentation activity [371].  
Schmieder’s group acknowledged  that for  Ms4a8a overexpression induction, the simultaneous 
treatment of bone marrow derived macrophages (BMDMs)  in vitro with both the M2 mediators 
Dex/IL-4 and  tumor-conditioned media (TCM) was required.  MS4A8A TAMs were also identified 
in vivo,  in subcutaneously transplanted tumors of murine malignant melanoma (B16F1) and murine 
mammary adenocarcinoma (TS/A) [229].  
Renal cell carcinoma (RCC), the most common human kidney cancer, and it is commonly 
infiltrated with tumor-associated macrophages (TAM) able to promote malignant progression [372].  
We consequently isolated RCC  tumors from a RCC xenograft model, purified the populations 
through magnetic selection,  and compared the expression of MS4A4A in TAM, tumor tissue and 
peritoneal cells from the same mice by qPCR. As reported in Fig.9, TAM population displayed the 
highest expression of the protein, with only a little expression within the tumor tissue, which might 
be due to the presence of residual  macrophages in the sample after  collagenase treatment.   
  
 
 
 
Fig.9.  Ms4a4a is expressed in TAM in vivo. 
Ms4a4a transcriptional analysis of RCC xenograft 
derived TAMs and  PECs. The values were 
normalized in GAPDH housekeeping gene and 
expressed as fold change on peritoneal macrophages 
set as 1. (n=3). *p<0.05. 
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In the attempt to characterize the behavior of the protein in humans and trying to reproduce the in 
vivo experiment in an in vitro setting, we  co-cultured human  mature macrophages with 
combinations of Dex/IL4 and the TCM of  breast cancer (MDA-MB-231), renal carcinoma (RCC), 
hepatocellular carcinoma (HepG2) and Burkitt's lymphoma (Daudi) for 48h and check at the 
MS4A4A expression by qPCR in vitro (Fig.10). 
 
 
Fig.10. MS4A4A is not affected by TCM in 
vitro. Expression analysis of MS4A4A mRNA 
(n=3) from human macrophages co-cultured for 
48h with TCM of the indicated cell lines alone 
or in combination with Dex/IL4. Results are  
shown as mean and SEM. The p-value was (*p 
< 0.05) according to ANOVA with Bonferroni 
algorithm. Values represent the relative 
induction of MS4A4A normalized to the 
housekeeping gene GAPDH and given as the 
fold-induction over M0 or set at 1. 
 
 
As shown in Fig.10,  MS4A4A didn’t respond to the same combination required for Ms4a8a up-
regulation in vitro, given that most of the TCM were not enhancing the molecule’s transcript. 
The stromal microenvironment certainly  represents a more realistic context in which analyze  
a TAM associated protein.  
 
The findings of an MS4A4A expression in vivo prompted us to evaluate its presence in human  
samples.  
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4.2.2. Identification of MS4A4A in human lymphoma 
 
Immunohistochemical stainings were first performed in normal tissues (spleen and lymph node) and 
showed a very weak expression of MS4A4A. In the spleen, no staining was observed within 
germinal centers or in lymphocytes, and the only positivity was derived from cells surrounding the  
vessels (Fig.11A). Regarding  the normal lymph-node the only immune-positive cells were found 
within the peri-lymphatic adipose tissue (Fig. 11B). 
 
 
 
 
Fig.11. Representative immunohistochemistry for MS4A4A in normal tissues.  
Immunohistochemical stainings of formalin fixed  paraffin- embedded sections of human normal 
spleen (upper panel) and normal lymph node (lower panel) with anti-MS4A4A  antibody, 
counterstained with hematoxylin. 
 
 
Hodgkin lymphomas (HL) bad prognosis has been long correlated with a high infiltration of TAM 
[104, 373]. We therefore analyzed the expression of MS4A4A in histological samples of nodular 
sclerosis, mixed cellularity and non-classic HL, subdividing them  in chemo resistant (n=13) and 
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chemo sensitive (n=11). The reactive lymph nodes isolated from the same patients that do not 
exhibit  neoplastic features were also examined  
 
The computer aided analysis of the immune reactive areas expressed as percentage of the total 
section of each sample revealed no significant differences either between tumor and  non-tumor 
samples (7.00 ± 0.91 vs 3.75 ± 1.30) or between chemo resistant and chemo sensitive samples (7.50 
± 1.37 vs 5.00 ± 1.03), yet the trend of the differences is in the right direction, particularly for the 
first comparison.   (Fig.12) 
 
 
 
Fig.12. Identification of MS4A4A positive cells in human lymphoma. A. Immunohistochemical 
stainings of formalin fixed  paraffin- embedded sections of normal lymph node, reactive LN, 
chemo-resistant  Hodgkin Lymphoma and  chemo-sensitive Hodgkin Lymphoma,  with anti- 
MS4A4A, counterstained with hematoxylin. B. Comparison of immune reactive areas  among 
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tumor and non tumoral samples. (upper) Comparison between lymphomas (7.00 ± 0.91) and non-
neoplastic, reactive LN (3.75 ± 1.30). (lower) Comparison between chemo-resistant (7.50 ± 1.37) 
versus chemo-sensitive lymphoma samples (5.00 ± 1.03).  
 
Because of the distribution of the positive staining  mainly within areas free of lymphocytes but 
potentially associated with macrophage activity (vascularization and fibrosis), we performed a 
double staining for the macrophage marker CD68 together with MS4A4A. 
As expected, the results showed that almost the totality (98%) of the cells  positive for MS4A4A 
were also positive for CD68 within the lymphatic tissue (Fig.13, left), while about 5% of cells 
staining positive for MS4A4A were observed in the fibrous subcapsular septa and in the adipose 
tissue, that were not positive for CD68 (Fig.13 right). Based on their smaller, round morphology, 
these cells are likely to embody recruited monocytes on their way to differentiation. On the other 
way around, not all the CD68 positive cells were also MS4A4A+, clearly indicating the existence of 
a subpopulation of macrophages that within the tumor, supports functions typically exerted by M2-
like macrophages.   
 
 
 
 
 
 
Fig.13. CD68-positive macrophages co-express MS4A4A. Double immunohystochemical 
staining for MS4A4A (blue) and macrophage marker CD68 (brown) of formalin fixed  paraffin- 
embedded sections of Hodgkin lymphoma, showing the presence of a subpopulation of MS4A4A+ 
macrophages. 
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In the set of stained lymphoma samples, tumors with uniform and strong expression, as well as 
specimens with weaker and more heterogeneous expression were observed (Fig. 12). However,  
reactivity was detected in all the sections analyzed, with a consistent progressive peripheral 
enhancement from the perinodular capsule to the more centripetal fill. The germinal centers were 
always negative, confirming MS4A4A is not expressed by lymphocytes. Interestingly, positivity 
was accentuated in all the perivascular regions and in the fibrotic areas surrounding the tumor (Fig. 
14), suggesting these positive cells might be associated with both neovascularization and tissue 
remodeling, in line with a TAM profile. Together, these evidence contribute in making MS4A4A a 
suitable target for antibody based therapy. 
 
 
 
 
Fig.14.  Predominance of MS4A4A positive cells within the perivascular area and in fibrotic 
tissue. Representative MS4A4A immunostaining of formalin fixed  paraffin- embedded sections of  
Hodgkin Lymphoma  indicating a consistent expression within fibrosis (upper) and around the 
vessels (lower). 
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4.3. Isolation of an MS4A4A targeting humanized 
antibody by phage display library  
 
Phage particles displaying the members of the library were isolated from a phage display library 
derived from 22 anonymous donors’ blood and  tissues, and consists of 3 × 1010 M13 phagemids, 
each one expressing a different antibody in a Fab format. DNA fragments encoding  Heavy Chains 
(HC), Light Chains (LC), and the linker were amplified by PCR and ligated into the  phagemid 
vector. Amplified products were then transformed  into TG1 E.coli, and rescued by  infection with 
the M13KO7 helper phage. Our strategy was based on panning this library against  transiently 
transfected HEK 293T  expressing the recombinant MS4A4A protein. 
 
 
 
 
Fig. 15. Scheme of human antibody libraries  generation procedure. The RNA is isolated from 
peripheral  blood and tissue of volunteers and retro-transcribed into cDNA. Its following 
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amplification by PCR  generates fragments which are going to be cloned in vectors   and expressed 
in frame with the phage surface protein (pIII ). The library will eventually undergo multiple steps of 
purification, to isolate the clones recognizing the antigen.  
Each phage binding better to the MS4A4A transfected HEK plate compare to non-transfected was 
further confirmed by repeating the binding experiment using the corresponding Fab. 
8 clones were selected as positives out of which 5 were identical hence reducing the number to 4 
unique clones, later confirmed by sequencing: D1 (+4 identical), H10, H12 and B8. 
These 4 selected phage clones were converted into full-length IgG1 molecules as previously 
described [374] and purified on affinity column. 
 
In order to evaluate the affinity of the positive clones for the target protein, HEK-293T cells were 
transiently transfected with the  hMS4A4A –pcDNA3 expressing  plasmid and stained with 
increasing concentrations (in a range from 100pg/mL to 10ug/mL) of each antibody for 1 h on ice. 
Anti-human IgG Alexa Fluor 488 conjugated  secondary antibody was used at 1:4000 dilution to 
detect the interactions. Fluorescence was examined for each interaction, revealing an absence of 
binding  in non-transfected cells and a really low affinity for the clones E12 and B8 in both species 
(Fig.16). D1 and H10 were instead chosen for further characterization, due to their good binding 
capacity  to the human protein transfectants, although only D1 was able to recognize the protein in 
both species (Fig.16B and C).  
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Fig.16. Relative affinities of 4 IgG clones for human MS4A4A and mouse Ms4a4a. (A) HEK 
cells transfected with the mock pcDNA3 plasmid showing no antibody binding to the cells. (B) 
Under the same experimental conditions, the D1 antibody recognized with nM affinity the human 
transfectant  (hMS4A4A) and (C) is also able to cross-react with the murine mMS4a4a. (D) Table 
showing relative affinities for D1 and H10 antibodies calculated on triplicate wells. 
 
 
In order to identify the epitope recognized by the two clones, an epitope mapping assay was 
performed. The sequence derived from  the clones CDR sequencing and corresponding to the 
second extracellular loop, were subjected to site directed mutagenesis. Six amino acids were 
mutated (Fig.17A) starting from the hMS4A4A-GFP vector, and the resulting plasmids were used to 
transfect HEK293 cells (Fig.17C) to validate the binding capacity of the antibodies by flow 
cytometry (Fig.17B). Two mutations, Y145A and Y148A resulted in a complete abrogation of the 
antibody binding. 
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Fig.17. Epitope mapping for D1 and H10 antibodies. (A) Bar graphs  showing % of  cells 
staining positive  for the respective antibodies and (B) Representative FACS plots of the same 
experiment. (C) Surface expression of hMS4A4A expression for WT, Y145A and Y148A  mutants 
was verified by immunofluorescence microscopy 
 
 
 
The binding affinity of the two clones was further confirmed in immunofluorescence in transfected 
cells. 24h after transfection with hMS4A4A construct HEK293 cells were coated on coverslips 
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pretreated by poly-L-Lysine. The day after, 1mg/ml of each clone  (D1 or H10) was incubated for 
1h on ice. After PBS washing, cells were fixed with 100% methanol for 5 min. Anti-human Alexa 
Fluor 488 IgG was used as a secondary antibody (Fig.18).  
 
 
 
 
Fig.18. Immunofluorescence staining for human MS4A4A on transfected HEK cells using D1 
and H10 clones. A punctate staining is observed for both antibodies (white arrows) as reported for 
CD20-like proteins. Immunoflourescence of HEK expressing hMS4A4A-GFP is shown for 
comparison. Images were taken using a Nikon TS100 inverted microscope. 
Antibody‐dependent cell‐mediated cytotoxicity (ADCC) is the mechanism of cell-mediated killing 
of an antibody opsonized cell by a cytotoxic effector cell through the lysis of the target, classically 
mediated by natural killer (NK) cells by the release of their cytotoxic granules content. ADCC 
efficacy depends on several factors, including the antibody affinity and FcR‐binding affinity. IgG 
are the most common subclass for therapeutic antibodies, and ADCC is the main mechanism of 
action for a number of therapeutic monoclonals, including the anti-MS4A1/CD20 rituximab. 
We hence performed an antibody dependent cytotoxicity assay to evaluate the effects of our two 
clones. 48 h after transfection with hMS4A4A-GFP tagged or untagged constructs, HEK-293T cells 
were loaded with 10 mM of the calcein-AM dye for 1 h at 37
o
C followed by 3 washes with 
complete media. Human NK cells were isolated on the same day from buffy coat using a human NK 
cell isolation kit (Macs Miltenyi). 10^
4
 HEK-293T cells were first incubated with increasing 
concentrations of antibodies in a round bottom 96-well plate for 1h at room temperature. 10^
5
 NK 
cells were then added to each well (1:10 ratio), spun down, and incubated for 4 h at 37
o
C. Plates 
were then centrifuged and 70 uL of supernatant was transferred in a black plate for fluorescence 
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assessment. Only background HEK-293T killing was observed using a control anti dengue antibody 
(H1L1 clone) as well as with un-transfected cells (Fig.19 mock). On the contrary, D1 clone was 
able to mediate cell killing of both transfectants with a dose dependent effect (Fig.19). 
 
 
   
         
 
Fig.19. D1 and H10 antibody-dependent cell cytotoxicity. The assay was performed in HEK cells 
transfected with empty vector (mock), MS4A4A-GFP or MS4A4A untagged plasmid. In live cells 
calcein-AM is converted to a green-fluorescent calcein by intracellular esterases. The insoluble 
product can be retained by cells with integral membranes but is released by damaged ones. Analysis 
was performed by plotting mean percentages of calcein release ±SD from 3 independent 
experiments. Excitation:485 nm; Band-pass filter: 530 nm. 
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Because of its better performances in most of the assays executed, we chose D1 for further 
characterization.  
To examine whether the D1 clone compete with the corresponding peptide  to bind with MS4A4A, 
a competitive binding by flow cytometry  was performed (Fig.20). A peptide corresponding to 
hMS4A4A  second extracellular loop was incubated at the indicated concentrations together with 
1ug/ml concentration of D1 PE Cy7–coupled antibody at room temperature for 30 min. HEK cells 
transfected with hMS4A4A were then added to the mix and incubated for another 30 min. When the 
peptide  concentration was increased, the binding of D1 antibody to MS4A4A  transfectants  was 
diminished. These results suggest that D1 clone is specific for the protein. 
 
 
 
 
 
Fig.20. Peptide competition assay for D1 
antibody. HEK-MS4A4A transfectants were 
incubated with increasing concentrations of the 
competing peptide and antibody staining was 
quantified by FACS. 
 
 
 
 
We then moved to test the antibody  on different types of transfectants and primary cells.  
First, we compared its binding capacity on cells transfected with the empty pcDNA3 plasmid or 
with the pcDNA3-MS4A4A. The staining with PE mouse anti-MS4A4A (R&D)  or D1-PECy7 
(100ng/sample) on the transfected cells was performed on ice for 30’ in PBS supplemented with 1% 
BSA. The cells were then washed and analyzed by flow cytometry (Fig.21).  
The results indicated that both the antibodies can effectively bind the MS4A4A transfectant with a 
higher efficiency than the empty vector (EV). However, the commercial Ab showed lower 
background (10% positives cells) along with a higher binding ability (45% positives cells) 
compared to D1 (14% staining against the EV vs 27% on the MS4A4A transfectant). 
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Fig.21. D1 recognizes the recombinant MS4A4A with a lower affinity when compared to the 
commercial monoclonal anti-MS4A4A. FACS analysis of HEK293 transfected with the control 
(EV) or the MS4A4A-pcDNA3 plasmid, to assess D1 ability to bind the target compared to the 
commercial monoclonal. 
 
 
The same staining was then performed on human primary monocytes and differentiated 
macrophages. PBMCs were isolated from healthy donors buffy coats by Ficoll gradient. The cells 
were depleted in erythrocytes and stained with the two antibodies as described above.  
In the case of PBMCs markers for B cells (CD19),  T cells (CD3) and CD14 to gate monocytes 
were added to the mix. The FACS analysis confirmed once again the non-specificity of D1 
compared to the commercial monoclonal. Indeed, the latter gave a positive staining within a 
subpopulation of CD14 intermediate, consistent with our previous findings according to which 
MS4A4A is not highly expressed in monocytes.  On the contrary, D1 recognized subpopulations of 
CD14 high, CD14 intermediate and also lymphocytes subpopulations (Fig. 22A). 
 
101 
 
 
 
 
 
 
 
A. 
B. 
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Fig.22. D1 recognizes the native MS4A4A with a lower specificity when compared to the 
commercial monoclonal anti-MS4A4A. FACS analysis of freshly isolated PBMCs (A) and 
differentiated macrophages (B) stained with the R&D antibody or D1 (100ng/sample).  
 
The monocytes isolated  from the same buffy coats were differentiated and polarized with both M1 
and M2 stimuli, in order to validate whether D1 was able to recognize the MS4A4A overexpression 
upon anti-inflammatory stimulation. Again, the home made antibody didn’t allow any distinction in 
terms of MS4A4A induction with M2 mediators, while the commercial one did. In the M1 
condition, in fact, the same percentage of positive cells as the Dex/IL4 combination (74%) was 
detected, meaning that the antibody is not recognizing only MS4A4A.The antibody was validated 
also in immunohistochemistry and immunofluorescence (Fig.23), and compared to the commercial 
antibody. In both cases, the pattern of the two Ig was not the same. 
 
 
 
 
 
 
Fig.23. Comparison between D1 and commercial anti-MS4A4A antibody in 
immunofluorescence and immunohistochemistry. (Upper panel) Double staining with anti-
MS4A4A and D1 on human macrophages. The image on the left represents the merge of the two, 
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demonstrating D1 non-specific  recognition of  MS4A4A.  (Lower panel) Immunohistochemistry of 
paraffin embedded stomach sections, stained with anti-MS4A4A (left) and D1 (right). 
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4.4. MS4A4A interactions and function  
4.4.1. MS4A4A is found within membrane lipid rafts upon GC 
stimulation  
    
MS4A4A belongs to the MS4A family, that  includes among its members some well characterized 
molecules, such as CD20 and Ms4a4b, which has been demonstrated co-localizing with  raft 
detergent-resistant lipid microdomains upon  recruitment [215, 375]. 
Lipid rafts are domains on the plasma membrane characterized by high concentrations of 
cholesterol and sphingolipids and are well known to be able to organize trafficking and signaling 
molecules on the membrane bilayer. Association of a molecule within the raft usually results in its 
activation or in a signal transmission [376]. 
As MS4A4A shares the same structure with these CD20 and Ms4a4b and it  is also expressed on the 
cell surface we verified whether it was as well  localized within  lipid rafts  by immunofluorescence.  
We therefore labeled human resting and polarized macrophages with the Cholera Toxin-B (CT-B), 
which binds to the glucosphingolipid GM1 ganglioside (GM1) localized within the rafts [377] and 
MS4A4A (Fig.24A). The cells were collected from three donors and an average of 150 ROI 
corresponding to single cells were evaluated in confocal microscopy in order to calculate for each 
of them the Pearson’s correlation between the two channels corresponding to the two markers CT-B 
and MS4A4A. The analysis generates a value between +1 and −1 included, where 1 means total 
positive correlation, 0 no correlation, and −1  total negative correlation.  
As shown in Fig.28B, at the basal level  no co-localization occurs between MS4A4A and the rafts, 
while once the cells are given with Dex, the co-localization index raise up to 0.7.  
This partially indicates the  re-localization of the molecule upon GC treatment, although a discrete 
portion of the proximity might be due to the de novo expression of the protein upon GC. 
Trying to clarify this point and understand whether Dex induces a re-localization of MS4A4A along 
with its neo synthesis, cells were treated for 2h with Dex and analyzed for co-localization. Such a 
range of time in fact is not enough for  GC to activate the transcription machinery, but is enough to 
promote the membrane reorganization.  As shown in Fig.24B  and confirmed by Pearson linear 
regression analysis (Fig.24C), re-localization occurred already after 2h Dex treatment, indicating 
the GC stimulation induces MS4A4A association with  the rafts. 
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A. 
B. 
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Fig.24. GC induce re-localization of MS4A4A within lipid rafts. A. Immunofluorescence of 
resting and polarized human macrophages labeled for MS4A4A (green) and Cholera Toxin-B (CT-
B, red) showing co-localization upon Dex challenge. The co-localization the two molecules is 
represented by overlay of the images, illustrated by yellow merge. (M0, resting macrophages; M1, 
IFN/LPS treated macrophages; Dex 24h, macrophages treated for 24h with GC). B.  Dex 2h, 
macrophages treated 2h with GC)  C. Pearson’s coefficient for  MS4A4A and CT-B channels,  
calculated on  150 ROIs per condition + SEM, analyzed from 3 donor’s macrophages. * denotes  
p<0.05.  
 
 
Cholesterol depletion is routinely employed to establish the lipid rafts’ contribution in cellular 
process and it can be  performed using methyl-beta-cyclodextrin (MβCD), which extracts 
cholesterol from the outer side  of the plasma membrane by sheltering it in a hydrophobic cavity 
[378, 379].  Cyclodextrins are cyclic oligosaccharides of α-(1–4)-linked D-glycopyranose units 
which typically exist as hexamers (α cyclodextrins), heptamers(β cyclodextrins) or octamers (γ 
cyclodextrins). β-cyclodextrins display the highest affinity for cholesterol and are the most effective 
in extracting cholesterol from cellular membranes. 
So, we set up a protocol of cholesterol depletion from primary macrophages, so as to observe 
whether alteration of rafts would affect MS4A4A expression (Fig.25). 
Macrophages were polarized as usual for 18-24h and then given with 5mM final MβCD. The 
medium was then removed and cells were labeled for the rafts with the CT-B, then  fixed in 4%PFA 
without permeabilization , stained with MS4A4A overnight and mounted for the confocal analysis 
C
. 
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(Fig.25A). In parallel, part of  the cells were stained with anti- MS4A4A to be analyzed by flow 
cytometry to look at the surface expression of MS4A4A (Fig.25B).  
Results showed a significant reduction of the protein upon cholesterol disruption, corroborating the 
hypothesis of an association of MS4A4A with cholesterol enriched microdomains. 
 
 
 
Fig.25. MS4A4A expression is impaired upon cholesterol depletion. (A) Immunofluorescence  
of cholesterol depletion following  MβCD (red: CT-B; green: MS4A4A). Cells were polarized for 
24h and afterwards given with 5mM MβCD for 1h. Co-localization of the markers is visible as 
yellow color. (B) FACS analysis showing the reduction of MS4A4A at the membrane level upon 
cholesterol enriched domains depletion by MBCD. *, P < 0.05 
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4.4.2. MS4A4A forms homo and heterodimers on the cell surface 
 
With the attempt of discover a bit more about MS4A4A role on the plasma membrane of 
macrophages, we decided to explore its  potential interactors adopting the yeast split-ubiquitin 
screen. This approach is a variation of the traditional yeast two hybrid, with the key advantage of 
allowing the measurement of the protein interactions at the surface level instead of in the nucleus, 
as described in Materials and Methods. [380]. The  library was generated  by Hybrigenic Services, 
France. The starting material was total RNA extracted from human monocytes derived 
macrophages treated for 24h with Dexamethasone. The resulting cDNA was directionally cloned 
into pPR3-N to generate the NubG-X library. 
MS4A4a was expressed as C-terminal ubiquitin LexA-VP16 fusion (pBT3-STE vector) in the S. 
cerevisiae strain NMY51 and tested for their capacity of activating the transcription of the histidine 
and adenine reporters exclusively upon ubiquitin re-association. The ability of MS4A4A to activate 
transcription of the reporters was verified with a transmembrane positive control. Then, the library 
was interrogated with MS4A4A as bait out on SD-Leu/-Trp/-His/-Ade agar plates complemented 
with 10mM 3-AT.  
A number of integral membrane proteins resulted interacting with MS4A4A in a bait-dependent 
fashion (Fig.26).  
A total of 89.7 million interactions were analyzed an 178 clones gave a positive readout and were 
sequenced. Most of them resulted in  false positive interactions, mostly by clones expressing  
ribosomal or mitochondrial proteins, heat shock proteins, cytochrome oxidase, proteasome subunits, 
collagen-related proteins, zinc finger-containing proteins. 
 9 specific integral membrane proteins were shown to interact with MS4A4A in a bait dependent 
fashion. Only the very high, high and good confidence-scored  interactions were considered for 
further investigation.  
Surprisingly, one third of the positive clones were represented by MS4A4A itself and other two 
MS4A members with unknown function, which have been however already described in a 
microarray study performed by Martinez and colleagues as associated with macrophages alternative 
polarization [381]. This suggests MS4A proteins form homo and heterodimers with the other 
members, within districts of the membrane that might resemble the tetraspanin enriched 
microdomains (TEM). 
Another third of the clones is represented by a set of molecules associated with fungal pathogens 
clearance. Among them, the β-glucan receptor Dectin1 is the most well-known one.  
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The rest of the clones were the Fc epsilon receptor 1 subunit gamma (FCƐRIɣ), the Ceramide 
synthase 2 (CerS2) and the  leptin receptor overlapping transcript (LEPROT). 
 
 
 
 
 
Fig.26. Identification of potential partners interacting with MS4A4A by Split Ubiquitin Yeast 
two Hybrid. (A) Scheme illustrating the procedure and topology of bait and prey constructs used in 
the split-ubiquitin screen. The bait is expressed in frame with the C-terminal portion of Ub and 
includes the sequence for a transcription factor. In the case of a positive interaction, the partner, 
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fused with the N-terminal, reconstitutes the Ub, which becomes cleavable, and releases the TF, 
which migrates into the nucleus, activating the transcription of the reporter genes. (B) Identities of 
the top scored bait-dependent MS4A4A binding partners from the yeast split-ubiquitin screen. 
 
Although the yeast two hybrid technique provides an important hint about possible co-expression 
and co-localization of two proteins, it doesn’t give evidences of a direct interaction.  
In order to validate the two hybrid results in a more “in vivo” environment, we therefore performed 
a FLIM-FRET experiment in CHO transfectants. 
As described in Materials and Methods, the FRET phenomenon occurs when the excited fluorescent 
donor transfers in a non-radiative way part of its energy to an acceptor molecule at its ground-state. 
The efficiency of this process is inversely reliant on the sixth power of the distance between the two 
molecules and the phenomenon  can only occur when the distance between the fluorophores is in 
the range of 10nm. Since intensity based FRET can be affected by several factors such as 
fluorophore concentration or environmental effects, therefore giving rise to a variety of optical 
artifacts [382], fluorescence lifetime imaging microscopy (FLIM), which is unaffected by these 
alterations, was chosen to validate MS4A4A interaction with the targets (Fig.27).  
 
 
 
 
 
 
 
Fig.27. Pseudocolor lifetime 
image of Dectin1-MS4A4A  axis. 
Reduction of lifetime corresponds 
to quenching  caused by non- 
radiative energy transfer  (FRET 
events). 
 
 
MS4A4A, MS4A6A, MS4A7, Dectin1, CD9 and CD63 were expressed as fusion proteins with  
111 
 
mCherry or eGFP and stably overexpressed in different combinations in  CHO cells maintained in 
medium supplemented with G418. 2*10^5 cells from each combination were seeded onto poly-L-
lysine treated coverslips, fixed and imaged using two photon  microscopy. FLIM images were 
produced to calculate the FRET activity between mCherry and eGFP and hence to evaluate the 
interaction between MS4A4A and its putative interactors.  
 
The analysis confirmed the interactions between MS4A4A and itself and the other two MS4A 
members, and between  MS4A6A and MS4A7, corroborating the hypothesis of the these proteins 
clustering on the plasma membrane. Also Dectin1 was confirmed interacting with both MS4A4A 
and MS4A6A and a decrease in the lifetime of MS4A7 with respect to Dectin1 was also detected, 
although not significant. No FRET took place between MS4A4A and neither CD63 nor CD9 
(Fig.28). 
Both CD9 and CD63 are known associate with Dectin1, taking part during the endosome and 
lysosome formation during the yeast/fungal particle internalization, respectively [333]. However, 
phagocytosis of pathogens requires specific PRRs and the activation of a cell-specific signaling 
cascade that might not be reproducible in a system like the one provided by CHO cells. 
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 Fig. 28. Validation of the YtH by FLIM-FRET.  Mean fluorescence lifetime values and their 
standard deviations of  eGFP  in CHO expressing combinations of molecules in frame with the 
fluorescent reporters (eGFP_X+ mCherry_Y)  . The decay was evaluated in comparison to the 
eGFP_X alone and the decrease of eGFP fluorescence lifetime in the presence of mCherry_Y 
indicates the incidence of FRET between mCherry and eGFP, hence the interaction of X and Y. 
FRET efficiency (E) and the Förster radius (R) expressing the distance between the molecules are 
given for the significant interactions (n>5) ±SD.  *, P < 0.05 
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We therefore moved back to primary cells in order to evaluate whether an interaction was 
detectable upon engagement of Dectin1 with its ligand, β-glucan, at different time points. 
Human macrophages differentiated on coverslips were challenged with Zymosan, an insoluble 
preparation of cell wall from S. cerevisiae, for 15’ and 1h.  Cells were then fixed in 4%PFA,  
permeabilized with TritonX-100, immune-stained with MS4A4A and Dectin1, CD63 or CD9 
antibodies and mounted for confocal microscopy analysis. 
Fig.29 shows the recruitment, at different extents, of all the molecules to phagosomes during 
internalization of Zymosan particles, indicating a possible cooperation in the clearance of 
pathogens. At the basal level, instead, MS4A4A seems to co-localize extensively only with Dectin1, 
which is normally expressed at the surface level and undergoes internalization upon activation. 
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Fig.29. MS4A4A is co-expressed with Dectin1, CD63 and CD9 before and after Zymosan 
treatment. Immunofluorescent staining of primary cultured macrophages challenged with Zymosan 
for the indicated time points. Pictures are representatives of at least 6 independent experiments.  
 
 
A co-immunoprecipitation (co-IP) assay was therefore employed to validate the YtH approach and 
to determine whether the co-expression seen by microscopy represents physical proteins 
interactions occurring  in human primary macrophages.  
Fig.30 shows the co-IP experiments on four of the interactions identified in the YTH assay, for 
which commercial antibodies were available. 
 In these experiments, human macrophages were isolated from three donors, left untreated (M0) or 
treated for 18h with Dexamethasone (DEX), or for 2h with the Dectin1 ligand  Zymosan (ZYMO), 
and lysed in NP-40 Lysis Buffer.  This detergent is weaker than TritonX-100 and helps better 
preserving  proteins interactions. After pre-clearing with protein-G to reduce non-specific binding, 
lysates were incubated overnight with the antibodies against Dectin1, CD9, CD63 or  MS4A6A. 
The following day cells were incubated with protein G-coated beads and eventually denatured in 
SDS-loading buffer. Proteins were then separated on a 12% SDS-PAGE, transferred  to 
nitrocellulose  membranes, and revealed with anti MS4A4A or, as a control, with the pull-down 
antibodies. 
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Fig.30.  Co-immunoprecipitation of MS4A4A with its potential interactors. Human 
macrophages left untreated or treated with 10
-6
M Dex for 18h  or Zymosan (100ug/mL) for 2h were 
lysed with 1% NP-40. 200ug of cell lysates were immunoprecipitated with 5ug anti-Dectin1 or anti 
CD63 (left), anti CD9 or anti-MS4A6A (right) and analyzed by immunoblotting. Every sample was 
blotted with the IP antibody to confirm the immunoprecipitation, and anti-MS4A4A, to confirm the 
interaction. 
 
The experiment confirmed  the interaction of MS4A4A with Dectin1 in all the conditions examined, 
in line with the YtH and the FLIM-FRET data. CD63 interaction with MS4A4A was also confirmed 
in primary cells, differently from what was seen in CHO cells, probably because of the  different 
features of these two cell types.  
On the other hand, opposite to YtH and FLIM-FRET,  neither CD9 nor MS4A6A were capable of 
immune-precipitate MS4A4A. This result may be due to several aspects that need further 
investigation. In both cases, the lack of interaction might depend either on the transient nature of the 
association, which occurs for a very limited period of time during the phagocytic process or on the 
detergent NP-40 used to lyse the cells, that may cause the disruption of  weak protein complexes  (a 
more gentile one should be therefore used for this purpose, e.g. Brij-35). Another explanation might 
be the indirect association of some of these molecules, which create complexes on the plasma 
membrane, but although in close proximity,  are not physically connected. 
 
4.4.3. MS4A4A response to different polysaccharides   
 
Considering that Dectin1 was the only molecule validated for MS4A4A in all the assays performed, 
we decided to focus our attention in studying the nature of this interaction.  Dectin 1 belongs to the  
pattern-recognition receptors family that includes among other members TLRs, Type 3 
Complement Receptors and Scavenger Receptors. As already addressed, Zymosan is a yeast cell 
wall preparation, mainly composed of glucan and mannan (a mannose polymer), which is 
consequently able to activate PRR other than Dectin1, particularly TLR2and TLR6 and the 
mannose receptor (MR).   
We therefore examined the MS4A4A expression in response to of various fungal polysaccharides in 
order to understand whether its regulation was differently affected by different components of 
microorganisms cell wall.  
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Human monocytes were differentiated into macrophages and passive adsorption  mannan/LPS 
opsonized  latex beads or Zymosan were added to the culture for different time points and mRNA 
and protein expression analyzed by q-PCR and FACS respectively. Expression levels of Dectin1 
were also assessed as control, since its behavior towards these components has already been 
established.  
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Fig.31. MS4A4A and Dectin 1 response to polysaccharides  opsonized particles (transcript) 
Transcriptional analysis of macrophages treated with polystyrene latex beads opsonized with 
Mannan or  LPS, or zymosan  (20 particles/cell) for the indicated time points. Expression was 
normalized on GAPDH (ΔCT) and ΔΔCT was further calculated on macrophages at time 0, set as 1. 
N=3 ±SEM. *, P < 0.05 
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Fig.32. MS4A4A and Dectin 1 response to polysaccharides  opsonized particles (protein) 
FACS analysis of macrophages treated with polystyrene latex beads opsonized with Mannan or  
LPS, or zymosan  (20particles/cell) for the indicated time points. Expression was normalized on 
isotype and the resulting MFI was normalized on M0 at T0 set as 1.  N=3 ±SEM. *, P < 0.05 
 
 
As shown in Fig.31 and  Fig.32, the treatment with the opsonized particles didn’t effect neither 
Dectin1 (as expected) nor MS4A4A, indicating that the activation upon Zymosan  mainly occurs 
because of  a β-glucan mediated effect. Also the distribution of the two markers resulted remarkably 
different when immunofluorescence  was performed by confocal microscopy, despite there were no 
differences in the number of  internalized  particles.(Fig.33) 
Interestingly the expression on the surface assessed by FACS of the two proteins suggest opposite 
behaviors in response to Zymosan binding, with an increase in MS4A4A expression that culminates 
at 2h of treatment and a parallel reduction, due to its ligand-dependent internalization [383], of the 
β-glucan receptor Dectin1. 
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Fig.33.  Distribution of MS4A4A  and Dectin1 upon  polysaccharides  opsonized particles 
AND Zymosan phagocytosis. Human macrophages were given with 20/cell particles of zymosan 
or mannan/LPS coated polystyrene latex beads of 3 μm (approximately the same size of a zymosan 
particle) for 2h at 37°C, fixed and permeabilized, and labeled with anti MS4A4A (green) and anti-
Dectin1 (red).  Phagocytosis was visualized by confocal microscopy. Pictures are representatives of 
at least 3 independent experiments. 
 
 
4.4.4. MS4A4A expression is negatively related to Dectin1 expression 
upon β-glucan stimulation  
 
Several works report a different ability by different β-glucans to induce Dectin1 activation [384, 
385]. Indeed  it has been demonstrated that Dectin1 is able to bind to all the types of β-glucan, but it 
exerts its antimicrobial activity only in the presence of particulate polymers, most likely through a  
mechanical effect of these latter on the formation of the so called “phagocytic synapse” which 
induces the  removal of the inhibitory  tyrosine phosphatases [386], allowing to activate a robust 
immune  response only when strictly required. 
Whole glucan particles (WGP), is a particulate from S. cerevisiae β-glucan preparation made of  
long polymers of β-1,3 [387]. Opposite to Zymosan, WGP lacks a TLR- promoting activity [386], 
but  similarly to it, it triggers Dectin-1-dependent responses, including phagocytosis, cytokines 
production and ROS by APCs.  
Similarly to particulate WGP, soluble PGG binds specifically to Dectin-1, yet it is incapable of 
activating the receptor dependent responses as all the others soluble b-glucans, in spite of their  
molecular weight.  
The fact MS4A4A and Dectin1 co-localizes at the membrane level but display opposite behavior 
upon Zymosan stimulation, prompted us to evaluate its response to other forms of β-glucan. 
The macrophages were  stained with  anti-MS4A4A and anti Dectin1 at 4°C for 20 min to prevent 
receptors internalization, then Zymosan, was added, part of each sample was shifted to 37°C to 
allow phagocytosis and/or internalization  to occur, part was kept on ice. After 1h and 2h 
incubations, the percentage of receptor internalized was calculated from the mean fluorescence 
intensity (MFI) values as 100 x [MFI (37°C sample) /MFI (4°C sample)], after normalization with 
the respective isotypes (Fig.34). 
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Fig.34. MS4A4A expression is negatively related to Dectin1 one. Staining for MS4A4A and 
Dectin1 of human macrophages untreated (0) or treated for  the indicated time with zymosan 
(50ug/mL). (A) Representative dot plot displaying the inverse correlation  between the expression 
of the two molecules. (B) Relative MFI±SEM of 3 independent experiments of antibody feeding. 
Macrophages were given with Zymosan , half of each sample was kept on ice, the rest shifted to 
121 
 
37°C to allow phagocytosis and/or internalization. After the indicated  incubations, cells were  
labeled with  anti-MS4A4A and anti Dectin1 at 4°C for 20’, and analyzed  by flow. The MFI were 
normalized on the respective isotype, and the percentage of receptor internalized (or not) was 
calculated from the mean fluorescence intensity (MFI) values as 100 x [MFI (37°C sample) /MFI 
(4°C sample)]. (*, P < 0.05) 
 
 
As shown in the dot plot (Fig.34A) Dectin1 positive cells drop from 83% at the basal level to 21% 
after an hour stimulation, to almost 10% after 2h. 
On the contrary, MS4A4A positives cells raise from ~5% in the resting cells, to 52% after 1h, to 
72% after 2h. The trend looks the same in all the experiments performed, indicating that a sort of 
regulation may exist between the two molecules, such that one negatively affects the other ones 
expression at the membrane level, considering that their levels are modulated within the same 
population of cells. 
The way the antibody feeding is carried out indicates Dectin1 is actually internalized and not only 
down-regulated upon β-glucans biding. 
We therefore repeated the FACS experiment on macrophages, this time challenging them with the 
particulate WPG and the soluble PGG, for 2h (Fig.35). 
What we found out, further reinforced the hypothesis of a mutual regulation between Dectin1 and 
MS4A4A. Indeed, besides responding with an up-regulation upon Zymosan, MS4A4A is 
significantly (+51%) overexpressed  in the presence of the specific Dectin1 ligand WGP, which as 
mentioned  above, is unable to trigger TLRs responses and is therefore an exclusive stimulus for the 
C-type lectin receptor, as confirmed by the reduction at the membrane level (-77%) due to its 
internalization. 
Moreover, MS4A4A does not respond to the soluble  β-glucan PGG, and so doesn’t Dectin, 
meaning the two molecules respond selectively to the same stimuli. Indeed, PGG is able to bind 
Dectin1, but it does not induce the activation of its signaling pathway. MS4A4A may therefore 
function as an adaptor molecule, regulating Dectin1 availability to signaling. 
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Fig.35. MS4A4A  responds selectively to particulate β-glucans, but not to soluble ones, 
reflecting Dectin1’s behavior. Flow cytometry analysis of surface expression of MS4A4A and 
Dectin1 upon treatment with Zymosan and WGP particulates, and the PGG soluble form of β-
glucans. The cells were treated 2h with the different polysaccharides and stained for 20’ with anti-
MS4A4A and anti- Dectin1 and analyzed by FACS. Results are mean ±SEM of three independent 
experiments. (*, P < 0.05) 
 
4.4.5. MS4A4A and Dectin1 localize within lipid rafts  after 
engagement with Zymosan 
 
It is well known that receptor  signaling can occur in specific membrane lipid raft or caveolae which 
act as platforms for the association of adaptors/receptors signaling complexes [127, 388].  
Dectin1 expression and function have been described being negatively regulated by Dexamethasone 
in both resident and elicited murine peritoneal macrophages. Noteworthy, the ability of the receptor 
to bind Zymosan was strongly impaired in the presence of GC [278]. 
Moreover, localization of Dectin1 within lipid rafts seems to be  required for its signaling and for 
the  activation of phagocytosis and cytokine secretion in DC [290]. 
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Starting from these assumptions, we performed an immunofluorescence experiment on primary 
macrophages to evaluate the localization of Dectin1 with respect to lipid rafts. Cells were labeled 
with the CT-B, fixed and stained with anti-Dectin1 and examined in confocal laser scanning 
microscopy (Fig.36A). 
As already demonstrated,  MS4A4A is barely found within the rafts in normal conditions (Fig. ) and 
as shown in Fig. 36A and B, Dectin1 is not co-localizing within lipid raft either.  
A further assessment of the lack of association of Dectin1 with the cholesterol enriched micro 
domains was performed by giving the cells with MβCD and analyzing Dectin1 expression at the 
cell surface by flow cytometry. As shown in Fig.36B, Dectin1 wasn’t affected by the cholesterol 
depletion induced by the cyclodextrins, indicating that, unlike MS4A4A which expression was at 
least partially  impaired upon the treatment, the C-type lectin receptor does not resides within these 
membrane compartments before engagement.  
On the other hand, once given with Zymosan, a strong co-localization is found between Dectin1 and 
MS4A4A in lipid rafts, particularly in proximity of the granules, suggesting a role in signaling 
and/or receptor clustering (Fig.37A). MS4A4A may in fact act as an adaptor molecule, transporting 
Dectin1 within the raft, favoring the interaction of this receptor with kinases and/or other signaling 
molecules contained in these membrane structures.  
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Fig. 36. Dectin1 does not localize within the lipid rafts  before and it is not affected by  
cholesterol depletion.  (A) Immunofluorescence staining for  Dectin1 and Lipid Rafts (CT-B) on  
macrophages, representative of 2 independent experiments. Co-localization (merge) between the 
proteins, if present,  is indicated in yellow. (B) Macrophages were treated for 1h with 5mM MβCD 
to deplete cholesterol, stained for MS4A4A and Dectin1, and analyzed by flow cytometry. The 
upper graph shows the mean ±SEM  of n=4 experiments. *p<0.05.The lower panel is a 
representative histogram of the expression of MS4A4A and Dectin1 upon MβCD treatment.  
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Fig37. Dectin1 and MS4A4A localize within lipid rafts  after engagement with Zymosan. (A) 
Immunofluorescence staining for  MS4A4A, Dectin1 and Lipid Rafts (CT-B) on  macrophages 
upon zymosan treatment, representative of 2 independent experiments. Co-localization (merge) 
between the proteins is indicated in yellow. (B) Schematic representation of lipid raft structures in a 
plasma membrane. Lipid rafts float in the membrane, constituting distinct signalling platforms 
depending on lipid raft subtype and composition. Adapted from Maguy 2006, Cardiovascular 
Research. 
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4.5. Identification of the murine Ms4a4a 
 
In an effort to identify the corresponding murine MS4A4A (Ms4a4a), with the perspective of 
generating a murine model lacking in the protein expression within the monocytes/macrophages 
lineage for the in vivo study of its function, a BLAST analysis has been performed in order to 
evaluate all the possible candidates. The MS4A gene family itself presents a murine correspondent 
[213], but on average the hortologs, with the exception of MS4A1/CD20 (80%), do not share high 
sequence homology. Indeed, based on the sequences available on genomes databases (Genome 
Brawser, NCBI), the only homologs identified for MS4A4A were the murine Ms4a4b, Ms4a4c and 
Ms4a4d. By the time we began studying this protein, indeed, the sequence for Ms4a4a hadn’t been 
identified yet by the Mouse Genome Project. The only evidence confirming its existence derived 
from a clone (clone I420104A15) from the cDNA of  osteoclast-like murine cell 
(http://www.ncbi.nlm.nih.gov/nucest/BY320061?report=GenBank) and a partial mRNA of 373 bp 
long was reconstructed from that cDNA clone, although it was incomplete at the 3' end. On the 
NCBI 37a, Aug 2007 genome, the pre-messenger resulted having  3 exons and covering 5.91 kb. 
The 5'UTR contains about 125 bp and there is an in frame stop 27 bp before the Met.  
Since the homology in the DNA sequence doesn’t necessary mean homology in the function, we 
started analyzing the protein sequence, in order to find something with a higher degree in homology 
with the human MS4A4A. We found out a sequence we named Ms4a4a, that, in spite of the low 
homology both at the genomic (42,4%) and transcript level (35,7%), displayed 74% similarity with 
the human protein. 
The analysis were performed with the global sequence alignment programs BLASTP 
(http://blast.ncbi.nlm.nih.gov) and Emboss-Needle 
(http://www.ebi.ac.uk/Tools/psa/emboss_needle/) using the Needleman-Wunsch algorithm. 
The data obtained are summarized in Fig. 38B 
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Fig. 38. Discovery of murine Ms4a4a sequence.  (A) Mouse Ms4a4 cluster. Adapted from 
Genome Browser website. (B) Percentages of similarity and identity  between human MS4A4A 
gene, transcript and protein and the murine putative hortologs. Alignments were performed with 
BLASTP and Emboss Needle programs. NCBI Reference Sequences: Ms4a4a: XM_986941.3; 
Ms4a4b: NM_021718.2; Ms4a4c: NM_029499.3; Ms4a4d: NM_025658.4 
 
No phenotype for Ms4a4a has yet been reported and the gene's in vivo function is yet unknown.  
PSORT II analysis for the prediction of protein localization sites in cells ( http://psort.hgc.jp/ ) 
trained on yeast data predicts that the subcellular location of this protein is most likely 33.3 %: 
endoplasmic reticulum;  22.2 %: plasma membrane;  22.2 %: mitochondrial;  11.1 %: vesicles of 
secretory system; 11.1 %: Golgi. The protein doesn’t display neither N-terminal signal peptide nor 
tyrosines within the tail, therefore seems unlikely it acts as a signal transduction molecule. No 
cleavage site motif for mitochondrial targeting were found, neither were ER Membrane and 
peroxisomal retention signals. 
Pfam analysis ( http://pfam.janelia.org ), confirmed the protein belongs to CD20-like family. 
At present, according to Entrez Gene database, Ms4a4a gene has been confirmed mapping on 
chromosome 19, its total length is 17268 bp (11450013-11467280), with an  mRNA of 836 bp, and 
a CDS of 711 bp which encodes for a protein of  236 aa. The intron-exon organization is maintained 
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between the two species (Fig.39A) and the prediction of the tertiary structure by TMHMM reveals 
the same four transmembrane domains architecture, with cytoplasmic terminals, and two 
extracellular loops (Fig.39B-C), consistent with MS4A4A characteristics. To examine whether 
mMs4a4a is also a trans membrane protein, HEK293 cells were transfected with the Ms4a4a-GFP 
plasmid. The TIRF analysis of the transfectants confirmed the same localization of the murine 
protein at the cell surface.(Fig.39D) 
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Fig.39. Molecular features of murine Ms4a4a. (A) The Ms4a4a gene record is predicted by 
automated computational analysis and derived from a genomic sequence (NT_039687.8) annotated 
using gene prediction method: Gnomon, supported by EST evidence. The gene contains 7 exons, 
displaying the same organization of the human gene, and codifies for a 236 aa protein.(B) 
Comparison of the amino acid sequences of the human and murine MS4. The predicted 
transmembrane domains are indicated in red. (C) Analysis of the amino acid sequences of the 
mMs4a4a, using TMHMM program (http://genome.cbs.dtu.dk/services/), predicting the expected 
four transmembrane hydrophobic domains resambling the human homolog, with cytoplasmic amino 
and carboxyl termini. (D) HEK293 cells were transfected with the mMs4a4a-GFP plasmid and the 
protein localization was assessed by TIRF microscopy, confirming the expression at the cell 
surface. 
 
4.5.1. Murine Ms4a4a expression in tissues and response to 
polarization 
 
Once identified the putative ortholog of MS4A4A, we evaluated its expression in primary cells and 
tissues, and its  responses to polarization compared to the other Ms4a4 members. RNA was 
collected from several cells and tissues of C57/B6 mice, including dendritic cells, CD8+/CD4+ T 
lymphocytes, B lymphocytes, liver, lung and kidney. (Fig40A) The Ms4a4a transcript distribution  
revealed the selective expression of Ms4a4a in macrophages, in line with the human protein 
expression pattern (Fig.39).   
Murine peritoneal elicited macrophages were obtained after 4 days thyoglicollate (injected  
intraperitoneally),  by washing the cavity with 5mL cold saline and subsequently  polarizing the 
cells with the same protocol applied for human cells:  M1 (LPS 100ng/mL+IFN-γ 20ng/mL) or M2 
(IL-4 20ng/mL or Dexamethasone 10^
-6
M). After 18h RNA was extracted by Trizol and Ms4a4a, 
Ms4a4b, Ms4a4c, Ms4a4d expression assessed by q-PCR  (Fig.40B and C). 
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Fig.40. Ms4a4a expression and  response to polarization.  (A) Ms4a4a expression in murine 
primary cells and tissues. qPCR for Ms4a4a highlighting its association with macrophages. (B) 
Ms4a4a response upon polarization analyzed by q-PCR, reflecting the same induction pattern of the 
human hortolog. (C). Ms4a4b, Ms4a4c and Ms4a4d expression upon polarization. Expression is 
indicated as fold increase respect to non-treated macrophages (M0). Results are expressed as mean 
±SD of 3 experiments. * p<0.05. 
 
 
As shown in Fig.40, Ms4a4a is exclusively expressed in macrophages and is the only homolog 
resembling the human MS4A4A polarization pattern of expression, with an increase of the 
transcript in the presence of GC and, to a lesser extent, IL4.  Ms4a4b is known not being expressed 
by macrophages. The other two members do not respond at all to alternative polarization stimuli, 
but result up-regulated only in the presence of pro-inflammatory mediators.  
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4.5.2. Con-Ms4a4a Ko mice display normal phenotype 
 
To examine the function of Ms4a4a in vivo we generated mice deficient in the protein selectively in 
the myeloid lineage breeding homozygous Ms4a4a-flox animals obtained from Ozgene with 
LysM/Cre animals. 
At first sight, mice were viable, had no visible abnormalities and had  normal peripheral leukocyte 
counts. Splenocytes  from Ms4a4a-conKO and WT mice had a similar antigen phenotype and no 
abnormalities were evident (Table.1). 
 
Cell type marker WT cells (%) KO cells (%) 
Neutrophils CD11b
hi
; Gr1
hi
 0.733+0.11 0.433+0.09 
Dendritic cells CD11c+; CD11b+ 2.402+0.07 2.042+0.36 
B lymphocytes B220 59.413+2.97 60.200+1.01 
T lymphocytes CD3 24.830+2.01 25.816+1.19 
NK cells NK1.1 0.019+0.001 0.013+0.01 
macrophages CD11b+; F4/80
hi
 0.710+0.07 0.556+0.18 
eosinophils Gr-1
int;
CD11b+;F4/80+ 0.346+0.10 0.386+0.09 
 
 
Table.1. Differential splenocyte counts. Splenocytes were isolated from matched Ms4a4a-
conditional knockout mice (KO) and wild-type mice (WT) and cell types were identified with flow 
cytometry. Macrophages were identified as autofluorescent, F4/80+ cells. Data represent average 
±SEM of n=3 mice per type. 
 
4.5.3. Con-Ms4a4a Ko mice derived macrophages show impaired 
response to Zymosan 
 
Given its proven association with Dectin1, the expression of the receptor at the cell surface was 
assessed by flow cytometry, together with two other molecules associated with fungal recognition, 
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TLR2 and MHCII. As shown in Fig. 41, Dectin1 expression was the only one resulting impaired in 
the conKO compared with the WT mice, with a significant reduction at the basal level. 
 
 
 
 
 
Fig.41. Ms4a4a-conKO displays a Lower basal expression of Dectin1. Peritoneal elicited 
macrophages were withdrown from the animals and immediately assessed in flow cytometry, after 
staining with anti-Dectin1, anti-TLR2 and anti MHCII antibodies.  
 
 
We next assessed the Ms4a4a KO macrophages response to zymosan. Thioglycollate PEC from 
Ms4a4a-knockout mice displayed comparable zymosan internalization, as confirmed by the FACS 
analysis performed on these cells challenged with Zymosan-FITC for 5, 15 and 30 minutes 
(Fig.42A). Also the levels of ERK phosphorilation were pretty much equal between the two 
conditions Fig42B). However, Dectin1 expression resulted somehow impared, with a lower basal 
level in the KO cells accompained by a delayed internalization of the receptor (Fig42C).  
As mentioned before, one critical cellular process  mediated by Dectin1 in rensponse to β-glucans 
binding  is the generation of ROS.  
We therefore examined that response in peritoneal-elicited macrophages and BMDM. ROS levels 
produced by Ms4a4a-conKO animals compared to WT, PEC and BMDM were seeded in 24well 
plates and were labeled with HOECHST to counterstain the nuclei and stained them with the ROS-
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responsive dye CellROX Deep Red reagent to detect the oxidative stress in time lapse. After 30’ 
incubation with the reagents, cells were transferred into the CellR microscope humidified chamber  
(37°C, 5%CO2) and imaged the fluorescence production for 2h. Although no respiratory burst was 
induced in PEC (data not shown), in line with previously described evidences [389] we observed a 
significant decrease of approximately 50% in ROS generation  in KO cells compared to the WT 
ones (Fig. 42D).    
 
 
 
 
 
 
 
 
Fig.42. Impaired inflammatory response in Ms4a4a KO macrophages. (A) PEC were treated 
with Zymosan-FITC for the indicated periods of time and  the internalized particles were evaluated 
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by flow cytometry. (B) ERK phosphorilation and (C) Dectin1 internalization were analyzed by flow 
cytometry in PEC given with non labeled Zymosan for the indicated time points. Data are 
represented as mean ±SEM of n≥3. (D) Diagram of the mean fluorescence intensity (± SEM)  
induced by ROS production  from BMDM in the presence of zymosan (50ug/mL) in WT and KO 
cells. An average of 100 ROI was analyzed for each time point in each sample. Every time,  n=3 
mice per condition were used, and the experiment was repeated twice. 
 
 
Besides the impairment in Dectin1 internalization and respiratory burst induction, the inability of 
the  Ms4a4a-conKO  to mount an inflammatory response against  zymosan  resulted also  from  the 
significant  impairment in the cytokines secretion,  evaluated by the release of  IL6, IL10 and TNFα 
in the supernatant of peritoneal elicited macrophages (Fig.43upper).  In this case,  we couldnt detect 
any substantial flaw in the production of the cytokines in Ms4a4a KO BMDMs cultured with 
zymosan,  (data not shown). 
Finally, in order to understand whether the downregulation of the cytokines derived form a defect in 
the induction of the gene expression or in a failure in the secretion mechanism A q-PCR was 
performed on the cytokines’ cDNA from PECs given with Zymosan for 6h or 24h. The experiment 
confirmed a significant reduction in the expression of IL10, accompained to a decrease in IL6 and 
TNFα in the KO cells compared to the WT (Fig.43lower). 
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Fig.43. Down-regulation of cytokines secretion in Ms4a4a-conKO. (upper panel) Dectin1- 
related cytokines secretion measured by ELISA in the supernatant of WT and KO PEC treated with 
zymosan for 24h. For every experiment n=3 mice  per condition were used. The graphs show mean 
(± SEM) of two independent experiments. *, P < 0.05 and **, P < 0.01. (lower panel) q-PCR of 
PECs for the analysis of the transcript of the examined cytokines. Cells were challenged with 
100ug/mL Zymosan and mRNA was extracted after 6h (TNF) or 24h (IL6 and IL10) to evaluate 
transcript regulation. Data represent mean (± SEM) of triplicates of two experiment. **, P < 0.01; 
and ***, P <0.001 
  
 
Together with these evidences, the observation of a substantial induction in IL12 transcript (not 
shown) , which upon fungal/yeast stimulation is driven exclusively by a TLR2-mediated, Dectin1-
independent pathway, suggests a mechanism by which the cell may compensate the impaired 
Dectin1 signaling cascade, mounting an alternative immune response-  
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5. DISCUSSION 
 
 
An significant amount of evidences has established a role for the MS4A protein family, especially 
CD20 and FcεRIβ, in the immune system context.  
MS4A4A is a novel member of the membrane-spanning 4-domain family, subfamily A, (MS4A) 
gene family, which members share structural features including four transmembrane domains, two 
extracellular loops and two cytoplasmic terminals [215]. The MS4A family counts at least 26 
members in human and mouse including CD20, FcεRIβ, HTm4 [7, 213]. Chromosome mapping 
revealed that most of these human genes are located in chromosome 11q12-q13, which is linked 
with higher susceptibility to allergy and atopic asthma [390, 391], while in the mouse, they are 
found in chromosome 19 [217, 392]. The presence of a cluster of genes and their chromosomal 
localization strongly suggests an immunological significance. Until few years ago, the only 
characterized members of the family were CD20 (MS4A1), HTm4 (MS4A2) and FcεRIβ (MS4A3). 
CD20 is a non-glycosylated transmembrane protein selectively associated with B cells [392, 393], 
but not found in plasma cells [394, 395]. Some works suggest it may act as a Ca
2+
 channel or 
Ca
2+
 channel regulator [233], although increasing evidences indicate it is not only implicated in 
Ca
2+
  signaling but also in the activation, differentiation and apoptosis of B cells [396, 397].  
Noteworthy, CD20 provided a fundamental target for the development of a therapeutic antibody 
against B cell lymphoma and autoimmune diseases, Rituximab, which up till now can be considered 
one of the most effective antibody therapeutic available [397].  
HTm4 is instead primarily located on the hematopoietic cells nuclear membrane, and plays a pivotal 
role in their differentiation [250].  
FcεRIβ is part of the IgE receptor complex, and as such contains an ITAM motif in its C-terminal 
domain that directly contributes to IgE mediated cell signaling [248, 398, 399]. The functions of 
most of the other members remain essentially indeterminate.  
In the first part of this thesis, we demonstrated that the family member MS4A4A is selectively 
expressed in macrophages and differentially up-regulated in M2-like macrophages. Among the 
stimuli tested, glucocorticoids resulted the most effective ones in inducing MS4A4A transcript and 
protein. A synergistic induction by GC and IL4 was also observed, although the restored MS4A4A 
basal expression levels upon treatment with the GC competitor antagonist Mifepristone and the 
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evidence of a strong up-regulation of the protein upon CG administration in vivo in human  
macrophages, indicates a direct effect mediated by the steroids. 
Indeed, the analysis of the putative promoter located upstream the MS4A4A gene revealed the 
presence of a considerable number of glucocorticoids responsive element (GRE) transcription factor 
binding sites, indicating the possibility of a direct effect mediated by the GC receptor (GCR). 
Although the pathway is likely to be mediated  directly via GCR, it has to be considered  GC can 
also modify the gene expression through a GRE-independent mechanism, which is partially 
mediated by protein-protein interactions of the GC receptor with other DNA-binding factors or co-
activators. For instance, through C/EBP interaction dexamethasone has also been acknowledged  
playing a role in the nuclear receptor  PPARɣ expression regulation, which in turn is known 
regulating, for instance, the phagocytosis of apoptotic cells [400].  
As it turned out from the bioinformatics sequence analysis,  MS4A4A does not include any ITAM 
domain, like other MS4A members do (e.g. FcεRIβ) ,and it’s therefore unlikely it functions as a 
signal transduction molecule. Alignment of the MS4A4A protein sequence with CD20 shows  a 
44%  similarity on the amino acid level, with the highest degree of identity within  the first three 
transmembrane domains, suggesting it may work more similarly to CD20, given that also the 
membrane topology is conserved between the two molecules.  
MS4A4A is a 239 amino acid protein with cytoplasmic amino- and carboxy-terminals and four 
transmembrane domains forming two extracellular loops. 
Cell membrane localization was experimentally confirmed by immunofluorescence microscopy of 
HEK cells transfected with eGFP-tagged MS4A4A or with the empty eGFP constructs and by 
staining human primary macrophages. Also at the protein level, MS4A4A displays an 
overexpression induced by M2 stimuli.  
In the meantime, the bioinformatics investigation was applied also for the murine MS4A4A 
homolog, and allowed us to discover a gene encoding for the putative Ms4a4a. Subsequent analysis 
of the molecule features and regulation upon polarizing M1 and M2 mediators acknowledged this 
gene as the human homolog, sharing the same GC dependence, structure and membrane topology.  
M2 macrophages play a crucial role in a variety of processes, such as tissue remodeling, 
homeostasis maintenance, angiogenesis, immunosuppression and tumor development. Opposite to 
classical pro-inflammatory M1 macrophages, M2 display a very low microbicide and tumoricide 
functions due to their reduced secretion of reactive oxygen and nitrogen species and pro-
inflammatory cytokines. Tumor-associated macrophages (TAM) are M2-like cells characterized by 
a heterogeneous population highly represented among stromal leukocytes in many malignances, and 
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which define the link between cancer and inflammation [401]. TAM dramatically withstand tumor 
growth, negatively affecting the clinical outcome of cancer bearing subjects [4, 104, 402].  
Particularly, overexpression of this type of macrophages in lymph-node specimens from patients 
with Hodgkin’s lymphoma (HL) has been  associated with poor prognosis [104]. 
Since MS4A4A was mainly found being expressed in M2 macrophages, and given that in mouse it 
resulted significantly overexpressed in RCC associated TAMs,  we analyzed the protein expression 
in a small cohort of Hodgkin’s lymphoma samples  by immunohistochemistry, finding out a 
considerable number of MS4A4A+ cells in all the samples examined. Although not statistically 
significant, the percentage of immune reactive area within the tumor samples was higher than in 
those samples we identified as control lymph nodes (7.00 + 0.91 vs 3.75 + 1.30).  
Other than the narrowness of the casuistry, the main reason for this lack of significance might be 
due to the fact these lymph nodes were derived from the same HL patients, and cannot therefore be 
referred as “normal”, since they were characterized by abnormal lymphadenitis, often associated 
with sinus histiocytosis. The only two cases of real normal tissues examined (spleen and lymph 
node) showed almost no positivity for MS4A4A. Subcapsular sinus macrophages in the lymph 
nodes physiologically support antiviral humoral immune responses [403, 404]. However, the 
predominant accumulation observed in perivascular areas within the lymphomas and within the 
fibrotic tissue surrounding the tumor is consistent with a TAM, or at least a M2-like phenotype. 
TAM differentiate from  circulating blood monocytes that infiltrate the tumor, where they can exert 
different functions. Perivascular macrophages may indeed play an important role in the 
vascularization process, enhancing tumor growth, invasion and metastasis. On the other hand, pro-
fibrotic macrophages can produce PDGF, TGFβ1 and insulin-like growth factor 1 (IGF1), 
activating fibroblasts, and overexpressing metalloproteinases (MMP) to orchestrate the extracellular 
matrix deposition, therefore directly participating in wound healing [405].  
Interestingly, some MS4A4A positivity was also found within the perinodal adipose tissue (PAT), 
fat depots in which lymph nodes are embedded and which supports the lymph node functions, 
providing lipid supply powering immune activation as well as making available fatty-acid that 
sustain local immunity [406]. These regions are characterized by a high number of DCs, particularly 
within the omental tissue. Charriere and colleagues described the ability of preadipocytes to develop 
into macrophages [407], and these cells display a diverse phenotype during inflammation or 
disease, expressing greater amounts of co-stimulatory molecules, apart from MHCII and T cells 
stimulation, which are lost [408]. Also these type of cells  seem to reflect an M2-like behavior.  
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Nevertheless, the heterogeneity observed  within the lymphoma subtypes, might also derive from 
the different content  in M1 or M2 polarized macrophages, resulting in different staining patterns. In 
fact, the double immunohistochemistry for MS4A4A and the macrophage marker CD68 revealed 
the presence of a subpopulation of MS4A4A positive macrophages, indicating that only 
macrophages can express MS4A4A, although not all of them do it. We therefore identified a 
subpopulation of macrophages that expresses MS4A4A and this subpopulation is highly represented 
within the tumor compared to non-neoplastic tissues.  
Recently,  a link between tumors and GC has been found which might at least provide a hint for the 
correlation  among  MS4A4A, GC ant TAM. These lipid hormones can in fact be produced, other 
than the adrenal gland by the intestinal epithelium. Sidler and colleagues demonstrated that both 
cell lines and primary tumors can express steroidogenic enzymes and bioactive GC, inhibiting the 
activation of T lymphocytes, contributing to tumor immune evasion [409]  Whether this occurs also 
in lymphomas, it has yet to be determined. 
 
Antibody-based cancer therapies have been effectively reflected  into clinic representing  the most 
encouraging treatments in oncology. The use of monoclonal antibodies (mAb) directed against  a 
particular lineage of hematopoietic cell have been proven as useful therapeutic targets [410]. 
Particularly, anti-CD20 mAbs dramatically improved the  treatment of lymphoma patients.  
MS4A4A+ macrophages resemble bona fide TAMs and its  expression was found in different types 
of lymphomas, as well as other types of cancers (e.g. gastric carcinoma, data not shown). Large-
scale analysis  of tumor specimens, might  validate its suitability for an even broader  targeted 
therapy. 
On top of that, MS4A4A is a surface molecule and   therefore easily detectable  by antibodies for 
specific cellular populations recognition. 
All these features including sequence similarity to other MS4A family members, especially CD20, 
suggest that MS4A4A might possess a therapeutic potential as antibody target. 
Using a phage-display system, various antibody fragments can be displayed on the surface of 
filamentous phages containing the antibody gene as a phagmid and in this way, humanized 
antibodies can be developed for clinical applications. In this study,  with the idea of generating a 
tool comparable with Rituximab, able to detect and selectively induce cytotoxicity in the target 
MS4A4A bearing macrophages, we made use of this technique to generate a human anti human 
monoclonal antibody.  
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Out of 4 clones identified from the library screening, the final product, clone D1, was able to 
mediate antibody dependent cytotoxicity and antibody-dependent (NK) cell-mediated cytotoxicity 
of the MS4A4A expressing cells. More importantly, D1 was the only clone cross-reacting with the 
mouse hortolog Ms4a4a. The epitope mapping confirmed a specificity of the antibody for a 
sequence of 6 amino acids within the second extracellular loop, and the binding of the clone was 
significantly impaired by the presence of a correspondent competitor peptide. 
Unfortunately, once evaluated in primary cells and compared with the commercially available 
antibodies recognizing MS4A4A, D1 showed a reduced affinity along with a decreased specificity 
for the target.  
Moreover, the antibody was not able to properly recognize the murine molecule. 
All these evidences might be caused by the wrong panning strategy. The library was in fact 
screened against  transfectants, therefore leading to the selection of clones able to recognize the 
protein in its recombinant form, not necessary in its native one, in which also the loops 
conformation might be altered.  
In the very next future the library is going to be screened again against primary cells, with the 
perspective of  isolating  a clone capable of binding the native MS4A4A. 
 
 
In the second part of the thesis the interactions and the functions of MS4A4A were explored. 
Lipid rafts are liquid-ordered specialized plasma  microdomains acknowledged to play an important 
role in regulating signaling by ITAM  receptors. Dexamethasone  treatment has been previously 
shown reducing membrane fluidity, altering raft lipid fatty acyl composition [411]. Since some 
members of the protein family were found co-localizing with  raft detergent-resistant lipid 
microdomains upon  recruitment [215, 375], we examined MS4A4A localization with respect to 
these compartments under resting and polarized conditions. Under  resting conditions  no co-
localization occurred between MS4A4A and the rafts, while in the presence of  GC almost the 
totality of MS4A4A was co-localizing with the rafts.  
Although a discrete ratio of the proximity might be due to the de novo expression of the protein 
upon GC, this mediator actually induces the re-localization of MS4A4A within the rafts, as proved 
by the evidence of an increase in the co-localization index after only 2h of GC treatment. As 
demonstrated in the first part of the results, in fact, the messenger starts being induced after 6h 
treatment, and the protein expression is not triggered before 18-24h, meaning that the co-
localization after 2h is a direct effect of GC on the membrane organization. 
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GC signaling via classical GRs has been previously demonstrated occurring also within lipid raft or 
caveolae microdomains platforms where multimeric signaling complexes can be clustered and it can 
be observed both in the presence or absence of a steroid ligand. 
Lipid rafts are considerably rich in sphingolipids and cholesterol [412] and CD20 association with 
these compartments is cholesterol-dependent [413]. 
The cholesterol-depleting agent MβCD was used to further confirm the association of MS4A4A 
with rafts. The treatment led to the disruption of cholesterol enriched microdomains and 
significantly diminished  the MS4A4A expression at the surface level, demonstrating an important 
role for  these structures  in MS4A4A surface localization and raising the hypothesis that the 
molecule may function as an adaptor, clustering membrane receptor complexes in the same way 
tetraspanins do.  
Noteworthy, lipid rafts and caveole are important scaffold for the correct functioning  of endocytic 
receptors and are associated with the phagocytic uptake of pathogens and particles [414]. Also 
microglia signaling is triggered  by Src-SHP-2 and CD36 recruitment to lipid  rafts [415] 
and  is required for phagocytosis of amyloid-β42 [416]. 
 
With the attempt of determine a role for MS4A4A on the plasma membrane of macrophages, we 
decided to explore its  potential interactors adopting the yeast split-ubiquitin screen, a variant of the 
traditional yeast two hybrid, with the key advantage of allowing the measurement of the protein 
interactions directly at the surface level. 6 integral membrane proteins were shown to interact with 
MS4A4A in a specific way, among which MS4A4A itself, MS4A6A and MS4A7,  the tetraspanins 
CD63 and CD9 and, more importantly,  the β-glucan receptor Dectin1. The validation of these 
interactions was assessed by FLIM-FRET on CHO transfectants and ultimately on human 
macrophages by classical co-immunoprecipitation.  
The interaction of MS4A4A with Dectin1was reproduced  in  all the experiments.  CD63 interaction 
with MS4A4A was confirmed only in primary cells, not in CHO cells, probably because of the  
different features and above all the different  functions exerted by these two cell types., while 
interactions among MS4A4A, MS4A6A and MS4A7 were validated only by FLIM-FRET, 
suggesting these molecules cluster on the plasma membrane in complexes comparable to the 
tetraspanin enriched microdomains, where they may orchestrate the localization of receptor 
complexes, such as the C-type lectin receptors one. 
On the other hand, we couldn’t validate association for CD9. In all cases, the lack of interaction 
might depend either on the transient  nature of the association, or on the indirect association of some 
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of these molecules, which create complexes on the plasma membrane, but although in close 
proximity,  are not physically connected.  
The evidence of MS4A members to associate with each other and with of other molecules was first 
described by Howie and colleagues, who reported MS4A4B self-association and with MS4A6B and 
the co-stimulatory molecules  GITR and Orai1 [230], again suggesting they may work as adaptors 
for the protein complexes assembly in the membrane [135, 417].  This type of associations are 
frequent among tetraspanins ,including CD9 and CD63 [418-421] but even so, highly specific, and 
are usually found within a  “raft” type microdomains [127, 422].  
CD63 antigen is usually detected in endosomal particles but it is also presented on cell surfaces 
(Latysheva et al., 2006) and it is known to interact with Dectin1 during the phagocytic process, 
when the particle is translocated through the endosomes in the lysosomes to be degraded.  
We next asked whether the interaction of MS4A4A with Dectin1, CD63 and CD9 had functional 
consequences, especially for Dectin1 co-stimulation.  
Zymosan is an extract from the cell wall of  S. cerevisiae, which is commonly  used to mimic fungal 
infection, since it stimulates innate immune cells to mount a response through the involvement of 
Dectin-1 and TLR2 [9, 283] [289, 328, 423].  
We observed the recruitment, at different degrees, of MS4A4A, CD63, CD9 and Dectin1 to 
phagosomes during internalization of  Zymosan  particles, indicating a possible cooperation in the 
clearance of pathogens mediated by MS4A4A which also at the basal level, co-localizes with 
Dectin1, which is normally expressed at the surface level and undergoes internalization upon 
activation [326, 386].  
We confirmed the interaction of MS4A4A with the PRR Dectin1 is highly specific because the two 
molecules are not affected  by other polysaccharides (mannan and LPS) because their regulation 
depends selectively on β-glucans. Moreover, we provided evidences that MS4A4A, as well as 
Dectin1, is able to discriminate among different types of β-glucan. Dectin1 in fact exerts its 
antimicrobial activity only in the presence of particulate polymers, not soluble ones,  through the 
formation of  a “phagocytic synapse” involving tyrosine phosphatases [386], inducing a robust 
immune  response only when strictly required.  The increase at the membrane level of MS4A4A 
was maximal in the presence of the Dectin1 specific ligand WGP, while the soluble form of 
polymer , PGG, was not inducing any up-regulation of the tetraspanin. Interestingly, to an increase 
of MS4A4A corresponds a decrease of Dectin1 at the surface level, indicating that a sort of mutual 
regulation may exist between the two molecules, such that MS4A4A overexpression corresponds to 
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the simultaneous Dectin1 internalization , considering that their levels are modulated within the 
same population of cells.  
Opposite to MS4A4A which in primary cells is strongly induced by GC, Dectin1 expression and 
function have been described  being negatively regulated by Dexamethasone in both resident and 
elicited murine peritoneal macrophages, where its efficiency in Zymosan binding was dramatically  
impaired in the presence of GC [278]. 
We demonstrated that Dectin1 and MS4A4A co-localize in resting macrophages and it is not 
constitutively expressed within cholesterol enriched membranes before engagement, as 
demonstrated by MBCD treatment, but re-localizes within these domains upon Zymosan 
stimulation, corroborating the assumption  that the receptor association  is required for its signaling 
and for the  activation of phagocytosis and cytokine secretion in DC (Xu, 2009). Indeed, two 
important members of Dectin1 signaling cascade,  Syk and PLCɣ2, are known being recruited to 
lipid rafts upon the activation of the receptor, suggesting that these  microdomains play a key role in  
Dectin-1 signaling. 
How previously described by Ms4a4b, which association with GITR on T cells  induces the TCR  
mediated signaling amplification upon  ligand stimulation, the association of MS4A4A with 
Dectin1 may influence the receptor activity, functioning as a tuner for the anti-fungi/yeasts 
response.   
Finally, in the attempt to better characterize the function of MS4A4A in more physiological 
environment, we moved to an in vivo setting, generating a conditional knockout  mouse lacking 
Ms4a4a in the myeloid lineage, and we assessed the response to Zymosan of these macrophages 
compared to wild type ones.  
Dectin-1 engagement  by Zymosan or fungi triggers the activation of several pathways, including 
NFAT and NF-kB activation upon Src-Syk  and MAPK-ERK phosphorylation  aimed to mount a 
variety of  immune responses. These responses include phagocytosis and killing of the pathogen, 
mediated by the secretion of  antimicrobial reactive oxygen species and the production of cytokines 
and chemokines. [424-426]. 
Our preliminary experiments showed a severe impairment in the macrophages driven response to 
Zymosan. Although the phagocytosis rate and the phosphorylation of ERK was not impaired, KO 
macrophages displayed a lower basal expression as well as a delayed internalization of Dectin1 
upon engagement, which reinforces the hypothesis of  an adaptor function for Ms4a4a, which seems 
to act in an opposite fashion compared to the leukocyte-specific tetraspanin CD37, which instead  
stabilizes Dectin1 in APC membranes, affecting IL6 production [166]. 
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Additionally, Ms4a4a  absence was reflected by a significant decrease in ROS production by 
BMDM upon Zymosan, that during phagocytosis is triggered by the assemblage of  the phagosomal 
membrane and is totally dependent on Src/Syk kinases.  
Furthermore, the inability of the  Ms4a4a-conKO  to mount an inflammatory response against  
zymosan  resulted also  from  the significant  impairment in the cytokines secretion,  evaluated by 
the release of  IL6, IL10 and TNFα which was determined by a downregulation at the mRNA level, 
indicating a defect in these genes transcription activation by the conKO. Interestingly, the transcript 
level of IL12, which is induced only via MyD88/TLR2 signaling, is increased in conKO zymosan 
stimulated macrophages (not shown), suggesting a compensation mechanism by which the cell can 
get rid of the pathogen. 
Dectin-1 triggers activation of Syk , which is not required for phagocytosis but is required for 
stimulation of ROS production and for some cytokines, such as IL-10 and IL-6 [427]. 
Therefore, it is likely that this kinase is the key to explain the majority of the effects observed in the 
conKO. Ms4a4a might in fact promote Syk  association to Dectin1, leading to the release of 
cytokines and triggering the respiratory burst. 
Although not totally understood yet,  this work describes  the first functional interaction between an 
MS4A member and a C-type lectin identified so far. 
Definitely, further efforts are required to uncover the role of MS4A4A in the context of tumors and 
fungal infections. One of the most urgent future perspectives will be definitely to assess its behavior 
in in vivo models of these two conditions, in order to characterize a defined phenotype for this 
molecule. 
A positive outcome from the second screening of the anti-MS4A4A antibody cross-reacting with 
the murine homolog would eventually provide us an irreplaceable tool to better examine MS4A4A 
function in vivo, given that by far, no commercial tools are available for targeting the murine 
molecule.  
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